UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year
ended DECEMBER 31,
2009
Commission
file number: 1-3433
THE
DOW CHEMICAL COMPANY
(Exact
name of registrant as specified in its charter)
|
|||||||
Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
38-1285128
(I.R.S.
Employer Identification No.)
|
||||||
2030
DOW CENTER, MIDLAND, MICHIGAN 48674
(Address
of principal executive
offices)
(Zip Code)
Registrant’s
telephone number, including area code: 989-636-1000
|
|||||||
Securities
registered pursuant to Section 12(b) of the Act:
|
|||||||
Title of each class
Common
Stock, par value $2.50 per share
Debentures,
6.85%, final maturity 2013
|
Name of each exchange on which
registered
Common
Stock registered on the New York and
Chicago
Stock Exchanges
Debentures
registered on the New York Stock Exchange
|
||||||
Indicate
by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.
|
|||||||
þ
Yes o
No
|
|||||||
Indicate
by check mark if the registrant is not required to file reports pursuant
to Section 13 or Section 15(d) of the Act.
|
|||||||
o
Yes þ
No
|
|||||||
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
|
|||||||
þ Yes o No
|
|||||||
Indicate
by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T
during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).
|
|||||||
þ Yes o No
|
|||||||
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.
|
|||||||
þ | |||||||
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated
filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act.
|
|||||||
Large
accelerated filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller reporting company
o
|
||||
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act).
|
o Yes þ No
|
||||||
The
aggregate market value of voting common stock held by non-affiliates as of
June 30, 2009 (based upon the closing price of $16.14 per common
share as quoted on the New York Stock Exchange), was approximately
$18.4 billion. For purposes of this computation, it is assumed that
the shares of voting stock held by Directors, Officers and the Dow
Employees’ Pension Plan Trust would be deemed to be stock held by
affiliates. Non-affiliated common stock outstanding at
June 30, 2009 was 1,140,566,930 shares.
Total
common stock outstanding at January 31, 2010 was 1,150,293,750
shares.
|
|||||||
DOCUMENTS
INCORPORATED BY REFERENCE
Part
III: Proxy Statement for the Annual Meeting of Stockholders to be
held on May 13, 2010.
|
The
Dow Chemical Company
ANNUAL
REPORT ON FORM 10-K
For
the fiscal year ended December 31, 2009
|
|||
PAGE
|
|||
PART
I
|
|||
Business.
|
3
|
||
Risk
Factors.
|
13
|
||
Unresolved
Staff Comments.
|
16
|
||
Properties.
|
17
|
||
Legal
Proceedings.
|
18
|
||
Submission
of Matters to a Vote of Security Holders.
|
23
|
||
PART
II
|
|||
Market
for Registrant’s Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities.
|
27
|
||
Selected
Financial Data.
|
28
|
||
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations.
|
30
|
||
Quantitative
and Qualitative Disclosures About Market Risk.
|
77
|
||
Financial
Statements and Supplementary Data.
|
78
|
||
Changes
in and Disagreements With Accountants on Accounting and Financial
Disclosure.
|
158
|
||
Controls
and Procedures.
|
159
|
||
Other
Information.
|
161
|
||
PART
III
|
|||
Directors,
Executive Officers and Corporate Governance.
|
162
|
||
Executive
Compensation.
|
162
|
||
Security
Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters.
|
162
|
||
Certain
Relationships and Related Transactions, and Director
Independence.
|
162
|
||
Principal
Accounting Fees and Services.
|
162
|
||
PART
IV
|
|||
Exhibits,
Financial Statement Schedules.
|
163
|
||
165
|
|||
|
·
|
Products: ACuPLANE™ CMP
slurries; AR™ antireflective coatings; AUROLECTROLESS™ immersion gold
process; COPPER GLEAM™ acid copper plating products; DURAPOSIT™
electroless nickel process; ENLIGHT™ products for photovoltaic
manufacturers; EPIC™ immersion photoresists; INTERVIA™ photodielectrics
for advanced packaging; LITHOJET™ digital imaging processes; OPTOGRADE™
metalorganic precursors; VISIONPAD™ CMP
pads
|
|
·
|
Products and Services:
Acrolein derivatives; ACUDYNE™ hair fixatives; ACULYN™ rheology modifiers;
ACUMER™ scale inhibitors and dispersants; AMBERLITE™ ion exchange resins;
AUTOMATE™ liquid dyes; Basic nitroparaffins and nitroparaffin-based
specialty chemicals; BOROL™ bleaching solution; CANGUARD™ BIT
preservatives; CELLOSIZE™ hydroxyethyl cellulose; Chiral compounds and
biocatalysts; CLEAR+STABLE™ carboxymethyl cellulose; CORRGUARD™ amino
alcohol; CYCLOTENE™ advanced electronics resins; DOW™ electrodeionization;
DOW™ latex powders; DOW™ ultrafiltration; DOWEX™ ion exchange resins;
DOWICIDE™ antimicrobial bactericides and fungicides; DURAPLUS™ floor care
polymers; ECOSURF™ biodegradable surfactants; EVOCAR™ vinyl acetate
ethylene; FILMTEC™ elements; FORTEFIBER™ soluble dietary fiber;
FOUNDATIONS™ latex; Hydrocarbon resins; Industrial biocides; METHOCEL™
cellulose ethers; MORTRACE™ marking technologies; NEOCAR™ branched vinyl
ester latexes; OPULYN™ opacifiers; POLYOX™ water-soluble resins; PRIMENE™
amines; Quaternaries; Reverse osmosis, electrodeionization and
ultrafiltration modules; SATINFX™ delivery system; SATISFIT™ Weight Care
Technology; SILK™ semiconductor dielectric resins; SOLTERRA™ Boost
ultraviolet protection-boosting polymers; SOLTEX™ waterproofing polymer;
SUNSPHERES™ SPF boosters; UCAR™ all-acrylic, styrene-acrylic and
vinyl-acrylic latexes; UCAR™ POLYPHOBE™ rheology modifiers; UCARE™
polymers; UCARHIDE™ opacifier; WALOCEL™ cellulose polymers; WALSRODER™
nitrocellulose
|
|
·
|
Products: ADCOTE™ and
AQUA-LAM™ laminating adhesives; MOR-FREE™ solventless adhesives; ROBOND™
acrylic adhesives; SERFENE™ barrier coatings; Solvent-based polyurethanes
and polyesters; TYMOR™ tie resins
|
|
·
|
Products: AQUASET™
acrylic thermosetting resins; CELLOSIZE™ hydroxyethyl cellulose;
FROTH-PAK™ polyurethane spray foam; GREAT STUFF™ polyurethane foam
sealant; INSTA-STIK™ roof insulation adhesive; POWERHOUSE™ solar shingle;
RHOPLEX™ aqueous acrylic polymer emulsions; STYROFOAM™ brand insulation
products (including extruded polystyrene and polyisocyanurate rigid foam
sheathing products); THERMAX™ insulation; TILE BOND™ roof tile adhesive;
WEATHERMATE™ weather barrier solutions (housewraps, sill pans, flashings
and tapes)
|
|
·
|
Products: ACRYSOL™
rheology modifiers; AVANSE™, ELASTENE™, PRIMAL™ and RHOPLEX™ acrylics;
CELLOSOLVE™ and the CARBITOL™ and DOWANOL™ series of oxygenated solvents;
D.E.H.™ curing agent and intermediates; D.E.R.™ and D.E.N.™ liquid and
epoxy resins; FORTEGRA™ Epoxy Tougheners; OROTAN™ and TAMOL™ dispersants;
ROPAQUE™ opaque polymers; TRITON™, TERGITOL™, DOWFAX™ and ECOSURF™ SA
surfactants
|
|
·
|
Products: AGROMEN™
seeds; BRODBECK™ seed; CLINCHER™ herbicide; DAIRYLAND™ seed; DELEGATE™
insecticide; DITHANE™ fungicide; FORTRESS™ fungicide; GARLON™ herbicide;
GLYPHOMAX™ herbicide; GRANITE™ herbicide; HERCULEX™ I, HERCULEX™ RW and
HERCULEX™ XTRA insect protection; KEYSTONE™ herbicides; LAREDO™ fungicide;
LONTREL™ herbicide; LORSBAN™ insecticides; MILESTONE™ herbicide; MUSTANG™
herbicide; MYCOGEN™ seeds; NEXERA™ canola and sunflower seeds; PHYTOGEN™
cottonseeds; PROFUME™ gas fumigant; RENZE™ seed; SENTRICON™ termite colony
elimination system; SIMPLICITY™ herbicide; STARANE™ herbicide; TELONE™
soil fumigant; TORDON™ herbicide; TRACER™ NATURALYTE™ insect control;
TRIUMPH™ seed; VIKANE™ structural fumigant; WIDESTRIKE™ insect
protection
|
|
·
|
Products: AERIFY™ diesel
particulate filters; BETAFOAM™ NVH acoustical foams; BETAMATE™ structural
adhesives; BETASEAL™ glass bonding systems; DOW™ polyethylene resins;
IMPAXX™ energy management foam; INSPIRE™ performance polymers; INTEGRAL™
adhesive films; ISONATE™ pure and modified methylene diphenyl diisocyanate
(MDI) products; MAGNUM™ ABS resins; PELLETHANE™ thermoplastic polyurethane
elastomers; Premium brake fluids and lubricants; PULSE™ engineering
resins; SPECFLEX™ semi-flexible polyurethane foam
systems
|
|
·
|
Products: ADVASTAB™
thermal stabilizer; AFFINITY™ polyolefin plastomers (POPs); AMPLIFY™
functional polymers; DOW™ Adhesive Film; DOW™ Backing Layer Film; DOW™
Medical Device Film; DOW™ Medical Packaging Film; DOW™ very low density
polyethylene; ENGAGE™ polyolefin elastomers; INFUSE™ olefin block
copolymers; INTEGRAL™ adhesive films; NORDEL™ hydrocarbon rubber; NYLOPAK™
nylon barrier films; OPTICITE™ films; PARALOID™ EXL impact modifier;
PRIMACOR™ copolymers; PROCITE™ window envelope films; PULSE™ engineering
resins; SARAN™ barrier resins; SARANEX™ barrier films; TRENCHCOAT™
protective films; TRYCITE™ polystyrene film; TYBRITE™ clear packaging
film; TYRIN™ chlorinated polyethylene; VERSIFY™ plastomers and
elastomers
|
|
·
|
Products: ENGAGE™
polyolefin elastomers; NORDEL™ hydrocarbon rubber; SI-LINK™ and REDI-LINK™
moisture crosslinkable polyethylene-based wire and cable insulation
compounds; TYRIN™ chlorinated polyethylene; UNIGARD™ flame retardant
compound for specialty wire and cable
applications
|
|
·
|
Products: AIRSTONE™
epoxy systems; Encapsulants and chemical compositions; ENFORCER™
Technology and ENHANCER™ Technology for polyurethane carpet and turf
backing; HYPERKOTE™, TRAFFIDECK™ and VERDISEAL™ waterproofing systems;
HYPOL™ hydrophilic polyurethane prepolymers; RENUVA™ Renewable Resource
Technology; SPECFIL™ urethane components; SPECFLEX™ copolymer polyols;
SPECTRIM™ reaction moldable products; VORACOR™ and VORALAST™ polyurethane
systems and VORALAST™ R renewable content system; VORAMER™ industrial
adhesives and binders; VORASTAR™ polymers; XITRACK™ polyurethane rail
ballast stabilization systems
|
|
·
|
Products: Alkyl
alkanolamines; Ethanolamines; Ethyleneamines; Isopropanolamines;
Piperazine; VERSENE™ chelating
agents
|
|
·
|
Products:
Styrene-butadiene latex
|
|
·
|
Products: D.E.H.™ epoxy
curing agents or hardeners; D.E.N.™ epoxy novolac resins; D.E.R.™ epoxy
resins (liquids, solids and solutions); Epoxy intermediates (acetone,
allyl chloride, epichlorohydrin and phenol); Epoxy resin waterborne
emulsions and dispersions; FORTEGRA™ epoxy tougheners; Glycidyl
methacrylate (GMA)
|
|
·
|
Products: Acetic esters;
Acetone derivatives; Alcohols; Aldehydes; Butyl CARBITOL™ and Butyl
CELLOSOLVE™ solvents; Carboxylic acids; DOWANOL™ glycol ethers; ECOSOFT™
IK solvent; PROGLYDE™ DMM solvent; UCAR™
propionates
|
|
·
|
Products: AMBITROL™ and
NORKOOL™ coolants; CARBOWAX™ and CARBOWAX SENTRY™ polyethylene glycols and
methoxypolyethylene glycols; DOW™ polypropylene glycols; DOW™ SYMBIO base
fluid; DOWFAX™, TERGITOL™ and TRITON™ surfactants; DOWFROST™ and DOWTHERM™
heat transfer fluids; ECOSURF™ biodegradable surfactants; SYNALOX™
lubricants; UCAR™ deicing fluids; UCON™
fluids
|
|
·
|
Products: Acrylic
acid/acrylic esters; ACUMER™, ACUSOL™, DURAMAX™, OPTIDOSE™, ROMAX™ and
TAMOL™ dispersants; Methyl
methacrylate
|
|
·
|
Products: ECHELON™
polyurethane prepolymer; ISONATE™ methylene diphenyl diisocyanate (MDI);
MONOTHANE™ single component polyurethane elastomers; PAPI™ polymeric MDI;
Propylene glycol; Propylene oxide; RENUVA™ Renewable Resource Technology;
VORANATE™ isocyanate; VORANOL™ VORACTIV™ polyether and copolymer
polyols
|
|
·
|
Products: ASPUN™ fiber
grade resins; ATTANE™ ultra low density polyethylene (ULDPE) resins;
CONTINUUM™ bimodal polyethylene resins; DOW™ high density polyethylene
(HDPE) resins; DOW™ low density polyethylene (LDPE) resins; DOWLEX™
polyethylene resins; ELITE™ enhanced polyethylene (EPE) resins; TUFLIN™
linear low density polyethylene (LLDPE) resins; UNIVAL™ HDPE
resins
|
|
·
|
Products: DOW™
homopolymer polypropylene resins; DOW™ impact copolymer polypropylene
resins; DOW™ random copolymer polypropylene resins; INSPIRE™ performance
polymers; UNIPOL™ PP process technology; SHAC™ and SHAC™ ADT catalyst
systems
|
|
·
|
Products: Licensing and
supply of related catalysts, process control software and services for the
Mass ABS process technology; STYRON A-TECH™ and C-TECH™ advanced
technology polystyrene resins and a full line of STYRON™ general purpose
polystyrene resins; STYRON™ high-impact polystyrene
resins
|
|
·
|
Products: Caustic soda;
Chlorine; Ethylene dichloride (EDC); Hydrochloric acid; Vinyl chloride
monomer (VCM)
|
|
·
|
Products: Ethylene oxide
(EO); Ethylene glycol (EG); METEOR™ EO/EG process technology and
catalysts
|
|
·
|
Products: Benzene;
Butadiene; Butylene; Cumene; Ethylene; Propylene; Styrene; Power, steam
and other utilities
|
Patents
Owned at December 31, 2009
|
||||||||
U.S.
|
Foreign
|
|||||||
Electronic
and Specialty Materials
|
1,029 | 2,653 | ||||||
Coatings
and Infrastructure
|
658 | 2,793 | ||||||
Health
and Agricultural Sciences
|
512 | 1,810 | ||||||
Performance
Systems
|
608 | 3,009 | ||||||
Performance
Products
|
318 | 1,360 | ||||||
Basic
Plastics
|
255 | 1,296 | ||||||
Basic
Chemicals
|
21 | 93 | ||||||
Hydrocarbons
and Energy
|
25 | 179 | ||||||
Corporate
|
235 | 600 | ||||||
Total
|
3,661 | 13,793 |
|
·
|
Americas
Styrenics LLC – 50 percent – a U.S. limited liability company that
manufactures polystyrene and styrene monomer.
|
|
·
|
Compañía
Mega S.A. – 28 percent – an Argentine company that owns a natural gas
separation and fractionation plant, which provides feedstocks to the
Company’s petrochemical plant located in Bahia Blanca,
Argentina.
|
|
·
|
Dow
Corning Corporation – 50 percent – a U.S. company that manufactures
silicone and silicone products. See Note N to the Consolidated
Financial Statements.
|
|
·
|
EQUATE
Petrochemical Company K.S.C. – 42.5 percent – a Kuwait-based company that
manufactures ethylene, polyethylene and ethylene glycol.
|
|
·
|
Equipolymers
– 50 percent – a company, headquartered in Horgen, Switzerland, that
manufactures purified terephthalic acid, and manufactures and markets
polyethylene terephthalate resins.
|
|
·
|
The
Kuwait Olefins Company K.S.C. – 42.5 percent – a Kuwait-based company
that manufactures ethylene and ethylene glycol.
|
|
·
|
MEGlobal
– 50 percent – a company, headquartered in Dubai, United Arab Emirates,
that manufactures and markets monoethylene glycol and diethylene
glycol.
|
|
·
|
The
SCG-Dow Group [consisting of Siam Polyethylene Company Limited –
49 percent; Siam Polystyrene Company Limited – 50 percent; Siam
Styrene Monomer Co., Ltd. – 50 percent; Siam Synthetic Latex Company
Limited – 50 percent] – Thailand-based companies that manufacture
polyethylene, polystyrene, styrene and latex.
|
|
·
|
Univation
Technologies, LLC – 50 percent – a U.S. limited liability company
that develops, markets and licenses polyethylene process technology and
related catalysts.
|
United
States:
|
Plaquemine
and Hahnville, Louisiana; Midland, Michigan; Freeport, Seadrift, Texas
City and Deer Park, Texas; Marlborough, Massachusetts.
|
Canada:
|
Fort
Saskatchewan, Alberta.
|
Germany:
|
Boehlen;
Leuna; Rheinmuenster; Schkopau; Stade.
|
France:
|
Drusenheim.
|
The
Netherlands:
|
Terneuzen.
|
Spain:
|
Tarragona.
|
Argentina:
|
Bahia
Blanca.
|
Brazil:
|
Aratu.
|
United
States:
|
62
manufacturing locations in 23 states.
|
Canada:
|
5
manufacturing locations in 3 provinces.
|
Europe:
|
64
manufacturing locations in 17 countries.
|
Latin
America:
|
29
manufacturing locations in 5 countries.
|
Asia
Pacific:
|
48
manufacturing locations in 9 countries.
|
India,
Middle East and Africa:
|
6
manufacturing locations in 4
countries.
|
2009
|
2008
|
2007
|
||||||||||
Claims
unresolved at January 1
|
75,706 | 90,322 | 111,887 | |||||||||
Claims
filed
|
8,455 | 10,922 | 10,157 | |||||||||
Claims
settled, dismissed or otherwise resolved
|
(9,131 | ) | (25,538 | ) | (31,722 | ) | ||||||
Claims
unresolved at December 31
|
75,030 | 75,706 | 90,322 | |||||||||
Claimants
with claims against both UCC and Amchem
|
24,146 | 24,213 | 28,937 | |||||||||
Individual
claimants at December 31
|
50,884 | 51,493 | 61,385 |
Defense
and Resolution Costs
|
Aggregate
Costs
|
|||||||||||||||
In
millions
|
2009
|
2008
|
2007
|
to
Date as of
Dec.
31, 2009
|
||||||||||||
Defense
costs
|
$ | 62 | $ | 60 | $ | 84 | $ | 687 | ||||||||
Resolution
costs
|
$ | 94 | $ | 116 | $ | 88 | $ | 1,480 |
Receivables
for Costs Submitted to Insurance Carriers With Settlement Agreements at
December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Receivables
for defense costs
|
$ | 91 | $ | 28 | ||||
Receivables
for resolution costs
|
357 | 244 | ||||||
Total
|
$ | 448 | $ | 272 |
Issuer
Purchases of Equity Securities
|
||||||||||||||||
Period
|
Total number of shares
purchased (1)
|
Average
price paid per share
|
Total
number of shares purchased as part of the Company’s publicly announced
share repurchase program
|
Approximate
dollar value of shares that may yet be purchased under the Company’s
publicly announced share repurchase program
|
||||||||||||
October
2009
|
2,442 | $ | 25.05 | - | - | |||||||||||
November
2009
|
2,187 | $ | 24.28 | - | - | |||||||||||
December
2009
|
- | - | - | - | ||||||||||||
Fourth
quarter 2009
|
4,629 | $ | 24.69 | - | - |
(1)
|
Represents
shares received from employees and non-employee directors to pay taxes
owed to the Company as a result of the exercise of stock options or the
delivery of deferred stock. For information regarding the Company’s stock
option plans, see Note S to the Consolidated Financial
Statements.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||||||||||
PART
II, Item 6. Selected Financial Data.
|
||||||||||||||||||||
In
millions, except as noted (Unaudited)
|
2009
|
2008
|
2007
|
2006
|
2005
|
|||||||||||||||
Summary of Operations
(1)
|
||||||||||||||||||||
Net sales
(2)
|
$ | 44,875 | $ | 57,361 | $ | 53,375 | $ | 49,009 | $ | 46,186 | ||||||||||
Cost of sales
(2)
|
39,148 | 51,913 | 46,302 | 41,448 | 38,194 | |||||||||||||||
Research
and development expenses
|
1,492 | 1,310 | 1,305 | 1,164 | 1,073 | |||||||||||||||
Selling,
general and administrative expenses
|
2,487 | 1,966 | 1,861 | 1,660 | 1,542 | |||||||||||||||
Amortization
of intangibles
|
399 | 92 | 72 | 50 | 55 | |||||||||||||||
Special
charges: restructuring, merger-related, asbestos-related, IPR&D,
impariment losses
|
869 | 1,117 | 635 | 414 | 114 | |||||||||||||||
Equity
in earnings of nonconsolidated affiliates
|
630 | 787 | 1,122 | 959 | 964 | |||||||||||||||
Sundry
income - net
|
891 | 89 | 324 | 137 | 755 | |||||||||||||||
Interest
expense - net
|
1,532 | 562 | 454 | 431 | 564 | |||||||||||||||
Income
(Loss) from continuing operations before income taxes
|
469 | 1,277 | 4,192 | 4,938 | 6,363 | |||||||||||||||
Provision
(Credit) for income taxes
|
(97 | ) | 651 | 1,230 | 1,142 | 1,769 | ||||||||||||||
Net
income (loss) from continuing operations
|
566 | 626 | 2,962 | 3,796 | 4,594 | |||||||||||||||
Income
from discontinued operations, net of income taxes
|
110 | 28 | 23 | 21 | 23 | |||||||||||||||
Net
income attributable to noncontrolling interests
|
28 | 75 | 98 | 93 | 82 | |||||||||||||||
Preferred
stock dividends
|
312 | - | - | - | - | |||||||||||||||
Income
(Loss) before cumulative effect of changes in accounting
principles
|
336 | 579 | 2,887 | 3,724 | 4,535 | |||||||||||||||
Cumulative
effect of changes in accounting principles
|
- | - | - | - | (20 | ) | ||||||||||||||
Net
income (loss) available for The Dow Chemical Company common
stockholders
|
$ | 336 | $ | 579 | $ | 2,887 | $ | 3,724 | $ | 4,515 | ||||||||||
Per share of common stock (in
dollars): (3)
|
||||||||||||||||||||
Net
income (loss) from continuing operations per common share -
basic
|
0.22 | 0.59 | 3.00 | 3.85 | 4.66 | |||||||||||||||
Discontinued
operations per common share - basic
|
0.10 | 0.03 | 0.03 | 0.02 | 0.03 | |||||||||||||||
Earnings
(Loss) per common share - basic
|
0.32 | 0.62 | 3.03 | 3.87 | 4.69 | |||||||||||||||
Net
income (loss) from continuing operations per common share -
diluted
|
0.22 | 0.59 | 2.97 | 3.80 | 4.60 | |||||||||||||||
Discontinued
operations per common share - diluted
|
0.10 | 0.03 | 0.02 | 0.02 | 0.02 | |||||||||||||||
Earnings
(Loss) per common share - diluted
|
0.32 | 0.62 | 2.99 | 3.82 | 4.62 | |||||||||||||||
Cash
dividends declared per share of common stock
|
0.60 | 1.68 | 1.635 | 1.50 | 1.34 | |||||||||||||||
Cash
dividends paid per share of common stock
|
0.87 | 1.68 | 1.59 | 1.46 | 1.34 | |||||||||||||||
Book
value per share of common stock
|
18.42 | 14.62 | 20.62 | 17.81 | 15.84 | |||||||||||||||
Weighted-average common shares
outstanding - basic (3)
|
1,043.2 | 930.4 | 953.1 | 962.3 | 963.2 | |||||||||||||||
Weighted-average common shares
outstanding - diluted (3)
|
1,053.9 | 939.0 | 965.6 | 974.4 | 976.8 | |||||||||||||||
Convertible
preferred shares outstanding (thousands)
|
4,000 | - | - | - | - | |||||||||||||||
Year-end
Financial Position
|
||||||||||||||||||||
Total
assets
|
$ | 65,937 | $ | 45,474 | $ | 48,801 | $ | 45,581 | $ | 45,934 | ||||||||||
Working
capital
|
6,454 | 2,952 | 6,209 | 6,608 | 6,741 | |||||||||||||||
Property
- gross
|
53,567 | 48,391 | 47,708 | 44,381 | 41,934 | |||||||||||||||
Property
- net
|
18,141 | 14,294 | 14,388 | 13,722 | 13,537 | |||||||||||||||
Long-term
debt and redeemable preferred stock
|
19,152 | 8,042 | 7,581 | 8,036 | 9,186 | |||||||||||||||
Total
debt
|
22,373 | 11,856 | 9,715 | 9,546 | 10,706 | |||||||||||||||
The
Dow Chemical Company's stockholders' equity
|
20,555 | 13,511 | 19,389 | 17,065 | 15,324 | |||||||||||||||
Financial
Ratios
|
||||||||||||||||||||
Research and development expenses
as percent of net sales (2)
|
3.3 | % | 2.3 | % | 2.4 | % | 2.4 | % | 2.3 | % | ||||||||||
Income
(Loss) from continuing operations before income taxes
|
||||||||||||||||||||
as percent of
net sales (2)
|
1.0 | % | 2.2 | % | 7.9 | % | 10.1 | % | 13.8 | % | ||||||||||
Return on stockholders' equity
(4)
|
2.0 | % | 4.3 | % | 14.9 | % | 21.8 | % | 29.5 | % | ||||||||||
Debt
as a percent of total capitalization
|
51.4 | % | 45.7 | % | 31.8 | % | 34.1 | % | 39.1 | % | ||||||||||
General
|
||||||||||||||||||||
Capital
expenditures
|
$ | 1,410 | $ | 2,276 | $ | 2,075 | $ | 1,775 | $ | 1,597 | ||||||||||
Depreciation
|
2,291 | 2,016 | 1,959 | 1,904 | 1,904 | |||||||||||||||
Salaries
and wages paid
|
5,152 | 4,681 | 4,404 | 3,935 | 4,309 | |||||||||||||||
Cost
of employee benefits
|
1,389 | 981 | 1,130 | 1,125 | 988 | |||||||||||||||
Number
of employees at year-end (thousands)
|
52.2 | 46.1 | 45.9 | 42.6 | 42.4 | |||||||||||||||
Number of Dow stockholders of
record at year-end (thousands) (5)
|
89.9 | 94.6 | 98.7 | 103.1 | 105.6 |
(1) |
Adjusted
to report sale of the Calcium Chloride business in 2009 as discontinued
operations.
|
(4) |
Included
Temporary Equity in 1999.
|
||||||||||||||||||
(2) |
Adjusted
for reclassification of freight on sales in 2000 and of insurance
operations in 2002.
|
(5) |
Stockholders
of record as reported by the transfer agent. The Company
|
||||||||||||||||||
(3) |
Adjusted
for 3-for-1 stock split in 2000.
|
estimates
that there were an additional 563,000 stockholders whose
shares
|
|||||||||||||||||||
were
held in nominee names at December 31, 2009.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||||||||||||||
PART
II, Item 6. Selected Financial Data.
|
||||||||||||||||||||||||
In
millions, except as noted (Unaudited)
|
2004
|
2003
|
2002
|
2001
|
2000
|
1999
|
||||||||||||||||||
Summary of Operations
(1)
|
||||||||||||||||||||||||
Net sales
(2)
|
$ | 40,063 | $ | 32,536 | $ | 27,545 | $ | 27,988 | $ | 29,727 | $ | 26,065 | ||||||||||||
Cost of sales
(2)
|
34,175 | 28,110 | 23,737 | 23,838 | 24,256 | 20,377 | ||||||||||||||||||
Research
and development expenses
|
1,022 | 981 | 1,066 | 1,072 | 1,119 | 1,075 | ||||||||||||||||||
Selling,
general and administrative expenses
|
1,434 | 1,390 | 1,595 | 1,762 | 1,822 | 1,773 | ||||||||||||||||||
Amortization
of intangibles
|
81 | 63 | 65 | 178 | 139 | 160 | ||||||||||||||||||
Special
charges: restructuring, merger-related, asbestos-related, IPR&D,
impariment losses
|
543 | - | 1,108 | 1,556 | 6 | 100 | ||||||||||||||||||
Equity
in earnings of nonconsolidated affiliates
|
923 | 322 | 40 | 29 | 354 | 95 | ||||||||||||||||||
Sundry
income - net
|
699 | 146 | 54 | 394 | 352 | 329 | ||||||||||||||||||
Interest
expense - net
|
661 | 736 | 708 | 648 | 519 | 432 | ||||||||||||||||||
Income
(Loss) from continuing operations before income taxes
|
3,769 | 1,724 | (640 | ) | (643 | ) | 2,572 | 2,572 | ||||||||||||||||
Provision
(Credit) for income taxes
|
867 | (92 | ) | (287 | ) | (239 | ) | 834 | 867 | |||||||||||||||
Net
income (loss) from continuing operations
|
2,902 | 1,816 | (353 | ) | (404 | ) | 1,738 | 1,705 | ||||||||||||||||
Income
from discontinued operations, net of income taxes
|
17 | 17 | 11 | 19 | 9 | 11 | ||||||||||||||||||
Net
income attributable to noncontrolling interests
|
122 | 94 | 63 | 32 | 72 | 74 | ||||||||||||||||||
Preferred
stock dividends
|
- | - | - | - | - | 5 | ||||||||||||||||||
Income
(Loss) before cumulative effect of changes in accounting
principles
|
2,797 | 1,739 | (405 | ) | (417 | ) | 1,675 | 1,637 | ||||||||||||||||
Cumulative
effect of changes in accounting principles
|
- | (9 | ) | 67 | 32 | - | (20 | ) | ||||||||||||||||
Net
income (loss) available for The Dow Chemical Company common
stockholders
|
$ | 2,797 | $ | 1,730 | $ | (338 | ) | $ | (385 | ) | $ | 1,675 | $ | 1,617 | ||||||||||
Per share of common stock (in
dollars): (3)
|
||||||||||||||||||||||||
Net
income (loss) from continuing operations per common share -
basic
|
2.96 | 1.86 | (0.38 | ) | (0.45 | ) | 1.87 | 1.84 | ||||||||||||||||
Discontinued
operations per common share - basic
|
0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | ||||||||||||||||||
Earnings
(Loss) per common share - basic
|
2.98 | 1.88 | (0.37 | ) | (0.43 | ) | 1.88 | 1.85 | ||||||||||||||||
Net
income (loss) from continuing operations per common share -
diluted
|
2.91 | 1.85 | (0.38 | ) | (0.45 | ) | 1.84 | 1.80 | ||||||||||||||||
Discontinued
operations per common share - diluted
|
0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | ||||||||||||||||||
Earnings
(Loss) per common share - diluted
|
2.93 | 1.87 | (0.37 | ) | (0.43 | ) | 1.85 | 1.82 | ||||||||||||||||
Cash
dividends declared per share of common stock
|
1.34 | 1.34 | 1.34 | 1.295 | 1.16 | 1.16 | ||||||||||||||||||
Cash
dividends paid per share of common stock
|
1.34 | 1.34 | 1.34 | 1.25 | 1.16 | 1.16 | ||||||||||||||||||
Book
value per share of common stock
|
12.88 | 9.89 | 8.36 | 11.04 | 13.22 | 12.40 | ||||||||||||||||||
Weighted-average common shares
outstanding - basic (3)
|
940.1 | 918.8 | 910.5 | 901.8 | 893.2 | 874.9 | ||||||||||||||||||
Weighted-average common shares
outstanding - diluted (3)
|
953.8 | 926.1 | 910.5 | 901.8 | 904.5 | 893.5 | ||||||||||||||||||
Convertible
preferred shares outstanding (thousands)
|
- | - | - | - | - | 1.3 | ||||||||||||||||||
Year-end
Financial Position
|
||||||||||||||||||||||||
Total
assets
|
$ | 45,885 | $ | 41,891 | $ | 39,562 | $ | 35,515 | $ | 35,991 | $ | 33,456 | ||||||||||||
Working
capital
|
5,384 | 3,578 | 2,519 | 2,183 | 1,150 | 2,848 | ||||||||||||||||||
Property
- gross
|
41,898 | 40,812 | 37,934 | 35,890 | 34,852 | 33,333 | ||||||||||||||||||
Property
- net
|
13,828 | 14,217 | 13,797 | 13,579 | 13,711 | 13,011 | ||||||||||||||||||
Long-term
debt and redeemable preferred stock
|
11,629 | 11,763 | 11,659 | 9,266 | 6,613 | 6,941 | ||||||||||||||||||
Total
debt
|
12,594 | 13,109 | 13,036 | 10,883 | 9,450 | 8,708 | ||||||||||||||||||
The
Dow Chemical Company's stockholders' equity
|
12,270 | 9,175 | 7,626 | 9,993 | 11,840 | 10,940 | ||||||||||||||||||
Financial
Ratios
|
||||||||||||||||||||||||
Research and development expenses
as percent of net sales (2)
|
2.6 | % | 3.0 | % | 3.9 | % | 3.8 | % | 3.8 | % | 4.1 | % | ||||||||||||
Income
(Loss) from continuing operations before income taxes
|
||||||||||||||||||||||||
as percent of
net sales (2)
|
9.4 | % | 5.3 | % | (2.3 | )% | (2.3 | )% | 8.7 | % | 9.9 | % | ||||||||||||
Return on stockholders' equity
(4)
|
22.8 | % | 18.9 | % | (4.4 | )% | (3.9 | )% | 14.1 | % | 14.7 | % | ||||||||||||
Debt
as a percent of total capitalization
|
47.9 | % | 55.4 | % | 59.2 | % | 48.9 | % | 42.5 | % | 42.2 | % | ||||||||||||
General
|
||||||||||||||||||||||||
Capital
expenditures
|
$ | 1,333 | $ | 1,100 | $ | 1,623 | $ | 1,587 | $ | 1,808 | $ | 2,176 | ||||||||||||
Depreciation
|
1,904 | 1,753 | 1,680 | 1,595 | 1,554 | 1,516 | ||||||||||||||||||
Salaries
and wages paid
|
3,993 | 3,608 | 3,202 | 3,215 | 3,395 | 3,536 | ||||||||||||||||||
Cost
of employee benefits
|
885 | 783 | 611 | 540 | 486 | 653 | ||||||||||||||||||
Number
of employees at year-end (thousands)
|
43.2 | 46.4 | 50.0 | 52.7 | 53.3 | 51.0 | ||||||||||||||||||
Number of Dow stockholders of
record at year-end (thousands) (5)
|
108.3 | 113.1 | 122.5 | 125.1 | 87.9 | 87.7 |
(1) |
Adjusted
to report sale of the Calcium Chloride business in 2009 as discontinued
operations.
|
(4) |
Included
Temporary Equity in 1999.
|
||||||||||||||||||
(2) |
Adjusted
for reclassification of freight on sales in 2000 and of insurance
operations in 2002.
|
(5) |
Stockholders
of record as reported by the transfer agent. The Company
|
||||||||||||||||||
(3) |
Adjusted
for 3-for-1 stock split in 2000.
|
estimates
that there were an additional 563,000 stockholders whose
shares
|
|||||||||||||||||||
were
held in nominee names at December 31, 2009.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
Page
|
|
2009
Overview
|
31
|
|
Acquisition
of Rohm and Haas
Company
|
33
|
|
Results
of
Operations
|
33
|
|
Segment
Results
|
40
|
|
Electronic
and Specialty
Materials
|
41
|
|
Coatings
and
Infrastructure
|
42
|
|
Health
and Agricultural
Sciences
|
43
|
|
Performance
Systems
|
44
|
|
Performance
Products
|
46
|
|
Basic
Plastics
|
49
|
|
Basic
Chemicals
|
51
|
|
Hydrocarbons
and
Energy
|
52
|
|
Sales
Price and Volume
Charts
|
55
|
|
Liquidity
and Capital
Resources
|
56
|
|
Cash
Flow
|
56
|
|
Working
Capital
|
57
|
|
Debt
|
57
|
|
Capital
Expenditures
|
60
|
|
Contractual
Obligations
|
61
|
|
Off-Balance
Sheet
Arrangements
|
61
|
|
Fair
Value
Measurements
|
62
|
|
Dividends
|
62
|
|
Outlook
for
2010
|
63
|
|
Critical
Accounting
Policies
|
64
|
|
Environmental
Matters
|
69
|
|
Asbestos-Related
Matters of Union Carbide
Corporation
|
73
|
|
Matters
Involving the Formation of K-Dow
Petrochemicals
|
76
|
|
|
·
|
Dow
completed its acquisition of Rohm and Haas, marking a significant
milestone in Dow’s transformation into an earnings growth company. With
this acquisition, Dow became a leading global specialty chemicals and
advanced materials company. See Note D to the Consolidated Financial
Statements for additional
information.
|
|
·
|
The
Company’s Board of Directors approved a restructuring plan related to
Dow’s acquisition of Rohm and Haas as well as actions to advance the
Company’s strategy and to respond to continued weakness in the global
economy. The restructuring plan includes the elimination of approximately
2,500 positions primarily resulting from synergies achieved as a result of
the acquisition of Rohm and Haas. In addition, the Company will shut down
a number of manufacturing facilities. These actions are expected to be
completed primarily during the next two years. Several ethylene and
ethylene-derivative assets were impacted by the announcement and these
shutdowns are expected to reduce Dow’s ethylene demand by approximately
30 percent on the U.S. Gulf Coast. See Note C to the
Consolidated Financial Statements for additional
information.
|
|
·
|
Dow
priced a public common stock offering of 150 million shares of common
stock, with total gross proceeds of approximately $2.25 billion. Of
these shares, approximately $1 billion in gross proceeds were through
shares offered by the Company and $1.25 billion were through shares
offered by accounts and funds managed by Paulson & Co. Inc. and trusts
created by members of the Haas family. All of the net proceeds received by
Dow were used to repay a portion of its term loan borrowings. See
Note W to the Consolidated Financial Statements for additional
information.
|
|
·
|
Dow
issued $6 billion of debt securities in a public offering in May. Of
the notes offered, $1.35 billion aggregate principal amount were
offered by accounts and funds managed by Paulson & Co. Inc. and trusts
created by members of the Haas family. Together with the common stock
offering priced earlier in the year, Dow retired all remaining Perpetual
Preferred Stock, Series B from its capital structure at par. Part of the
net proceeds received by Dow was used to repay a portion of its term loan
borrowings. Dow issued an additional $2.75 billion of debt securities
in a public offering in August. Part of the net proceeds received by Dow
was used to repay a portion of its term loan borrowings. See Notes O
and V to the Consolidated Financial Statements for additional
information.
|
|
·
|
Dow
converted Cumulative Convertible Perpetual Preferred Stock, Series C
(“preferred series C”), issued to partially finance the acquisition
of Rohm and Haas, into 31.0 million shares of the Company’s common
stock in June and all shares of preferred series C were retired. See
Note V to the Consolidated Financial Statements for additional
information.
|
|
·
|
The
Company repaid the outstanding balance of its revolving credit facility.
See Note O to the Consolidated Financial Statements for additional
information.
|
|
·
|
Dow
completed the sale of its Calcium Chloride business for net proceeds of
$204 million.
|
|
·
|
Dow
completed the sale of its ownership interest in Total Raffinaderij
Nederland N.V. (“TRN”), a joint venture with Total S.A., and related
inventory for $742 million.
|
|
·
|
Dow
completed the sale of its ownership interest in the OPTIMAL Group of
Companies, nonconsolidated affiliates, to Petroliam Nasional Berhad for
net proceeds of $660 million.
|
|
·
|
Dow
completed the divestiture of Morton International, Inc., the Salt business
of Rohm and Haas, to K+S Aktiengesellschaft for net proceeds of
$1,576 million. Approximately $1 billion in proceeds from the
transaction were used to pay the remaining outstanding balance of Dow’s
term loan borrowings.
|
|
·
|
Dow
AgroSciences LLC and Monsanto Company announced the completion of U.S. and
Canadian regulatory authorizations for SmartStax™, the agriculture
industry’s most advanced, all-in-one corn trait
platform.
|
|
·
|
Dow
unveiled its line of POWERHOUSE™ solar shingle, revolutionary photovoltaic
solar panels in the form of solar shingles that can be integrated into
rooftops with standard asphalt shingle materials. The product was named
one of “The 50 Best Inventions of 2009” by TIME
Magazine.
|
|
·
|
Dow
and its joint venture partner selected Midland, Michigan as the site to
construct a new facility to produce affordable advanced superior lithium
polymer battery technology for hybrid and electric vehicles. The first
phase of the site is projected to cost more than $300 million and
cover 400,000 square feet. The joint venture – between the Company and
Townsend Kokam LLC, known as Dow Kokam – announced that it had been
awarded a $161 million federal grant from the United States
Department of Energy.
|
|
·
|
Dow
and BASF SE jointly announced their support for the Patent Asset Index™, a
new methodology that measures R&D effectiveness, innovation strength
and how these factors lead to sustained competitive advantage. Findings
based on 2008 results rank Dow first in the critical measurement of
Competitive Impact™. These results show that Dow is among the most
innovative companies in the global chemical
industry.
|
|
·
|
Dow
launched a new business and innovation hub in the Asia Pacific region, the
Shanghai Dow Center. The center is comprised of a state-of-the-art R&D
facility and Dow’s regional headquarters for its businesses and
functions.
|
Production
Costs and Operating Expenses
|
||||||||||||
Cost
components as a percent of total
|
2009
|
2008
|
2007
|
|||||||||
Hydrocarbon
feedstocks and energy
|
35 | % | 48 | % | 49 | % | ||||||
Salaries,
wages and employee benefits
|
15 | 10 | 11 | |||||||||
Maintenance
|
3 | 3 | 3 | |||||||||
Depreciation
|
5 | 4 | 4 | |||||||||
Restructuring
charges
|
2 | 1 | 1 | |||||||||
Supplies,
services and other raw materials
|
40 | 34 | 32 | |||||||||
Total
|
100 | % | 100 | % | 100 | % |
Certain
Items Impacting Results
|
Pretax
|
Impact
on Net Income (2)
|
Impact
on EPS (3)
|
|||||||||||||||||||||||||||||||||
In
millions, except per share amounts
|
2009
|
2008
|
2007
|
2009
|
2008
|
2007
|
2009
|
2008
|
2007
|
|||||||||||||||||||||||||||
Cost
of sales:
|
||||||||||||||||||||||||||||||||||||
One-time
increase in cost of sales related to fair valuation of Rohm and Haas
inventories
|
$ | (209 | ) | - | - | $ | (132 | ) | - | - | $ | (0.13 | ) | - | - | |||||||||||||||||||||
Impact
of Hurricanes Gustav and Ike
|
- | $ | (181 | ) | - | - | $ | (115 | ) | - | - | $ | (0.12 | ) | - | |||||||||||||||||||||
K-Dow
related expenses
|
- | (69 | ) | - | - | (44 | ) | - | - | (0.05 | ) | - | ||||||||||||||||||||||||
Goodwill
impairment losses
|
(7 | ) | (239 | ) | - | (7 | ) | (230 | ) | - | (0.01 | ) | (0.25 | ) | - | |||||||||||||||||||||
Restructuring
charges
|
(689 | ) | (839 | ) | $ | (578 | ) | (466 | ) | (628 | ) | $ | (436 | ) | (0.45 | ) | (0.68 | ) | $ | (0.46 | ) | |||||||||||||||
Purchased
in-process research and development charges
|
(7 | ) | (44 | ) | (57 | ) | (5 | ) | (44 | ) | (50 | ) | (0.01 | ) | (0.05 | ) | (0.05 | ) | ||||||||||||||||||
Transaction,
integration and other acquisition costs
|
(226 | ) | (49 | ) | - | (170 | ) | (43 | ) | - | (0.16 | ) | (0.05 | ) | - | |||||||||||||||||||||
Equity
in earnings of nonconsolidated affiliates:
|
||||||||||||||||||||||||||||||||||||
Dow
Corning restructuring
|
(29 | ) | - | - | (27 | ) | - | - | (0.03 | ) | - | - | ||||||||||||||||||||||||
Equipolymers
impairment
|
(65 | ) | - | - | (65 | ) | - | - | (0.06 | ) | - | - | ||||||||||||||||||||||||
Sundry
income - net:
|
||||||||||||||||||||||||||||||||||||
Net
gain on sale of TRN (4)
|
457 | - | - | 321 | - | - | 0.29 | - | - | |||||||||||||||||||||||||||
Gain
on sale of OPTIMAL
|
339 | - | - | 198 | - | - | 0.18 | - | - | |||||||||||||||||||||||||||
Loss
on early extinguishment of debt
|
(56 | ) | - | - | (36 | ) | - | - | (0.03 | ) | - | - | ||||||||||||||||||||||||
Provision
for income taxes:
|
||||||||||||||||||||||||||||||||||||
German
tax law change
|
- | - | - | - | - | (362 | ) | - | - | (0.38 | ) | |||||||||||||||||||||||||
Change
in EQUATE legal ownership structure
|
- | - | - | - | - | 113 | - | - | 0.12 | |||||||||||||||||||||||||||
Total
|
$ | (492 | ) | $ | (1,421 | ) | $ | (635 | ) | $ | (389 | ) | $ | (1,104 | ) | $ | (735 | ) | $ | (0.41 | ) | $ | (1.20 | ) | $ | (0.77 | ) |
(1)
|
Impact
on “Income from Continuing Operations Before Income
Taxes”
|
(2)
|
Impact
on “Net Income from Continuing
Operations”
|
(3)
|
Impact
on “Net income from continuing operations available for common
stockholders - Earnings per common share -
diluted”
|
(4)
|
Consists
of a $513 million gain in “Sundry income – net” and hedging losses of
$56 million in “Cost of
sales.”
|
Certain
Items Impacting Rohm and Haas Results
In
millions
|
Three
months ended March 31, 2009
|
Year
ended Dec. 31, 2008
|
||||||
Impact
of Hurricanes Gustav and Ike
|
$ | (2 | ) | $ | (29 | ) | ||
Restructuring
charges
|
(2 | ) | (199 | ) | ||||
Transaction
and other acquisition costs
|
(80 | ) | (54 | ) | ||||
Gain
on sale of 40 percent equity investment in UP Chemical
Company
|
- | 87 | ||||||
Total
Rohm and Haas Certain Items
|
$ | (84 | ) | $ | (195 | ) |
|
·
|
results
of Morton International, Inc. (see Note E to the Consolidated
Financial Statements),
|
|
·
|
results
of insurance company operations,
|
|
·
|
gains
and losses on sales of financial
assets,
|
|
·
|
stock-based
compensation expense and severance
costs,
|
|
·
|
changes
in the allowance for doubtful
receivables,
|
|
·
|
expenses
related to Ventures,
|
|
·
|
asbestos-related
defense and resolution costs,
|
|
·
|
foreign
exchange hedging results, and
|
|
·
|
certain
overhead and other cost recovery variances not allocated to the operating
segments.
|
Sales
Price and Volume by Operating Segment and Geographic Area
Pro
Forma Comparison
|
||||||||||||
2009
|
||||||||||||
Percent
change from prior year
|
Volume
|
Price
|
Total
|
|||||||||
Operating
Segments:
|
||||||||||||
Electronic
and Specialty Materials
|
(15 | )% | (4 | )% | (19 | )% | ||||||
Coatings
and Infrastructure
|
(16 | ) | (7 | ) | (23 | ) | ||||||
Health
and Agricultural Sciences
|
4 | (6 | ) | (2 | ) | |||||||
Performance
Systems
|
(18 | ) | (11 | ) | (29 | ) | ||||||
Performance
Products
|
(12 | ) | (19 | ) | (31 | ) | ||||||
Basic
Plastics
|
(3 | ) | (27 | ) | (30 | ) | ||||||
Basic
Chemicals
|
(14 | ) | (28 | ) | (42 | ) | ||||||
Hydrocarbons
and Energy
|
(25 | ) | (28 | ) | (53 | ) | ||||||
Total
|
(13 | )% | (17 | )% | (30 | )% | ||||||
Geographic
Areas:
|
||||||||||||
United
States
|
(19 | )% | (14 | )% | (33 | )% | ||||||
Europe
|
(15 | ) | (21 | ) | (36 | ) | ||||||
Rest
of World
|
(4 | ) | (17 | ) | (21 | ) | ||||||
Total
|
(13 | )% | (17 | )% | (30 | )% |
Sales
Price and Volume by Operating Segment and Geographic Area
Actual
Comparison
|
||||||||||||||||||||||||
2008
|
2007
|
|||||||||||||||||||||||
Percent
change from prior year
|
Volume
|
Price
|
Total
|
Volume
|
Price
|
Total
|
||||||||||||||||||
Operating
Segments:
|
||||||||||||||||||||||||
Electronic
and Specialty Materials
|
19 | % | 8 | % | 27 | % | 20 | % | 3 | % | 23 | % | ||||||||||||
Coatings
and Infrastructure
|
40 | 5 | 45 | (2 | ) | 4 | 2 | |||||||||||||||||
Health
and Agricultural Sciences
|
8 | 12 | 20 | 9 | 2 | 11 | ||||||||||||||||||
Performance
Systems
|
2 | 12 | 14 | 10 | 6 | 16 | ||||||||||||||||||
Performance
Products
|
(18 | ) | 12 | (6 | ) | - | 6 | 6 | ||||||||||||||||
Basic
Plastics
|
(11 | ) | 12 | 1 | 1 | 8 | 9 | |||||||||||||||||
Basic
Chemicals
|
(17 | ) | 13 | (4 | ) | (10 | ) | 5 | (5 | ) | ||||||||||||||
Hydrocarbons
and Energy
|
5 | 21 | 26 | 3 | 12 | 15 | ||||||||||||||||||
Total
|
(5 | )% | 12 | % | 7 | % | 2 | % | 7 | % | 9 | % | ||||||||||||
Geographic
Areas:
|
||||||||||||||||||||||||
United
States
|
(11 | )% | 12 | % | 1 | % | (1 | )% | 1 | % | - | |||||||||||||
Europe
|
(3 | ) | 14 | 11 | 5 | 12 | 17 | % | ||||||||||||||||
Rest
of World
|
(2 | ) | 12 | 10 | 4 | 6 | 10 | |||||||||||||||||
Total
|
(5 | )% | 12 | % | 7 | % | 2 | % | 7 | % | 9 | % |
Cash
Flow Summary
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Cash
provided by (used in):
|
||||||||||||
Operating
activities
|
$ | 2,075 | $ | 4,711 | $ | 4,484 | ||||||
Investing
activities
|
(14,767 | ) | (2,737 | ) | (2,858 | ) | ||||||
Financing
activities
|
12,659 | (978 | ) | (2,728 | ) | |||||||
Effect
of exchange rate changes on cash
|
79 | 68 | 81 | |||||||||
Net
increase (decrease) in cash and cash equivalents
|
$ | 46 | $ | 1,064 | $ | (1,021 | ) |
|
·
|
On
December 3, 2007, the Board of Directors approved a restructuring
plan (the “2007 Plan”) that included the shutdown of a number of assets
and organizational changes within targeted functions. These restructuring
activities were substantially complete at the end of
2009.
|
|
·
|
On
December 5, 2008, the Board of Directors approved a restructuring
plan (the “2008 Plan”) that included the shutdown of a number of
facilities and a global workforce reduction. These restructuring
activities are targeted to be completed by the end of
2010.
|
|
·
|
On
June 30, 2009, following the acquisition of Rohm and Haas, the Board
of Directors approved a restructuring plan (the “2009 Plan”) that includes
the elimination of approximately 2,500 positions and the shutdown of a
number of manufacturing facilities. These restructuring activities are
scheduled to be completed primarily during the next two
years.
|
|
|
|
·
|
Included
in the liabilities assumed with the April 1, 2009 acquisition of Rohm
and Haas was a reserve of $122 million for severance and employee
benefits for the separation of 1,255 employees associated with Rohm
and Haas’ 2008 restructuring initiatives. The separations resulted from
plant shutdowns, production schedule adjustments, productivity
improvements and reductions in support services. These restructuring
activities are scheduled to be completed during the next two
years.
|
Working
Capital at December 31
In
millions
|
2009
|
2008
|
||||||
Current
assets
|
$ | 19,560 | $ | 16,060 | ||||
Current
liabilities
|
13,106 | 13,108 | ||||||
Working
capital
|
$ | 6,454 | $ | 2,952 | ||||
Current
ratio
|
1.49:1
|
1.23:1
|
Total
Debt at December 31
In
millions
|
2009
|
2008
|
||||||
Notes
payable
|
$ | 2,139 | $ | 2,360 | ||||
Long-term
debt due within one year
|
1,082 | 1,454 | ||||||
Long-term
debt
|
19,152 | 8,042 | ||||||
Total
debt
|
$ | 22,373 | $ | 11,856 | ||||
Debt
as a percent of total capitalization
|
51.4 | % | 45.7 | % |
Contractual
Obligations at December 31, 2009
|
Payments
Due by Year
|
|||||||||||||||||||||||||||
In
millions
|
2010
|
2011
|
2012
|
2013
|
2014
|
2015
and beyond
|
Total
|
|||||||||||||||||||||
Long-term
debt – current and noncurrent (1)
|
$ | 1,082 | $ | 1,796 | $ | 2,843 | $ | 862 | $ | 2,201 | $ | 11,935 | $ | 20,719 | ||||||||||||||
Deferred
income tax liabilities – noncurrent (2)
|
- | - | - | - | - | 1,285 | 1,285 | |||||||||||||||||||||
Pension
and other postretirement benefits
|
496 | 565 | 1,188 | 1,327 | 1,330 | 2,241 | 7,147 | |||||||||||||||||||||
Other
noncurrent obligations (3)
|
133 | 327 | 198 | 139 | 133 | 3,098 | 4,028 | |||||||||||||||||||||
Uncertain
tax positions, including interest and penalties (4)
|
76 | - | - | - | - | 600 | 676 | |||||||||||||||||||||
Other
contractual obligations:
|
||||||||||||||||||||||||||||
Minimum
operating lease commitments
|
245 | 168 | 132 | 111 | 85 | 1,225 | 1,966 | |||||||||||||||||||||
Purchase
commitments – take-or-pay and throughput obligations
|
2,845 | 2,655 | 1,716 | 1,088 | 944 | 5,969 | 15,217 | |||||||||||||||||||||
Purchase
commitments – other (5)
|
20 | 5 | 3 | - | - | 20 | 48 | |||||||||||||||||||||
Expected
cash requirements for interest
|
1,364 | 1,319 | 1,229 | 1,095 | 1,045 | 9,354 | 15,406 | |||||||||||||||||||||
Total
|
$ | 6,261 | $ | 6,835 | $ | 7,309 | $ | 4,622 | $ | 5,738 | $ | 35,727 | $ | 66,492 |
(1)
|
Excludes
unamortized debt discount of $485 million, which is reflected in
“2015 and beyond.”
|
|
(2)
|
Deferred
income tax liabilities may vary according to changes in tax laws, tax
rates and the operating results of the Company. As a result, it is
impractical to determine whether there will be a cash impact to an
individual year. All noncurrent deferred income tax liabilities have been
reflected in “2015 and beyond.”
|
|
(3)
|
Annual
payments to resolve asbestos litigation will vary based on changes in
defense strategies, changes in state and national law, and claims filing
and resolution rates. As a result, it is impractical to determine the
anticipated payments in any given year. Therefore, the majority of the
noncurrent asbestos-related liability of $734 million has been
reflected in “2015 and beyond.”
|
|
(4)
|
Due to
uncertainties in the timing of the effective settlement of tax positions
with the respective taxing authorities, the Company is unable to determine
the timing of payments related to its uncertain tax positions, including
interest and penalties. Amounts beyond the current year are therefore
reflected in “2015 and beyond.”
|
|
(5)
|
Includes
outstanding purchase orders and other commitments greater than $1 million,
obtained through a survey conducted within the
Company.
|
|
Net
Decrease (Increase) in Market-Related Asset Value Due to Recognition of
Prior Gains and Losses
In
millions
|
||||
2010
|
$ | 573 | ||
2011
|
662 | |||
2012
|
724 | |||
2013
|
(174 | ) | ||
Total
|
$ | 1,785 |
Environmental
Sites
|
Dow-owned Sites (1)
|
Superfund Sites (2)
|
||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Number
of sites at January 1
|
252 | 251 | 85 | 94 | ||||||||||||
Sites
acquired from Rohm and Haas
|
42 | - | 39 | - | ||||||||||||
Sites
added during year
|
2 | 3 | 6 | 9 | ||||||||||||
Sites
closed during year
|
(5 | ) | (2 | ) | (6 | ) | (18 | ) | ||||||||
Number
of sites at December 31
|
291 | 252 | 124 | 85 |
(1)
|
Dow-owned sites are sites currently or formerly owned by Dow, where remediation obligations are imposed in the United States by the Resource Conservation Recovery Act or analogous state law. 153 of these sites were formerly owned by Dowell Schlumberger, Inc., a group of companies in which the Company previously owned a 50 percent interest. Dow sold its interest in Dowell Schlumberger in 1992. |
|
(2)
|
Superfund sites are sites, including sites not owned by Dow, where remediation obligations are imposed by Superfund Law. |
|
2009
|
2008
|
2007
|
||||||||||
Claims
unresolved at January 1
|
75,706 | 90,322 | 111,887 | |||||||||
Claims
filed
|
8,455 | 10,922 | 10,157 | |||||||||
Claims
settled, dismissed or otherwise resolved
|
(9,131 | ) | (25,538 | ) | (31,722 | ) | ||||||
Claims
unresolved at December 31
|
75,030 | 75,706 | 90,322 | |||||||||
Claimants
with claims against both UCC and Amchem
|
24,146 | 24,213 | 28,937 | |||||||||
Individual
claimants at December 31
|
50,884 | 51,493 | 61,385 |
Defense
and Resolution Costs
|
Aggregate
Costs
|
|||||||||||||||
In
millions
|
2009
|
2008
|
2007
|
to
Date as of
Dec.
31, 2009
|
||||||||||||
Defense
costs
|
$ | 62 | $ | 60 | $ | 84 | $ | 687 | ||||||||
Resolution
costs
|
$ | 94 | $ | 116 | $ | 88 | $ | 1,480 |
Receivables
for Costs Submitted to Insurance Carriers With Settlement Agreements at
December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Receivables
for defense costs
|
$ | 91 | $ | 28 | ||||
Receivables
for resolution costs
|
357 | 244 | ||||||
Total
|
$ | 448 | $ | 272 |
Total
Daily VAR at December 31
|
2009
|
2008
|
||||||||||||||
In
millions
|
Year-end
|
Average
|
Year-end
|
Average
|
||||||||||||
Foreign
exchange
|
$ | 1 | $ | 3 | $ | 1 | $ | 3 | ||||||||
Interest
rate
|
$ | 207 | $ | 205 | $ | 161 | $ | 105 | ||||||||
Equities
|
$ | 7 | $ | 11 | $ | 24 | $ | 16 | ||||||||
Commodities
|
$ | 3 | $ | 2 | $ | 6 | $ | 13 | ||||||||
Composite
|
$ | 212 | $ | 207 | $ | 158 | $ | 112 |
The
Dow Chemical Company and Subsidiaries
|
||||||||||||
Consolidated
Statements of Income
|
||||||||||||
(In
millions, except per share amounts) For the years ended
December 31
|
2009
|
2008
|
2007
|
|||||||||
Net
Sales
|
$ | 44,875 | $ | 57,361 | $ | 53,375 | ||||||
Cost
of sales
|
39,148 | 51,913 | 46,302 | |||||||||
Research
and development expenses
|
1,492 | 1,310 | 1,305 | |||||||||
Selling,
general and administrative expenses
|
2,487 | 1,966 | 1,861 | |||||||||
Amortization
of intangibles
|
399 | 92 | 72 | |||||||||
Goodwill
impairment losses
|
7 | 239 | - | |||||||||
Restructuring
charges
|
689 | 839 | 578 | |||||||||
Purchased
in-process research and development charges
|
7 | 44 | 57 | |||||||||
Acquisition
and integration related expenses
|
166 | 49 | - | |||||||||
Asbestos-related
credit
|
- | 54 | - | |||||||||
Equity
in earnings of nonconsolidated affiliates
|
630 | 787 | 1,122 | |||||||||
Sundry
income - net
|
891 | 89 | 324 | |||||||||
Interest
income
|
39 | 86 | 130 | |||||||||
Interest
expense and amortization of debt discount
|
1,571 | 648 | 584 | |||||||||
Income
from Continuing Operations Before Income Taxes
|
469 | 1,277 | 4,192 | |||||||||
Provision
(Credit) for income taxes
|
(97 | ) | 651 | 1,230 | ||||||||
Net
Income from Continuing Operations
|
566 | 626 | 2,962 | |||||||||
Income
from discontinued operations, net of income taxes
|
110 | 28 | 23 | |||||||||
Net
Income
|
676 | 654 | 2,985 | |||||||||
Net
income attributable to noncontrolling interests
|
28 | 75 | 98 | |||||||||
Net
Income Attributable to The Dow Chemical Company
|
648 | 579 | 2,887 | |||||||||
Preferred
stock dividends
|
312 | - | - | |||||||||
Net
Income Available for The Dow Chemical Company Common
Stockholders
|
$ | 336 | $ | 579 | $ | 2,887 | ||||||
Per
Common Share Data:
|
||||||||||||
Net
income from continuing operations available for common
stockholders
|
$ | 0.22 | $ | 0.59 | $ | 3.00 | ||||||
Discontinued
operations attributable to common stockholders
|
0.10 | 0.03 | 0.03 | |||||||||
Earnings
per common share - basic
|
$ | 0.32 | $ | 0.62 | $ | 3.03 | ||||||
Net
income from continuing operations available for common
stockholders
|
$ | 0.22 | $ | 0.59 | $ | 2.97 | ||||||
Discontinued
operations attributable to common stockholders
|
0.10 | 0.03 | 0.02 | |||||||||
Earnings
per common share - diluted
|
$ | 0.32 | $ | 0.62 | $ | 2.99 | ||||||
Common
stock dividends declared per share of common stock
|
$ | 0.60 | $ | 1.68 | $ | 1.635 | ||||||
Weighted-average
common shares outstanding - basic
|
1,043.2 | 930.4 | 953.1 | |||||||||
Weighted-average
common shares outstanding - diluted
|
1,053.9 | 939.0 | 965.6 | |||||||||
See
Notes to the Consolidated Financial Statements.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||
Consolidated
Balance Sheets
|
||||||||
(In
millions, except share amounts) At December 31
|
2009
|
2008
|
||||||
Assets
|
||||||||
Current
Assets
|
||||||||
Cash
and cash equivalents
|
$ | 2,846 | $ | 2,800 | ||||
Accounts
and notes receivable:
|
||||||||
Trade
(net of allowance for doubtful receivables - 2009: $160; 2008:
$124)
|
5,656 | 3,782 | ||||||
Other
|
3,539 | 3,074 | ||||||
Inventories
|
6,847 | 6,036 | ||||||
Deferred
income tax assets - current
|
672 | 368 | ||||||
Total
current assets
|
19,560 | 16,060 | ||||||
Investments
|
||||||||
Investment
in nonconsolidated affiliates
|
3,224 | 3,204 | ||||||
Other
investments (investments carried at fair value - 2009: $2,136; 2008:
$1,853)
|
2,561 | 2,245 | ||||||
Noncurrent
receivables
|
210 | 276 | ||||||
Total
investments
|
5,995 | 5,725 | ||||||
Property
|
||||||||
Property
|
53,567 | 48,391 | ||||||
Less
accumulated depreciation
|
35,426 | 34,097 | ||||||
Net
property
|
18,141 | 14,294 | ||||||
Other
Assets
|
||||||||
Goodwill
|
13,114 | 3,394 | ||||||
Other
intangible assets (net of accumulated amortization - 2009: $1,302; 2008:
$825)
|
5,966 | 829 | ||||||
Deferred
income tax assets - noncurrent
|
2,039 | 3,900 | ||||||
Asbestos-related
insurance receivables - noncurrent
|
330 | 658 | ||||||
Deferred
charges and other assets
|
792 | 614 | ||||||
Total
other assets
|
22,241 | 9,395 | ||||||
Total
Assets
|
$ | 65,937 | $ | 45,474 | ||||
Liabilities
and Equity
|
||||||||
Current
Liabilities
|
||||||||
Notes
payable
|
$ | 2,139 | $ | 2,360 | ||||
Long-term
debt due within one year
|
1,082 | 1,454 | ||||||
Accounts
payable:
|
||||||||
Trade
|
4,153 | 3,306 | ||||||
Other
|
2,014 | 2,227 | ||||||
Income
taxes payable
|
186 | 637 | ||||||
Deferred
income tax liabilities - current
|
78 | 88 | ||||||
Dividends
payable
|
254 | 411 | ||||||
Accrued
and other current liabilities
|
3,200 | 2,625 | ||||||
Total
current liabilities
|
13,106 | 13,108 | ||||||
Long-Term
Debt
|
19,152 | 8,042 | ||||||
Other
Noncurrent Liabilities
|
||||||||
Deferred
income tax liabilities - noncurrent
|
1,285 | 746 | ||||||
Pension
and other postretirement benefits - noncurrent
|
7,242 | 5,466 | ||||||
Asbestos-related
liabilities - noncurrent
|
734 | 824 | ||||||
Other
noncurrent obligations
|
3,294 | 3,208 | ||||||
Total
other noncurrent liabilities
|
12,555 | 10,244 | ||||||
Preferred
Securities of Subsidiaries
|
- | 500 | ||||||
Stockholders'
Equity
|
||||||||
Preferred
stock, series A ($1.00 par, $1,000 liquidation preference, 4,000,000
shares)
|
4,000 | - | ||||||
Common
stock (authorized 1,500,000,000 shares of $2.50 par value each;
issued
1,162,375,462 shares)
|
2,906 | 2,453 | ||||||
Additional
paid-in capital
|
1,913 | 872 | ||||||
Retained
earnings
|
16,704 | 17,013 | ||||||
Accumulated
other comprehensive loss
|
(3,892 | ) | (4,389 | ) | ||||
Unearned
ESOP shares
|
(519 | ) | - | |||||
Treasury
stock at cost (2009: 12,158,605 shares; 2008: 57,031,291
shares)
|
(557 | ) | (2,438 | ) | ||||
The
Dow Chemical Company's stockholders' equity
|
20,555 | 13,511 | ||||||
Noncontrolling
interests
|
569 | 69 | ||||||
Total
equity
|
21,124 | 13,580 | ||||||
Total
Liabilities and Equity
|
$ | 65,937 | $ | 45,474 | ||||
See
Notes to the Consolidated Financial Statements.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||
Consolidated
Statements of Cash Flows
|
||||||||||||
(In
millions) For the years ended December 31
|
2009
|
2008
|
2007
|
|||||||||
Operating
Activities
|
||||||||||||
Net
Income
|
$ | 676 | $ | 654 | $ | 2,985 | ||||||
Adjustments
to reconcile net income to net cash provided by operating
activities:
|
||||||||||||
Depreciation
and amortization
|
2,827 | 2,236 | 2,190 | |||||||||
Purchased
in-process research and development charges
|
7 | 44 | 57 | |||||||||
Provision
(Credit) for deferred income tax
|
(652 | ) | (260 | ) | 494 | |||||||
Earnings
of nonconsolidated affiliates less than (in excess of) dividends
received
|
60 | 49 | (348 | ) | ||||||||
Pension
contributions
|
(355 | ) | (185 | ) | (183 | ) | ||||||
Net
loss (gain) on sales of investments
|
(9 | ) | 1 | (143 | ) | |||||||
Net
gain on sales of property, businesses and consolidated
companies
|
(256 | ) | (127 | ) | (108 | ) | ||||||
Other
net loss (gain)
|
(22 | ) | 15 | (75 | ) | |||||||
Net
gain on sales of ownership interest in nonconsolidated
affiliates
|
(795 | ) | - | - | ||||||||
Goodwill
impairment losses
|
7 | 239 | - | |||||||||
Restructuring
charges
|
684 | 837 | 577 | |||||||||
Asbestos-related
credit
|
- | (54 | ) | - | ||||||||
Excess
tax benefits from share-based payment arrangements
|
(10 | ) | (8 | ) | (31 | ) | ||||||
Changes
in assets and liabilities, net of effects of acquired and divested
companies:
|
||||||||||||
Accounts
and notes receivable
|
(990 | ) | 2,853 | (1,002 | ) | |||||||
Inventories
|
63 | 812 | (712 | ) | ||||||||
Accounts
payable
|
304 | (1,062 | ) | 799 | ||||||||
Other
assets and liabilities
|
536 | (1,333 | ) | (16 | ) | |||||||
Cash
provided by operating activities
|
2,075 | 4,711 | 4,484 | |||||||||
Investing
Activities
|
||||||||||||
Capital
expenditures
|
(1,410 | ) | (2,276 | ) | (2,075 | ) | ||||||
Capital
expenditures of consolidated variable interest entity
|
(273 | ) | - | - | ||||||||
Proceeds
from sales of property and businesses
|
294 | 252 | 211 | |||||||||
Acquisitions
of businesses
|
(35 | ) | - | (143 | ) | |||||||
Purchases
of previously leased assets
|
(713 | ) | (63 | ) | (30 | ) | ||||||
Investments
in consolidated companies, net of cash acquired
|
(15,045 | ) | (336 | ) | (867 | ) | ||||||
Proceeds
from sales of consolidated companies
|
1,563 | 66 | - | |||||||||
Investments
in nonconsolidated affiliates
|
(122 | ) | (331 | ) | (78 | ) | ||||||
Distributions
from nonconsolidated affiliates
|
9 | 6 | 63 | |||||||||
Proceeds
from sales of ownership interests in nonconsolidated
affiliates
|
1,413 | - | 30 | |||||||||
Purchase
of unallocated Rohm and Haas ESOP shares
|
(552 | ) | - | - | ||||||||
Purchases
of investments
|
(580 | ) | (855 | ) | (1,952 | ) | ||||||
Proceeds
from sales and maturities of investments
|
684 | 800 | 1,983 | |||||||||
Cash
used in investing activities
|
(14,767 | ) | (2,737 | ) | (2,858 | ) | ||||||
Financing
Activities
|
||||||||||||
Changes
in short-term notes payable
|
(418 | ) | 825 | 1,220 | ||||||||
Proceeds
from revolving credit facility
|
3,000 | - | - | |||||||||
Payments
on revolving credit facility
|
(3,000 | ) | - | - | ||||||||
Proceeds
from Term Loan
|
9,226 | - | - | |||||||||
Payments
on Term Loan
|
(9,226 | ) | - | - | ||||||||
Proceeds
from issuance of long-term debt
|
8,283 | 1,453 | 21 | |||||||||
Payments
on long-term debt
|
(1,790 | ) | (760 | ) | (1,354 | ) | ||||||
Redemption
of preferred securities of subsidiaries and payment of accrued
dividends
|
(520 | ) | - | - | ||||||||
Purchases
of treasury stock
|
(5 | ) | (898 | ) | (1,462 | ) | ||||||
Proceeds
from issuance of common stock
|
966 | - | - | |||||||||
Proceeds
from issuance of preferred stock
|
7,000 | - | - | |||||||||
Proceeds
from sales of common stock
|
555 | 72 | 379 | |||||||||
Issuance
costs for debt and equity securities
|
(368 | ) | (70 | ) | - | |||||||
Excess
tax benefits from share-based payment arrangements
|
10 | 8 | 31 | |||||||||
Distributions
to noncontrolling interests
|
(24 | ) | (45 | ) | (51 | ) | ||||||
Dividends
paid to stockholders
|
(1,030 | ) | (1,563 | ) | (1,512 | ) | ||||||
Cash
provided by (used in) financing activities
|
12,659 | (978 | ) | (2,728 | ) | |||||||
Effect
of Exchange Rate Changes on Cash
|
79 | 68 | 81 | |||||||||
Summary
|
||||||||||||
Increase
(Decrease) in cash and cash equivalents
|
46 | 1,064 | (1,021 | ) | ||||||||
Cash
and cash equivalents at beginning of year
|
2,800 | 1,736 | 2,757 | |||||||||
Cash
and cash equivalents at end of year
|
$ | 2,846 | $ | 2,800 | $ | 1,736 | ||||||
See
Notes to the Consolidated Financial Statements.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||
Consolidated
Statements of Equity
|
||||||||||||
(In
millions) For the years ended December 31
|
2009
|
2008
|
2007
|
|||||||||
Preferred
Stock
|
||||||||||||
Balance
at beginning of year
|
- | - | - | |||||||||
Preferred
stock issued
|
$ | 7,000 | - | - | ||||||||
Preferred
stock repurchased
|
(2,500 | ) | - | - | ||||||||
Preferred
stock converted to common stock
|
(500 | ) | - | - | ||||||||
Balance
at end of year
|
4,000 | - | - | |||||||||
Common
Stock
|
||||||||||||
Balance
at beginning of year
|
2,453 | $ | 2,453 | $ | 2,453 | |||||||
Common
stock issued
|
453 | - | - | |||||||||
Balance
at end of year
|
2,906 | 2,453 | 2,453 | |||||||||
Additional
Paid-in Capital
|
||||||||||||
Balance
at beginning of year
|
872 | 902 | 830 | |||||||||
Common
stock issued
|
2,643 | - | - | |||||||||
Sale
of shares to ESOP
|
(1,529 | ) | - | - | ||||||||
Stock-based
compensation and allocation of ESOP shares
|
(73 | ) | (30 | ) | 72 | |||||||
Balance
at end of year
|
1,913 | 872 | 902 | |||||||||
Retained
Earnings
|
||||||||||||
Balance
at beginning of year
|
17,013 | 18,004 | 16,987 | |||||||||
Net
income available for The Dow Chemical Company common
stockholders
|
336 | 579 | 2,887 | |||||||||
Dividends
declared on common stock (Per share: $0.60 in 2009, $1.68 in 2008
and
$1.635 in 2007)
|
(639 | ) | (1,556 | ) | (1,548 | ) | ||||||
Other
|
(6 | ) | (14 | ) | (32 | ) | ||||||
Impact
of the adoption of FIN No. 48
|
- | - | (290 | ) | ||||||||
Balance
at end of year
|
16,704 | 17,013 | 18,004 | |||||||||
Accumulated
Other Comprehensive Loss
|
||||||||||||
Unrealized
(Losses) Gains on Investments at beginning of year
|
(111 | ) | 71 | 42 | ||||||||
Net
change in unrealized gains (losses)
|
190 | (182 | ) | 29 | ||||||||
Balance
at end of year
|
79 | (111 | ) | 71 | ||||||||
Cumulative
Translation Adjustments at beginning of year
|
221 | 723 | (12 | ) | ||||||||
Translation
adjustments
|
403 | (502 | ) | 735 | ||||||||
Balance
at end of year
|
624 | 221 | 723 | |||||||||
Pension
and Other Postretirement Benefit Plans at beginning of
year
|
(4,251 | ) | (989 | ) | (2,192 | ) | ||||||
Net
prior service credit (cost)
|
19 | 16 | (74 | ) | ||||||||
Net
(loss) gain
|
(355 | ) | (3,278 | ) | 1,277 | |||||||
Balance
at end of year
|
(4,587 | ) | (4,251 | ) | (989 | ) | ||||||
Accumulated
Derivative (Loss) Gain at beginning of year
|
(248 | ) | 25 | (73 | ) | |||||||
Net
hedging results
|
(65 | ) | (452 | ) | 20 | |||||||
Reclassification
to earnings
|
305 | 179 | 78 | |||||||||
Balance
at end of year
|
(8 | ) | (248 | ) | 25 | |||||||
Total
accumulated other comprehensive loss
|
(3,892 | ) | (4,389 | ) | (170 | ) | ||||||
Unearned
ESOP Shares
|
||||||||||||
Balance
at beginning of year
|
- | - | - | |||||||||
Shares
acquired
|
(553 | ) | - | - | ||||||||
Shares
allocated to ESOP participants
|
34 | - | - | |||||||||
Balance
at end of year
|
(519 | ) | - | - | ||||||||
Treasury
Stock
|
||||||||||||
Balance
at beginning of year
|
(2,438 | ) | (1,800 | ) | (970 | ) | ||||||
Purchases
|
(5 | ) | (898 | ) | (1,455 | ) | ||||||
Sale
of shares to ESOP
|
1,529 | - | - | |||||||||
Issuance
to employees and employee plans
|
357 | 260 | 625 | |||||||||
Balance
at end of year
|
(557 | ) | (2,438 | ) | (1,800 | ) | ||||||
The
Dow Chemical Company's Stockholders' Equity
|
20,555 | 13,511 | 19,389 | |||||||||
Noncontrolling
Interests
|
||||||||||||
Balance
at beginning of year
|
69 | 414 | 365 | |||||||||
Net
income attributable to noncontrolling interests
|
28 | 75 | 98 | |||||||||
Purchase
of noncontrolling interests' share of subsidiaries
|
- | (376 | ) | (1 | ) | |||||||
Distributions
to noncontrolling interests
|
(24 | ) | (45 | ) | (51 | ) | ||||||
Acquisition
of Rohm and Haas Company noncontrolling interests
|
432 | - | - | |||||||||
Consolidation
of variable interest entity
|
46 | - | - | |||||||||
Other
|
18 | 1 | 3 | |||||||||
Balance
at end of year
|
569 | 69 | 414 | |||||||||
Total
Equity
|
$ | 21,124 | $ | 13,580 | $ | 19,803 | ||||||
See
Notes to the Consolidated Financial Statements.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||
Consolidated
Statements of Comprehensive Income
|
||||||||||||
(In
millions) For the years ended December 31
|
2009
|
2008
|
2007
|
|||||||||
Net
Income
|
$ | 676 | $ | 654 | $ | 2,985 | ||||||
Other
Comprehensive Income (Loss), Net of Tax (tax amounts shown below for 2009,
2008, 2007)
|
||||||||||||
Unrealized
gains (losses) on investments:
|
||||||||||||
Unrealized
holding gains (losses) during the period (net of tax of $53, $(70),
$42)
|
134 | (158 | ) | 70 | ||||||||
Less: Reclassification
adjustments for net amounts included in net income (net of tax
of $30,
$(13), $(22))
|
56 | (24 | ) | (41 | ) | |||||||
Cumulative
translation adjustments (net of tax of $(15), $(22), $5)
|
403 | (502 | ) | 735 | ||||||||
Defined
benefit pension plans:
|
||||||||||||
Prior
service cost arising during period (net of tax of $(1), $-,
$(53))
|
(1 | ) | (4 | ) | (88 | ) | ||||||
Net
gain (loss) arising during period (net of tax of $(257), $(1,561),
$630)
|
(433 | ) | (3,307 | ) | 1,150 | |||||||
Less: Amortization
of prior service cost included in net periodic pension costs (net of
tax
of $8, $8, $5)
|
20 | 20 | 14 | |||||||||
Less: Amortization
of net loss included in net periodic pension costs (net of tax of
$40,
$13, $67)
|
78 | 29 | 127 | |||||||||
Net
gains (losses) on cash flow hedging derivative instruments (net of tax of
$56, $(49), $14)
|
240 | (273 | ) | 98 | ||||||||
Total
other comprehensive income (loss)
|
497 | (4,219 | ) | 2,065 | ||||||||
Comprehensive
Income (Loss)
|
1,173 | (3,565 | ) | 5,050 | ||||||||
Comprehensive
income attributable to noncontrolling interests, net of
tax
|
28 | 75 | 98 | |||||||||
Comprehensive
Income (Loss) Attributable to The Dow Chemical Company
|
$ | 1,145 | $ | (3,640 | ) | $ | 4,952 | |||||
See
Notes to the Consolidated Financial Statements.
|
Note
|
Page
|
||
A
|
Summary
of Significant Accounting Policies
|
84
|
|
B
|
Recent
Accounting Guidance
|
87
|
|
C
|
Restructuring
|
90
|
|
D
|
Acquisitions
|
98
|
|
E
|
Divestitures
|
101
|
|
F
|
Inventories
|
103
|
|
G
|
Property
|
103
|
|
H
|
Nonconsolidated
Affiliates and Related Company Transactions
|
104
|
|
I
|
Goodwill
and Other Intangible Assets
|
106
|
|
J
|
Financial
Instruments
|
108
|
|
K
|
Fair
Value Measurements
|
114
|
|
L
|
Supplementary
Information
|
116
|
|
M
|
Earnings
Per Share Calculations
|
117
|
|
N
|
Commitments
and Contingent Liabilities
|
118
|
|
O
|
Notes
Payable, Long-Term Debt and Available Credit Facilities
|
126
|
|
P
|
Pension
Plans and Other Postretirement Benefits
|
129
|
|
Q
|
Leased
Property
|
136
|
|
R
|
Variable
Interest Entities
|
136
|
|
S
|
Stock-Based
Compensation
|
137
|
|
T
|
Limited
Partnership
|
141
|
|
U
|
Preferred
Securities of Subsidiaries
|
141
|
|
V
|
Redeemable
Preferred Stocks
|
142
|
|
W
|
Stockholders’
Equity
|
142
|
|
X
|
Income
Taxes
|
144
|
|
Y
|
Operating
Segments and Geographic Areas
|
147
|
|
·
|
The
Consolidated Statements of Income now present “Net Income,” which includes
“Net income attributable to noncontrolling interests” and “Net Income
Attributable to The Dow Chemical Company.” “Net Income Available for The
Dow Chemical Company Common Stockholders” is equivalent to the previously
reported “Net Income Available for Common Stockholders.” No change was
required to the presentation of earnings per
share.
|
|
·
|
The
Consolidated Balance Sheets now present “Noncontrolling interests” as a
component of “Total equity.” “Noncontrolling interests” is equivalent to
the previously reported “Minority Interest in Subsidiaries.” “The Dow
Chemical Company’s stockholders’ equity” is equivalent to the previously
reported “Net stockholders’
equity.”
|
|
·
|
The
Consolidated Statements of Cash Flows now begin with “Net Income” instead
of “Net Income Available for Common
Stockholders.”
|
|
·
|
The
Consolidated Statements of Equity now include a section for
“Noncontrolling interests.”
|
|
·
|
The
Consolidated Statements of Comprehensive Income now separately present the
components of “Comprehensive Income (Loss),” “Comprehensive income
attributable to noncontrolling interests, net of tax” and “Comprehensive
Income (Loss) Attributable to The Dow Chemical Company.” “Comprehensive
Income (Loss) Attributable to The Dow Chemical Company” is equivalent to
the previously reported “Comprehensive
Income.”
|
2009
Restructuring Charges by Operating Segment
|
||||||||||||||||
In
millions
|
Impairment
of Long-Lived Assets and Other Assets
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Electronic
and Specialty Materials
|
$ | 68 | - | - | $ | 68 | ||||||||||
Coatings
and Infrastructure
|
167 | $ | 4 | - | 171 | |||||||||||
Performance
Products
|
73 | - | - | 73 | ||||||||||||
Basic
Plastics
|
1 | - | - | 1 | ||||||||||||
Basic
Chemicals
|
75 | - | - | 75 | ||||||||||||
Hydrocarbons
and Energy
|
65 | - | - | 65 | ||||||||||||
Corporate
|
5 | 64 | $ | 155 | 224 | |||||||||||
Total
2009 restructuring charges
|
$ | 454 | $ | 68 | $ | 155 | $ | 677 | ||||||||
Adjustments
to restructuring charges:
|
||||||||||||||||
2009
- Corporate
|
- | 13 | - | 13 | ||||||||||||
2008
- Corporate
|
- | - | 19 | 19 | ||||||||||||
2007
- Health and Agricultural Sciences
|
- | (15 | ) | - | (15 | ) | ||||||||||
2007
- Corporate
|
- | - | (5 | ) | (5 | ) | ||||||||||
Net
2009 restructuring charges
|
$ | 454 | $ | 66 | $ | 169 | $ | 689 |
|
·
|
Due
to continued weakness in the global economy, the decision was made to shut
down a number of hydrocarbon and basic chemicals facilities, with an
impact of $126 million, including the
following:
|
|
·
|
Ethylene
manufacturing facility in Hahnville, Louisiana. A write-off of the net
book value of the related buildings, machinery and equipment against the
Hydrocarbons and Energy segment was recorded. The facility shut down in
the second quarter of 2009.
|
|
·
|
Ethylene
oxide/ethylene glycol manufacturing facility in Hahnville, Louisiana. A
write-off of the net book value of the related buildings, machinery and
equipment against the Basic Chemicals segment was recorded. The facility
shut down in the second quarter of
2009.
|
|
·
|
Ethylene
dichloride and vinyl chloride monomer manufacturing facility in
Plaquemine, Louisiana. A write-down of the net book value of the related
buildings, machinery and equipment against the Basic Chemicals segment was
recorded. The facility will shut down in
mid-2011.
|
|
·
|
With
the completion of the Company’s acquisition of Rohm and Haas, the
following charges were recognized:
|
|
·
|
Due
to an expected loss arising from the FTC required divestitures of certain
acrylic monomer and specialty latex assets within eight months of the
closing of the acquisition of Rohm and Haas, the Company recognized an
impairment charge of $205 million against the Coatings and
Infrastructure ($134 million) and Performance Products ($71 million)
segments in the second quarter of 2009. The divestiture of the assets was
completed in January 2010 (see
Note E).
|
|
·
|
The
decision was made to shut down a number of small manufacturing facilities
to optimize the assets of the Company. Write-downs of $96 million were
recorded in the second quarter of 2009, primarily impacting the Electronic
and Specialty Materials ($66 million) and Coatings and Infrastructure ($28
million) segments.
|
2009
Restructuring Activities
In
millions
|
Impairment
of Long-Lived Assets and Other Assets
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Restructuring
charges recognized in the second quarter of 2009
|
$ | 454 | $ | 68 | $ | 155 | $ | 677 | ||||||||
Cash
payments
|
- | - | (72 | ) | (72 | ) | ||||||||||
Charges
against reserve
|
(454 | ) | (13 | ) | - | (467 | ) | |||||||||
Adjustment
to reserve
|
- | 13 | - | 13 | ||||||||||||
Foreign
currency impact
|
- | - | 1 | 1 | ||||||||||||
Reserve
balance at December 31, 2009
|
- | $ | 68 | $ | 84 | $ | 152 |
Restructuring
Reserve Assumed from Rohm and Haas
|
||||
In
millions
|
Severance
Costs
|
|||
Reserve
balance assumed on April 1, 2009
|
$ | 122 | ||
Cash
payments
|
(43 | ) | ||
Adjustments
to reserve
|
(9 | ) | ||
Foreign
currency impact
|
(2 | ) | ||
Reserve
balance at December 31, 2009
|
$ | 68 |
2008
Restructuring Charges by Operating Segment
|
||||||||||||||||
In
millions
|
Impairment
of Long-Lived Assets and Other Assets
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Electronic
and Specialty Materials
|
$ | 10 | - | - | $ | 10 | ||||||||||
Coatings
and Infrastructure
|
15 | $ | 1 | - | 16 | |||||||||||
Performance
Systems
|
67 | 1 | - | 68 | ||||||||||||
Performance
Products
|
39 | - | - | 39 | ||||||||||||
Basic
Plastics
|
96 | 2 | - | 98 | ||||||||||||
Basic
Chemicals
|
86 | 20 | - | 106 | ||||||||||||
Hydrocarbons
and Energy
|
15 | 3 | - | 18 | ||||||||||||
Corporate
|
8 | 101 | $ | 321 | 430 | |||||||||||
Total
2008 restructuring charges
|
$ | 336 | $ | 128 | $ | 321 | $ | 785 | ||||||||
Adjustments
to 2007 restructuring charge:
|
||||||||||||||||
Performance
Systems
|
- | 2 | - | 2 | ||||||||||||
Health
and Agricultural Sciences
|
- | 3 | - | 3 | ||||||||||||
Basic
Plastics
|
30 | 20 | - | 50 | ||||||||||||
Corporate
|
- | 5 | - | 5 | ||||||||||||
Adjustments
to 2006 restructuring charge:
|
||||||||||||||||
Basic
Chemicals
|
- | (3 | ) | - | (3 | ) | ||||||||||
Corporate
|
- | - | (3 | ) | (3 | ) | ||||||||||
Net
2008 restructuring charges
|
$ | 366 | $ | 155 | $ | 318 | $ | 839 |
|
·
|
Due
to a severe economic downturn, the Company decided in the fourth quarter
of 2008 to shut down a number of facilities, including the
following:
|
|
·
|
Chlor-alkali
manufacturing facility in Oyster Creek, Texas. A $31 million
write-off of the net book value of the related buildings, machinery and
equipment against the Basic Chemicals segment was recorded in the fourth
quarter of 2008. This facility was shut down in the first quarter of
2009.
|
|
·
|
Styrene
and styrene derivatives manufacturing facilities principally in Freeport,
Texas; Pittsburg, California; Terneuzen, The Netherlands; King’s Lynn,
England; and Varennes, Canada. A $37 million write-off of the net
book value of the related buildings, machinery and equipment was recorded
in the fourth quarter of 2008 against the Hydrocarbons and Energy
($14 million), Basic Plastics ($6 million), Performance Products
($10 million) and Coatings and Infrastructure ($2 million)
segments, as well as Corporate ($5 million). The facilities were shut
down in the fourth quarter of 2009.
|
|
·
|
Facilities
that manufacture NORDEL™ hydrocarbon rubber in Seadrift, Texas, and TYRIN™
chlorinated polyethylene in Plaquemine, Louisiana. A $36 million
write-down of the net book value of the related buildings, machinery and
equipment against the Performance Systems segment was recorded in the
fourth quarter of 2008. Both facilities were closed in the first quarter
of 2009.
|
|
·
|
Solution
vinyl resin manufacturing facilities in Texas City, Texas. A
$26 million write-down of the net book value of the related
buildings, machinery and equipment against the Performance Products
segment was recorded in the fourth quarter of 2008. This plant was shut
down in the third quarter of 2009.
|
|
·
|
Perchloroethylene/carbon
tetrachloride manufacturing facility in Aratu, Brazil. An $11 million
write-off of the net book value of the related buildings, machinery and
equipment against the Basic Chemicals segment was recorded in the fourth
quarter of 2008. This facility is expected to be shut down by the end of
the first quarter of 2010.
|
|
·
|
In
addition to the locations described above, the restructuring charges for
plant closures included $26 million related to the shutdown of
several small production
facilities.
|
|
·
|
The
Company decided in the fourth quarter of 2008 to pursue strategic
alternatives regarding its Wilton, England, ethylene oxide/ethylene glycol
(“EO/EG”) plant. Based on the results of asset impairment testing, an
impairment charge of $30 million against the Basic Chemicals segment
was recorded in the fourth quarter of 2008. The plant was shut down in
January 2010.
|
|
·
|
Due
to an expected loss on the pending sale of the automotive sealants
business in Europe, an impairment charge of $8 million against the
Performance Systems segment was recorded in the fourth quarter of 2008.
The business was sold in the first quarter of
2009.
|
|
·
|
Due
to a change in scope, the Company’s investment (primarily engineering
costs) in a project to form a joint venture to design, build and operate a
petrochemical complex in Oman was written down. An $83 million
write-down of the project-related spending against the Basic Plastics
segment was recorded in the fourth quarter of
2008.
|
2008
Restructuring Activities
In
millions
|
Impairment
of Long-Lived Assets and Other Assets
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Restructuring
charges recognized in the fourth quarter of 2008
|
$ | 336 | $ | 128 | $ | 321 | $ | 785 | ||||||||
Cash
payments
|
- | - | (2 | ) | (2 | ) | ||||||||||
Charges
against reserve
|
(336 | ) | - | - | (336 | ) | ||||||||||
Reserve
balance at December 31, 2008
|
- | $ | 128 | $ | 319 | $ | 447 | |||||||||
Adjustment
to reserve
|
- | - | 19 | 19 | ||||||||||||
Cash
payments
|
- | - | (287 | ) | (287 | ) | ||||||||||
Foreign
currency impact
|
- | 7 | 2 | 9 | ||||||||||||
Reserve
balance at December 31, 2009
|
- | $ | 135 | $ | 53 | $ | 188 |
2007
Restructuring Charges by Operating Segment
|
||||||||||||||||
In
millions
|
Impairment
of Long-Lived Assets, Other Intangible Assets and Equity
Investments
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Electronic
and Specialty Materials
|
$ | 25 | $ | 2 | - | $ | 27 | |||||||||
Coatings
and Infrastructure
|
19 | 1 | - | 20 | ||||||||||||
Health
and Agricultural Sciences
|
58 | 19 | - | 77 | ||||||||||||
Performance
Systems
|
123 | 32 | - | 155 | ||||||||||||
Performance
Products
|
59 | - | - | 59 | ||||||||||||
Basic
Plastics
|
96 | - | - | 96 | ||||||||||||
Basic
Chemicals
|
7 | - | - | 7 | ||||||||||||
Hydrocarbons
and Energy
|
31 | 13 | - | 44 | ||||||||||||
Corporate
|
4 | 15 | $ | 86 | 105 | |||||||||||
Total
2007 restructuring charges
|
$ | 422 | $ | 82 | $ | 86 | $ | 590 | ||||||||
Adjustments
to 2006 restructuring charge:
|
||||||||||||||||
Performance
Products
|
- | (4 | ) | - | (4 | ) | ||||||||||
Corporate
|
- | - | (8 | ) | (8 | ) | ||||||||||
Net
2007 restructuring charges
|
$ | 422 | $ | 78 | $ | 78 | $ | 578 |
|
·
|
Due
to overcapacity within the industry, a disadvantaged cost position and
increasing pressure from generic suppliers, the Company launched an
information/consultation process with local employee representatives on a
closure project in the fourth quarter of 2007 and recorded an asset
impairment charge related to its agricultural products manufacturing site
located in Lauterbourg, France. Upon completion of the
information/consultation process, the plant was shut down in the fourth
quarter of 2008. A $44 million write-down of the net book value of
the related buildings, machinery and equipment against the Health and
Agricultural Sciences segment was recorded in the fourth quarter of
2007.
|
|
·
|
The
Company evaluated the economic and financial feasibility of its styrene
plant in Camaçari, Brazil, and due to raw material competitiveness, the
age of the facility, as well as the ready availability of styrene within
the global marketplace, the Company idled the facility in the fourth
quarter of 2007 and recorded a $14 million write-down of the net book
value of the related buildings, machinery and equipment against the
Hydrocarbons and Energy segment. The assets were sold in the fourth
quarter of 2009.
|
|
·
|
The
Company decided to close its hydroxyethyl cellulose manufacturing facility
located in Aratu, Brazil, due to a number of factors, including capacity
limitations, high structural and raw material costs, and older technology.
A $12 million write-down of the net book value of the related
buildings, machinery and equipment was recorded against the Electronic and
Specialty Materials segment in the fourth quarter of 2007. The facility
was shut down in the first quarter of
2008.
|
|
·
|
The
Company determined that the operating costs of its fiber solution
manufacturing plant in Tarragona, Spain, could not be sustained. The
Company is continuing to evaluate more economically viable alternative
manufacturing options. As a result, the Company recorded a
$29 million impairment write-down of the net book value of the
related buildings, machinery and equipment against the Performance Systems
segment in the fourth quarter of
2007.
|
|
·
|
Due
to a number of factors, including the inability to secure an economically
sustainable source of propylene and the use of older technologies at the
plant, Union Carbide decided in the fourth quarter of 2007 to shut down
its polypropylene facility at St. Charles Operations in Hahnville,
Louisiana. As a result of the decision, a $23 million write-down of
the net book value of the related buildings, machinery and equipment was
recorded against the Basic Plastics segment in the fourth quarter of 2007.
The plant was shut down in the first quarter of
2008.
|
|
·
|
The
Company determined that it would not be possible to renegotiate an
economically viable contract manufacturing agreement to continue the
operations of the rubber plant located in Berre, France. A
$27 million impairment write-down of the net book value of the
related buildings, machinery and equipment was recorded against the
Performance Systems segment in the fourth quarter of 2007. The plant was
shut down in the second quarter of
2008.
|
|
·
|
The
Company assessed the long-term profitability of its participation in the
automotive sealants business and determined that the projected results are
inconsistent with the financial performance expected of a market-facing
business. As a result, in the fourth quarter of 2007, the Company made the
decision to exit the automotive sealants business in North America, Asia
Pacific and Latin America by mid-2009, which was completed in 2009. The
business explored strategic options within Europe and decided in the
fourth quarter of 2008 to divest the automotive sealants business within
Europe. A $58 million write-down of the net book value of the related
buildings, machinery and equipment against the Performance Systems segment
was recorded in the fourth quarter of
2007.
|
|
·
|
Due
to an unfavorable financial outlook, reflecting significant long-term
economic challenges, the Company determined in the fourth quarter of 2007
that its equity investment in Pétromont, a 50 percent owned company,
was other-than-temporarily impaired and recorded a $46 million
write-down of its interest in Pétromont against the Basic Plastics
segment. In the fourth quarter of 2008, the joint venture announced the
permanent shutdown of its operations. As a result of this announcement,
the Company recorded an additional charge of $50 million in the
fourth quarter of 2008.
|
|
·
|
Due
to the loss of a significant portion of business and the lack of
replacement business opportunities, the Company determined its equity
investment in Dow Reichhold Specialty Latex LLC, a 50:50 joint venture, to
be other-than-temporarily impaired and recorded a $42 million
write-down of its interest in Dow Reichhold Specialty Latex LLC against
the Performance Products segment in the fourth quarter of 2007. An
agreement was reached in the third quarter of 2008 to end the Company’s
involvement in the joint venture.
|
2007
Restructuring Activities
In
millions
|
Impairment
of Long-Lived Assets, Other Intangible Assets and Equity
Investments
|
Costs
associated with Exit or Disposal Activities
|
Severance
Costs
|
Total
|
||||||||||||
Restructuring
charges recognized in the fourth quarter of 2007
|
$ | 422 | $ | 82 | $ | 86 | $ | 590 | ||||||||
Cash
payments
|
- | - | (1 | ) | (1 | ) | ||||||||||
Charges
against reserve
|
(422 | ) | (3 | ) | - | (425 | ) | |||||||||
Reserve
balance at December 31, 2007
|
- | $ | 79 | $ | 85 | $ | 164 | |||||||||
Adjustments
to reserve
|
$ | 30 | 30 | - | 60 | |||||||||||
Cash
payments
|
- | (7 | ) | (47 | ) | (54 | ) | |||||||||
Charges
against reserve
|
(30 | ) | - | - | (30 | ) | ||||||||||
Foreign
currency impact
|
- | (9 | ) | (1 | ) | (10 | ) | |||||||||
Reserve
balance at December 31, 2008
|
- | $ | 93 | $ | 37 | $ | 130 | |||||||||
Adjustments
to reserve
|
- | (15 | ) | (5 | ) | (20 | ) | |||||||||
Cash
payments
|
- | (38 | ) | (23 | ) | (61 | ) | |||||||||
Foreign
currency impact
|
- | 11 | - | 11 | ||||||||||||
Reserve
balance at December 31, 2009
|
- | $ | 51 | $ | 9 | $ | 60 |
Rohm
and Haas Results of Operations
In
millions
|
April 1
- Dec. 31, 2009
|
|||
Net
sales
|
$ | 5,599 | ||
Loss
from Continuing Operations Before Income Taxes
|
$ | (134 | ) |
Pro
Forma Results of Operations
In
millions, except per share amounts
|
2009
|
2008
|
||||||
Net
sales
|
$ | 45,853 | $ | 65,704 | ||||
Net
income (loss) available for The Dow Chemical Company common
stockholders
|
$ | (501 | ) | $ | (317 | ) | ||
Earnings
(Loss) per common share - diluted
|
$ | (0.45 | ) | $ | (0.29 | ) |
Assets
Acquired and Liabilities Assumed on April 1, 2009
In
millions
|
Initial
Valuation
|
Net
Adjustments to Fair Value
|
As
Adjusted
|
|||||||||
Purchase
Price
|
$ | 15,681 | - | $ | 15,681 | |||||||
Fair
Value of Assets Acquired
|
||||||||||||
Current
assets
|
$ | 2,710 | - | $ | 2,710 | |||||||
Property
|
3,930 | $ | (138 | ) | 3,792 | |||||||
Other
intangible assets (1)
|
4,475 | 830 | 5,305 | |||||||||
Other
assets
|
1,288 | 32 | 1,320 | |||||||||
Net
assets of the Salt business (2)
|
1,475 | (167 | ) | 1,308 | ||||||||
Total
Assets Acquired
|
$ | 13,878 | $ | 557 | $ | 14,435 | ||||||
Fair
Value of Liabilities and Noncontrolling Interests Assumed
|
||||||||||||
Current
liabilities
|
$ | 1,218 | $ | (11 | ) | $ | 1,207 | |||||
Long-term
debt
|
2,528 | 13 | 2,541 | |||||||||
Accrued
and other liabilities and noncontrolling interests
|
702 | - | 702 | |||||||||
Pension
benefits
|
1,119 | - | 1,119 | |||||||||
Deferred
tax liabilities – noncurrent
|
2,482 | 311 | 2,793 | |||||||||
Total
Liabilities and Noncontrolling Interests Assumed
|
$ | 8,049 | 313 | $ | 8,362 | |||||||
Goodwill
(1)
|
$ | 9,852 | $ | (244 | ) | $ | 9,608 |
(1)
|
See Note I for additional
information.
|
(2)
|
Morton International, Inc.; see
Note E.
|
Deferred
Tax Liabilities Assumed on April 1, 2009
In
millions
|
As
Adjusted
|
|||
Intangible
assets
|
$ | 1,491 | ||
Property
|
475 | |||
Long-term
debt
|
233 | |||
Inventory
|
80 | |||
Other
accruals and reserves
|
514 | |||
Total
Deferred Tax Liabilities
|
$ | 2,793 |
In-Process
Research and Development Projects Acquired
In
millions
|
Date
of Acquisition
|
Estimated
Value Assigned to IPR&D
|
|||
2009
|
|||||
Lithium
ion battery technology purchase
|
October
30, 2009
|
$ | 7 | ||
2008
|
|||||
Germplasm
from Triumph Seed Co., Inc.
|
February
29, 2008
|
$ | 4 | ||
Germplasm
from Dairyland Seed Co., Inc. and Bio-Plant Research Ltd.
|
August
29, 2008
|
23 | |||
Germplasm
from Südwestsaat GbR
|
December 16,
2008
|
17 | |||
Total
2008 IPR&D
|
$ | 44 | |||
2007
|
|||||
Germplasm
from Maize Technologies International
|
May
1, 2007
|
$ | 2 | ||
Manufacturing
process R&D from Wolff Walsrode
|
June
30, 2007
|
7 | |||
Germplasm
from Agromen Tecnologia Ltda.
|
August
1, 2007
|
26 | |||
Germplasm
from Duo Maize
|
August
30, 2007
|
3 | |||
Intellectual
property for crop trait discovery from Exelixis Plant
Sciences
|
September
4, 2007
|
19 | |||
Total
2007 IPR&D
|
$ | 57 |
Salt
Business Assets and Liabilities Divested
In
millions
|
At
Oct. 1, 2009
|
|||
Current
assets
|
$ | 374 | ||
Property
|
434 | |||
Other
intangible assets
|
1,151 | |||
Deferred
charges and other assets
|
102 | |||
Assets
divested
|
$ | 2,061 | ||
Current
liabilities
|
$ | 124 | ||
Deferred
income tax liabilities - noncurrent
|
311 | |||
Pension
and other post retirement benefits
|
89 | |||
Other
noncurrent obligations
|
14 | |||
Liabilities
divested
|
$ | 538 |
Discontinued
Operations
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Net
sales
|
$ | 70 | $ | 153 | $ | 138 | ||||||
Income
before income taxes
|
$ | 175 | $ | 44 | $ | 37 | ||||||
Provision
for income taxes
|
$ | 65 | $ | 16 | $ | 14 | ||||||
Income
from discontinued operations, net of income taxes
|
$ | 110 | $ | 28 | $ | 23 |
Inventories
at December 31
In
millions
|
2009
|
2008
|
||||||
Finished
goods
|
$ | 3,887 | $ | 3,351 | ||||
Work
in process
|
1,593 | 1,217 | ||||||
Raw
materials
|
671 | 830 | ||||||
Supplies
|
696 | 638 | ||||||
Total
inventories
|
$ | 6,847 | $ | 6,036 |
Property
at December 31
|
Estimated
|
|||||||||||
In
millions
|
Useful
Lives
(Years)
|
2009
|
2008
|
|||||||||
Land
|
- | $ | 942 | $ | 590 | |||||||
Land
and waterway improvements
|
15-25 | 1,342 | 1,308 | |||||||||
Buildings
|
5-55 | 4,811 | 3,700 | |||||||||
Machinery
and equipment
|
3-20 | 39,983 | 36,285 | |||||||||
Utility
and supply lines
|
5-20 | 2,306 | 2,248 | |||||||||
Other
property
|
3-30 | 2,170 | 2,166 | |||||||||
Construction
in progress
|
- | 2,013 | 2,094 | |||||||||
Total
property
|
$ | 53,567 | $ | 48,391 |
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Depreciation
expense
|
$ | 2,291 | $ | 2,016 | $ | 1,959 | ||||||
Manufacturing
maintenance and repair costs
|
$ | 1,473 | $ | 1,622 | $ | 1,482 | ||||||
Capitalized
interest
|
$ | 61 | $ | 97 | $ | 85 |
Principal
Nonconsolidated Affiliates at December 31
|
Ownership
Interest
|
|||||||||||
2009
|
2008
|
2007
|
||||||||||
Americas
Styrenics LLC
|
50 | % | 50 | % | - | |||||||
Compañía
Mega S.A.
|
28 | % | 28 | % | 28 | % | ||||||
Dow
Corning Corporation
|
50 | % | 50 | % | 50 | % | ||||||
EQUATE
Petrochemical Company K.S.C.
|
42.5 | % | 42.5 | % | 42.5 | % | ||||||
Equipolymers
|
50 | % | 50 | % | 50 | % | ||||||
The
Kuwait Olefins Company K.S.C.
|
42.5 | % | 42.5 | % | 42.5 | % | ||||||
MEGlobal
|
50 | % | 50 | % | 50 | % | ||||||
The
OPTIMAL Group of Companies: (1)
|
||||||||||||
OPTIMAL
Chemicals (Malaysia) Sdn. Bhd.
|
- | 50 | % | 50 | % | |||||||
OPTIMAL
Glycols (Malaysia) Sdn. Bhd.
|
- | 50 | % | 50 | % | |||||||
OPTIMAL
Olefins (Malaysia) Sdn. Bhd.
|
- | 23.75 | % | 23.75 | % | |||||||
The
SCG-Dow Group:
|
||||||||||||
Pacific
Plastics (Thailand) Limited
|
- | - | 49 | % | ||||||||
Siam
Polyethylene Company Limited
|
49 | % | 49 | % | 49 | % | ||||||
Siam
Polystyrene Company Limited
|
50 | % | 50 | % | 49 | % | ||||||
Siam
Styrene Monomer Co., Ltd.
|
50 | % | 50 | % | 49 | % | ||||||
Siam
Synthetic Latex Company Limited
|
50 | % | 50 | % | 49 | % | ||||||
Univation
Technologies, LLC
|
50 | % | 50 | % | 50 | % |
(1)
|
On September 30, 2009, the Company completed the sale of its ownership interest in the OPTIMAL Group of Companies; see Note E. |
|
Summarized
Balance Sheet Information at December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Current
assets
|
$ | 6,916 | $ | 6,391 | ||||
Noncurrent
assets
|
14,538 | 14,226 | ||||||
Total
assets
|
$ | 21,454 | $ | 20,617 | ||||
Current
liabilities
|
$ | 4,147 | $ | 3,644 | ||||
Noncurrent
liabilities
|
10,504 | 9,876 | ||||||
Total
liabilities
|
$ | 14,651 | $ | 13,520 |
Summarized
Income Statement Information
|
||||||||||||
In
millions
|
2009 (1)
|
2008 (2)
|
2007
|
|||||||||
Sales
|
$ | 12,590 | $ | 15,508 | $ | 13,884 | ||||||
Gross
profit
|
$ | 2,910 | $ | 4,064 | $ | 3,492 | ||||||
Net
income
|
$ | 1,281 | $ | 1,940 | $ | 2,451 |
(1)
|
The summarized income statement information for 2009 includes the results for the OPTIMAL Group of Companies from January 1, 2009 through September 30, 2009 (see Note E). |
|
(2)
|
The summarized income statement information for 2008 includes the results for Americas Styrenics LLC from May 1, 2008 through December 31, 2008. |
|
Impact
of Sales to MEGlobal by Operating Segment
|
||||||||||||
Percent
of segment sales
|
2009
|
2008
|
2007
|
|||||||||
Basic
Chemicals
|
11 | % | 14 | % | 21 | % | ||||||
Hydrocarbons
and Energy
|
4 | % | 3 | % | 4 | % |
Goodwill
In
millions
|
Electronic
and Specialty Materials
|
Coatings
and Infrastructure
|
Health
and Ag Sciences
|
Perf
Systems
|
Perf
Products
|
Basic
Plastics
|
Hydrocarbons
and Energy
|
Total
|
||||||||||||||||||||||||
Gross
goodwill at
Jan. 1, 2009
|
$ | 785 | $ | 91 | $ | 1,391 | $ | 785 | $ | 427 | $ | 95 | $ | 63 | $ | 3,637 | ||||||||||||||||
Accumulated
impairments at
Jan. 1, 2009
|
- | - | - | (213 | ) | - | (30 | ) | - | (243 | ) | |||||||||||||||||||||
Net
goodwill at
Jan. 1, 2009
|
$ | 785 | $ | 91 | $ | 1,391 | $ | 572 | $ | 427 | $ | 65 | $ | 63 | $ | 3,394 | ||||||||||||||||
Goodwill
related to 2009 acquisition of:
|
||||||||||||||||||||||||||||||||
Rohm
and Haas
|
5,077 | 3,881 | 154 | 378 | 118 | - | - | 9,608 | ||||||||||||||||||||||||
Hyland
Seed assets
|
- | - | 1 | - | - | - | - | 1 | ||||||||||||||||||||||||
Adjustment
related to 2008 acquisition of:
|
||||||||||||||||||||||||||||||||
Dairyland
Seed Co., Inc.
|
- | - | (2 | ) | - | - | - | - | (2 | ) | ||||||||||||||||||||||
Poly-Carb,
Inc.
|
- | - | - | (1 | ) | - | - | - | (1 | ) | ||||||||||||||||||||||
Stevens
Roofing Systems
|
- | 3 | - | - | - | - | - | 3 | ||||||||||||||||||||||||
Impairment
loss
|
- | - | - | - | (7 | ) | - | - | (7 | ) | ||||||||||||||||||||||
Foreign
currency impact
|
49 | 53 | - | 10 | 6 | - | - | 118 | ||||||||||||||||||||||||
Net
goodwill at
Dec. 31, 2009
|
$ | 5,911 | $ | 4,028 | $ | 1,544 | $ | 959 | $ | 544 | $ | 65 | $ | 63 | $ | 13,114 | ||||||||||||||||
Accumulated
impairments at
Dec. 31, 2009
|
- | - | - | 213 | 7 | 30 | - | 250 | ||||||||||||||||||||||||
Gross
goodwill at
Dec. 31, 2009
|
$ | 5,911 | $ | 4,028 | $ | 1,544 | $ | 1,172 | $ | 551 | $ | 95 | $ | 63 | $ | 13,364 |
Other
Intangible Assets at December 31
|
2009
|
2008
|
||||||||||||||||||||||
In
millions
|
Gross
Carrying Amount
|
Accumulated
Amortization
|
Net
|
Gross
Carrying Amount
|
Accumulated
Amortization
|
Net
|
||||||||||||||||||
Intangible
assets with finite lives:
|
||||||||||||||||||||||||
Licenses
and intellectual property
|
$ | 1,729 | $ | (320 | ) | $ | 1,409 | $ | 316 | $ | (192 | ) | $ | 124 | ||||||||||
Patents
|
140 | (107 | ) | 33 | 139 | (100 | ) | 39 | ||||||||||||||||
Software
|
875 | (439 | ) | 436 | 700 | (363 | ) | 337 | ||||||||||||||||
Trademarks
|
694 | (110 | ) | 584 | 169 | (61 | ) | 108 | ||||||||||||||||
Customer
related
|
3,613 | (261 | ) | 3,352 | 210 | (66 | ) | 144 | ||||||||||||||||
Other
|
142 | (65 | ) | 77 | 120 | (43 | ) | 77 | ||||||||||||||||
Total
other intangible assets, finite lives
|
$ | 7,193 | $ | (1,302 | ) | $ | 5,891 | $ | 1,654 | $ | (825 | ) | $ | 829 | ||||||||||
IPR&D,
indefinite lives
|
75 | - | 75 | - | - | - | ||||||||||||||||||
Total
other intangible assets
|
$ | 7,268 | $ | (1,302 | ) | $ | 5,966 | $ | 1,654 | $ | (825 | ) | $ | 829 |
Rohm
and Haas Intangible Assets
In
millions
|
Gross
Carrying Amount
|
Weighted-average
Amortization Period
|
||||||
Intangible
assets with finite lives:
|
||||||||
Licenses
and intellectual property
|
$ | 1,410 |
10
years
|
|||||
Software
|
73 |
3
years
|
||||||
Trademarks
|
513 |
10
years
|
||||||
Customer
related
|
3,235 |
16
years
|
||||||
Total
intangible assets, finite lives
|
$ | 5,231 |
14
years
|
|||||
IPR&D,
indefinite lives
|
74 | - | ||||||
Total
intangible assets
|
$ | 5,305 |
Amortization
Expense
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Other
intangible assets, excluding software
|
$ | 399 | $ | 92 | $ | 72 | ||||||
Software,
included in “Cost of sales”
|
$ | 76 | $ | 48 | $ | 47 |
Estimated
Amortization Expense
for
Next Five Years
In
millions
|
||||
2010
|
$ | 575 | ||
2011
|
$ | 566 | ||
2012
|
$ | 548 | ||
2013
|
$ | 527 | ||
2014
|
$ | 504 |
Investing
Results
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Proceeds
from sales of available-for-sale securities
|
$ | 593 | $ | 851 | $ | 1,994 | ||||||
Gross
realized gains
|
$ | 32 | $ | 56 | $ | 137 | ||||||
Gross
realized losses
|
$ | (28 | ) | $ | (18 | ) | $ | (23 | ) |
Contractual
Maturities of Debt Securities at December 31, 2009
|
||||||||
In
millions
|
Amortized
Cost
|
Fair
Value
|
||||||
Within
one year
|
$ | 41 | $ | 41 | ||||
One
to five years
|
600 | 636 | ||||||
Six
to ten years
|
614 | 640 | ||||||
After
ten years
|
289 | 302 | ||||||
Total
|
$ | 1,544 | $ | 1,619 |
Temporarily
Impaired Securities at December 31, 2009
|
||||||||||||||||||||||||
Less
than 12 months
|
12
months or more
|
Total
|
||||||||||||||||||||||
In
millions
|
Fair
Value
|
Unrealized
Losses
|
Fair
Value
|
Unrealized
Losses
|
Fair
Value
|
Unrealized
Losses
|
||||||||||||||||||
Debt
securities:
|
||||||||||||||||||||||||
U.S.
Treasury obligations and direct obligations of U.S. government
agencies
|
$ | 217 | $ | (4 | ) | - | - | $ | 217 | $ | (4 | ) | ||||||||||||
Corporate
bonds
|
27 | (1 | ) | $ | 13 | $ | (1 | ) | 40 | (2 | ) | |||||||||||||
Total
debt securities
|
$ | 244 | $ | (5 | ) | $ | 13 | $ | (1 | ) | $ | 257 | $ | (6 | ) | |||||||||
Equity
securities
|
40 | (2 | ) | 7 | (1 | ) | 47 | (3 | ) | |||||||||||||||
Total
temporarily impaired securities
|
$ | 284 | $ | (7 | ) | $ | 20 | $ | (2 | ) | $ | 304 | $ | (9 | ) |
Temporarily
Impaired Securities at December 31, 2008
|
||||||||||||||||||||||||
Less
than 12 months
|
12
months or more
|
Total
|
||||||||||||||||||||||
In
millions
|
Fair
Value
|
Unrealized
Losses
|
Fair
Value
|
Unrealized
Losses
|
Fair
Value
|
Unrealized
Losses
|
||||||||||||||||||
Debt
securities:
|
||||||||||||||||||||||||
U.S.
Treasury obligations and direct obligations of U.S. government
agencies
|
$ | 14 | - | - | - | $ | 14 | - | ||||||||||||||||
Corporate
bonds
|
388 | $ | (35 | ) | $ | 8 | $ | (1 | ) | 396 | $ | (36 | ) | |||||||||||
Other
|
4 | - | 2 | - | 6 | - | ||||||||||||||||||
Total
debt securities
|
$ | 406 | $ | (35 | ) | $ | 10 | $ | (1 | ) | $ | 416 | $ | (36 | ) | |||||||||
Equity
securities
|
268 | (152 | ) | 37 | (25 | ) | 305 | (177 | ) | |||||||||||||||
Total
temporarily impaired securities
|
$ | 674 | $ | (187 | ) | $ | 47 | $ | (26 | ) | $ | 721 | $ | (213 | ) |
Fair
Value of Financial Instruments at December 31
|
||||||||||||||||||||||||||||||||
2009
|
2008
|
|||||||||||||||||||||||||||||||
In
millions
|
Cost
|
Gain
|
Loss
|
Fair
Value
|
Cost
|
Gain
|
Loss
|
Fair
Value
|
||||||||||||||||||||||||
Marketable
securities (1):
|
||||||||||||||||||||||||||||||||
Debt
securities
|
$ | 1,544 | $ | 81 | $ | (6 | ) | $ | 1,619 | $ | 1,443 | $ | 88 | $ | (36 | ) | $ | 1,495 | ||||||||||||||
Equity
securities
|
455 | 65 | (3 | ) | 517 | 518 | 17 | (177 | ) | 358 | ||||||||||||||||||||||
Total
marketable securities
|
$ | 1,999 | $ | 146 | $ | (9 | ) | $ | 2,136 | $ | 1,961 | $ | 105 | $ | (213 | ) | $ | 1,853 | ||||||||||||||
Long-term
debt including debt due within one year (2)
|
$ | (20,234 | ) | $ | 126 | $ | (1,794 | ) | $ | (21,902 | ) | $ | (9,496 | ) | $ | 551 | $ | (38 | ) | $ | (8,983 | ) | ||||||||||
Derivatives
relating to:
|
||||||||||||||||||||||||||||||||
Foreign
currency
|
- | $ | 81 | $ | (20 | ) | $ | 61 | - | $ | 122 | $ | (163 | ) | $ | (41 | ) | |||||||||||||||
Commodities
|
- | $ | 5 | $ | (18 | ) | $ | (13 | ) | - | $ | 65 | $ | (220 | ) | $ | (155 | ) | ||||||||||||||
(1)
Included in “Other investments” in the consolidated balance
sheets.
|
||||||||||||||||||||||||||||||||
(2)
Cost includes fair value adjustments of $25 million in 2009 and
$27 million in 2008.
|
Commodity
|
2009
|
2008
|
Notional
Volume Unit
|
||||||
Crude
Oil
|
0.7 | 1.8 |
million
barrels
|
||||||
Naphtha
|
50 | 33 |
kilotons
|
||||||
Natural
Gas
|
2.0 | 11.8 |
million
million British thermal units
|
Commodity
|
2009
|
2008
|
Notional
Volume Unit
|
||||||
Ethane
|
0.9 | - |
million
barrels
|
||||||
Natural
Gas
|
2.8 | - |
million
million British thermal units
|
Fair
Value of Derivative Instruments at December 31
|
|||||||||
In
millions
|
Balance
Sheet Classification
|
2009
|
2008
|
||||||
Asset
Derivatives
|
|||||||||
Derivatives
designated as hedges:
|
|||||||||
Foreign
currency
|
Accounts
and notes receivable – Other
|
$ | 4 | $ | 77 | ||||
Commodities
|
Accounts
and notes receivable – Other
|
4 | 68 | ||||||
Total
derivatives designated as hedges
|
$ | 8 | $ | 145 | |||||
Derivatives
not designated as hedges:
|
|||||||||
Foreign
currency
|
Accounts
and notes receivable – Other
|
$ | 125 | $ | 235 | ||||
Commodities
|
Accounts
and notes receivable – Other
|
28 | 63 | ||||||
Total
derivatives not designated as hedges
|
$ | 153 | $ | 298 | |||||
Total
asset derivatives
|
$ | 161 | $ | 443 | |||||
Liability
Derivatives
|
|||||||||
Derivatives
designated as hedges:
|
|||||||||
Foreign
currency
|
Accounts
payable – Other
|
$ | 3 | $ | 69 | ||||
Commodities
|
Accounts
payable – Other
|
- | 262 | ||||||
Commodities
|
Other
noncurrent obligations
|
- | 22 | ||||||
Total
derivatives designated as hedges
|
$ | 3 | $ | 353 | |||||
Derivatives
not designated as hedges:
|
|||||||||
Foreign
currency
|
Accounts
payable – Other
|
$ | 65 | $ | 284 | ||||
Commodities
|
Accounts
payable – Other
|
42 | 61 | ||||||
Total
derivatives not designated as hedges
|
$ | 107 | $ | 345 | |||||
Total
liability derivatives
|
$ | 110 | $ | 698 |
Effect
of Derivative Instruments
at
December 31, 2009
In
millions
|
Change
in Unrealized Loss in AOCI (1)
|
Income
Statement Classification
|
Gain (Loss) Reclassified from
AOCI to Income (2)
|
Additional
Gain (Loss) Recognized
in Income (2,3)
|
||||||||||||
Derivatives
designated as hedges:
|
||||||||||||||||
Fair
value:
|
||||||||||||||||
Interest
rates
|
- |
Interest
expense (4)
|
- | $ | (1 | ) | ||||||||||
Cash
flow:
|
||||||||||||||||
Interest
rates
|
- |
Cost
of sales
|
$ | (9 | ) | - | ||||||||||
Interest
rates
|
- |
Interest
expense (4)
|
(1 | ) | - | |||||||||||
Commodities
|
$ | (2 | ) |
Cost
of sales
|
(306 | ) | (1 | ) | ||||||||
Foreign
currency
|
(10 | ) |
Cost
of sales
|
11 | - | |||||||||||
Net
foreign investment:
|
||||||||||||||||
Foreign
currency
|
- | n/a | - | - | ||||||||||||
Total
derivatives designated as hedges
|
$ | (12 | ) | $ | (305 | ) | $ | (2 | ) | |||||||
Derivatives
not designated as hedges:
|
||||||||||||||||
Foreign
currency (5)
|
- |
Sundry
income – net
|
- | $ | (32 | ) | ||||||||||
Commodities
|
- |
Cost
of sales
|
- | 3 | ||||||||||||
Total
derivatives not designated as hedges
|
- | - | $ | (29 | ) | |||||||||||
Total
derivatives
|
$ | (12 | ) | $ | (305 | ) | $ | (31 | ) |
Effect
of Derivative Instruments
at
December 31, 2008
In
millions
|
Change in Unrealized Gain
(Loss) in AOCI (1)
|
Income
Statement Classification
|
Loss Reclassified from AOCI to
Income (2)
|
Additional Loss Recognized in
Income (2,3)
|
||||||||||||
Derivatives
designated as hedges:
|
||||||||||||||||
Fair
value:
|
||||||||||||||||
Interest
rates
|
- |
Interest
expense (4)
|
- | $ | (2 | ) | ||||||||||
Cash
flow:
|
||||||||||||||||
Interest
rates
|
- |
Cost
of sales
|
$ | (12 | ) | - | ||||||||||
Interest
rates
|
- |
Interest
expense (4)
|
(1 | ) | - | |||||||||||
Commodities
|
$ | (353 | ) |
Cost
of sales
|
(154 | ) | (1 | ) | ||||||||
Foreign
currency
|
7 |
Cost
of sales
|
(12 | ) | - | |||||||||||
Net
foreign investment:
|
||||||||||||||||
Foreign
currency
|
1 | n/a | - | - | ||||||||||||
Total
derivatives designated as hedges
|
$ | (345 | ) | $ | (179 | ) | $ | (3 | ) | |||||||
Derivatives
not designated as hedges:
|
||||||||||||||||
Foreign
currency (5)
|
- |
Sundry
income – net
|
- | $ | (167 | ) | ||||||||||
Commodities
|
- |
Cost
of sales
|
- | (34 | ) | |||||||||||
Total
derivatives not designated as hedges
|
- | - | $ | (201 | ) | |||||||||||
Total
derivatives
|
$ | (345 | ) | $ | (179 | ) | $ | (204 | ) |
(1)
|
Net
unrealized gains/losses from hedges related to interest rates and
commodities are included in “Accumulated Derivative Gain (Loss) – Net
hedging results” in the consolidated statements of equity; net unrealized
gains/losses from hedges related to foreign currency (net of tax) are
included in “Cumulative Translation Adjustments – Translation adjustments”
in the consolidated statements of
equity.
|
(2)
|
Pretax
amounts.
|
(3)
|
Amounts
impacting income not related to AOCI reclassification; also includes
immaterial amounts of hedge
ineffectiveness.
|
(4)
|
Interest
expense and amortization of debt
discount.
|
(5)
|
Foreign
currency derivatives not designated as hedges are offset by foreign
exchange gains/losses resulting from the underlying exposures of foreign
currency denominated assets and
liabilities.
|
Basis
of Fair Value Measurements on a Recurring Basis
at
December 31, 2009
In
millions
|
Quoted
Prices in Active Markets for Identical Items
(Level
1)
|
Significant
Other Observable Inputs
(Level
2)
|
Counterparty and Cash
Collateral Netting (1)
|
Total
|
||||||||||||
Assets
at fair value:
|
||||||||||||||||
Equity
securities (2)
|
$ | 483 | $ | 34 | - | $ | 517 | |||||||||
Debt
securities (2)
|
- | 1,619 | - | 1,619 | ||||||||||||
Derivatives
relating to: (3)
|
||||||||||||||||
Foreign
currency
|
- | 129 | $ | (48 | ) | 81 | ||||||||||
Commodities
|
28 | 4 | (27 | ) | 5 | |||||||||||
Total
assets at fair value
|
$ | 511 | $ | 1,786 | $ | (75 | ) | $ | 2,222 | |||||||
Liabilities
at fair value:
|
||||||||||||||||
Derivatives
relating to: (3)
|
||||||||||||||||
Foreign
currency
|
- | $ | 68 | $ | (48 | ) | $ | 20 | ||||||||
Commodities
|
$ | 24 | 18 | (24 | ) | 18 | ||||||||||
Total
liabilities at fair value
|
$ | 24 | $ | 86 | $ | (72 | ) | $ | 38 |
Basis
of Fair Value Measurements on a Recurring Basis
at
December 31, 2008
In
millions
|
Quoted
Prices in Active Markets for Identical Items
(Level
1)
|
Significant
Other Observable Inputs
(Level
2)
|
Counterparty and Cash
Collateral Netting (1)
|
Total
|
||||||||||||
Assets
at fair value:
|
||||||||||||||||
Equity
securities (2)
|
$ | 337 | $ | 21 | - | $ | 358 | |||||||||
Debt
securities (2)
|
- | 1,495 | - | 1,495 | ||||||||||||
Derivatives
relating to: (3)
|
||||||||||||||||
Foreign
currency
|
- | 312 | $ | (190 | ) | 122 | ||||||||||
Commodities
|
- | 131 | (66 | ) | 65 | |||||||||||
Total
assets at fair value
|
$ | 337 | $ | 1,959 | $ | (256 | ) | $ | 2,040 | |||||||
Liabilities
at fair value:
|
||||||||||||||||
Derivatives
relating to: (3)
|
||||||||||||||||
Foreign
currency
|
- | $ | 353 | $ | (190 | ) | $ | 163 | ||||||||
Commodities
|
$ | 49 | 296 | (125 | ) | 220 | ||||||||||
Total
liabilities at fair value
|
$ | 49 | $ | 649 | $ | (315 | ) | $ | 383 |
(1)
|
Cash collateral is classified as “Accounts and notes receivable – Other” in the consolidated balance sheets. Amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty. |
|
(2)
|
The Company’s investments in equity and debt securities are primarily classified as available-for-sale and are included in “Other investments” in the consolidated balance sheets. |
|
(3)
|
See Note J for the classification of derivatives in the consolidated balance sheets. |
|
Basis
of Fair Value Measurements on a Nonrecurring Basis in 2009
In
millions
|
Significant
Other Observable Inputs
(Level
2)
|
Significant
Other Unobservable Inputs
(Level
3)
|
Total
|
Total
Losses 2009
|
||||||||||||
Assets
at fair value:
|
||||||||||||||||
Long-lived
and other assets
|
- | $ | 30 | $ | 30 | $ | (464 | ) | ||||||||
Net
assets held for sale
|
$ | 1,657 | - | 1,657 | - | |||||||||||
Goodwill
|
- | - | - | (7 | ) | |||||||||||
Total
assets at fair value
|
$ | 1,657 | $ | 30 | $ | 1,687 | $ | (471 | ) |
Sundry
Income – Net
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Gain
on sale of TRN
|
$ | 513 | - | - | ||||||||
Gain
on sale of OPTIMAL
|
339 | - | - | |||||||||
Gain
on sales of other assets and securities
|
100 | $ | 91 | $ | 171 | |||||||
Foreign
exchange gain (loss)
|
1 | (17 | ) | 73 | ||||||||
Dividend
income
|
- | 3 | 9 | |||||||||
Other
– net
|
(62 | ) | 12 | 71 | ||||||||
Total
sundry income – net
|
$ | 891 | $ | 89 | $ | 324 |
Other
Supplementary Information
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Cash
payments for interest
|
$ | 1,140 | $ | 713 | $ | 671 | ||||||
Cash
payments for income taxes
|
$ | 1,034 | $ | 864 | $ | 966 | ||||||
Provision
for doubtful receivables (1)
|
$ | 11 | $ | 20 | $ | 2 | ||||||
(1)
Included in “Selling, general and administrative expenses” in the
consolidated statements of income.
|
Net
Income
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Net
income from continuing operations
|
$ | 566 | $ | 626 | $ | 2,962 | ||||||
Income
from discontinued operations, net of income taxes
|
110 | 28 | 23 | |||||||||
Net
income attributable to noncontrolling interests
|
(28 | ) | (75 | ) | (98 | ) | ||||||
Net
income attributable to The Dow Chemical Company
|
$ | 648 | $ | 579 | $ | 2,887 | ||||||
Preferred
stock dividends
|
(312 | ) | - | - | ||||||||
Net
income available for common stockholders
|
$ | 336 | $ | 579 | $ | 2,887 |
Earnings Per
Share Calculations - Basic
Dollars
per share
|
2009
|
2008
|
2007
|
|||||||||
Net
income from continuing operations
|
$ | 0.54 | $ | 0.67 | $ | 3.10 | ||||||
Income
from discontinued operations, net of income taxes
|
0.10 | 0.03 | 0.03 | |||||||||
Net
income attributable to noncontrolling interests
|
(0.02 | ) | (0.08 | ) | (0.10 | ) | ||||||
Net
income attributable to The Dow Chemical Company
|
$ | 0.62 | $ | 0.62 | $ | 3.03 | ||||||
Preferred
stock dividends
|
(0.30 | ) | - | - | ||||||||
Net
income available for common stockholders
|
$ | 0.32 | $ | 0.62 | $ | 3.03 |
Earnings Per
Share Calculations - Diluted
Dollars
per share
|
2009
|
2008
|
2007
|
|||||||||
Net
income from continuing operations
|
$ | 0.54 | $ | 0.67 | $ | 3.07 | ||||||
Income
from discontinued operations, net of income taxes
|
0.10 | 0.03 | 0.02 | |||||||||
Net
income attributable to noncontrolling interests
|
(0.02 | ) | (0.08 | ) | (0.10 | ) | ||||||
Net
income attributable to The Dow Chemical Company
|
$ | 0.62 | $ | 0.62 | $ | 2.99 | ||||||
Preferred
stock dividends (1)
|
(0.30 | ) | - | - | ||||||||
Net
income available for common stockholders
|
$ | 0.32 | $ | 0.62 | $ | 2.99 |
Shares
in millions
|
||||||||||||
Weighted-average
common shares - basic
|
1,043.2 | 930.4 | 953.1 | |||||||||
Plus
dilutive effect of stock options and awards
|
10.7 | 8.6 | 12.5 | |||||||||
Weighted-average
common shares - diluted
|
1,053.9 | 939.0 | 965.6 | |||||||||
Stock
options and deferred stock awards excluded from EPS calculations (2)
|
57.3 | 42.8 | 21.9 | |||||||||
Conversion
of preferred stock excluded from EPS calculations (3)
|
78.5 | - | - |
(1)
|
Preferred stock dividends were not added back in the calculation of diluted earnings per share because the effect of adding them back would have been antidilutive. |
|
(2)
|
These outstanding options to purchase shares of common stock and deferred stock awards were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive. |
|
(3)
|
Conversion of the Cumulative Convertible Perpetual Preferred Stock, Series A into shares of the Company’s common stock was excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive. |
|
Accrued
Obligations for Environmental Matters
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Balance
at January 1
|
$ | 312 | $ | 322 | ||||
Additional
accruals
|
271 | 141 | ||||||
Assumed
from Rohm and Haas
|
159 | - | ||||||
Charges
against reserve
|
(143 | ) | (138 | ) | ||||
Adjustments
to reserve
|
20 | (13 | ) | |||||
Balance
at December 31
|
$ | 619 | $ | 312 |
Receivables
for Costs Submitted to Insurance Carriers With Settlement Agreements
at
December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Receivables
for defense costs
|
$ | 91 | $ | 28 | ||||
Receivables
for resolution costs
|
357 | 244 | ||||||
Total
|
$ | 448 | $ | 272 |
Fixed
and Determinable Portion of Take-or-Pay and
Throughput
Obligations at December 31, 2009
In
millions
|
||||
2010
|
$ | 2,845 | ||
2011
|
2,655 | |||
2012
|
1,716 | |||
2013
|
1,088 | |||
2014
|
944 | |||
2015
and beyond
|
5,969 | |||
Total
|
$ | 15,217 |
Guarantees
at December 31, 2009
In
millions
|
Final
Expiration
|
Maximum
Future Payments
|
Recorded
Liability
|
||||||
Guarantees
|
2020
|
$ | 358 | $ | 52 | ||||
Residual
value guarantees
|
2014
|
695 | 5 | ||||||
Total
guarantees
|
$ | 1,053 | $ | 57 |
Guarantees
at December 31, 2008
In
millions
|
Final
Expiration
|
Maximum
Future Payments
|
Recorded
Liability
|
||||||
Guarantees
|
2014
|
$ | 330 | $ | 23 | ||||
Residual
value guarantees
|
2015
|
985 | 4 | ||||||
Total
guarantees
|
$ | 1,315 | $ | 27 |
Asset
Retirement Obligations
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Balance
at January 1
|
$ | 106 | $ | 116 | ||||
Additional
accruals (1)
|
7 | 7 | ||||||
Assumed
from Rohm and Haas (2)
|
13 | - | ||||||
Sold
with Salt business (3)
|
(12 | ) | - | |||||
Liabilities
settled
|
(21 | ) | (14 | ) | ||||
Accretion
expense
|
1 | 3 | ||||||
Revisions
in estimated cash flows
|
1 | 1 | ||||||
Other
|
6 | (7 | ) | |||||
Balance
at December 31
|
$ | 101 | $ | 106 |
(1)
|
In 2008, the Company recognized asset retirement obligations of $4 million related to the 2008 restructuring plan (see Note C). |
|
(2)
|
See Note D. |
|
(3)
|
See Note E. |
|
Notes
Payable at December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Commercial
paper
|
$ | 721 | $ | 1,597 | ||||
Notes
payable to banks
|
1,285 | 661 | ||||||
Notes
payable to related companies
|
131 | 102 | ||||||
Notes
payable trade
|
2 | - | ||||||
Total
notes payable
|
$ | 2,139 | $ | 2,360 | ||||
Year-end
average interest rates
|
2.18 | % | 4.04 | % |
Long-Term
Debt at December 31
In
millions
|
2009
Average Rate
|
2009
|
2008
Average Rate
|
2008
|
||||||||||||
Promissory
notes and debentures:
|
||||||||||||||||
Final
maturity 2009
|
- | - | 6.76 | % | $ | 682 | ||||||||||
Final
maturity 2010
|
9.13 | % | $ | 281 | 9.14 | % | 275 | |||||||||
Final
maturity 2011
|
5.32 | % | 1,054 | 6.13 | % | 806 | ||||||||||
Final
maturity 2012
|
5.14 | % | 2,280 | 6.00 | % | 907 | ||||||||||
Final
maturity 2013
|
6.05 | % | 389 | 6.85 | % | 139 | ||||||||||
Final
maturity 2014
|
7.60 | % | 1,750 | - | - | |||||||||||
Final
maturity 2015 and thereafter
|
7.70 | % | 10,130 | 7.05 | % | 2,682 | ||||||||||
Other
facilities:
|
||||||||||||||||
U.S.
dollar loans, various rates and maturities
|
1.95 | % | 35 | 2.43 | % | 700 | ||||||||||
Foreign
currency loans, various rates and maturities
|
3.65 | % | 754 | 3.23 | % | 73 | ||||||||||
Medium-term
notes, varying maturities through 2022
|
6.39 | % | 1,624 | 6.25 | % | 1,072 | ||||||||||
Foreign
medium-term notes, various rates and maturities
|
4.13 | % | 1 | 4.13 | % | 1 | ||||||||||
Foreign
medium-term notes, final maturity 2010, Euro
|
4.37 | % | 576 | 4.37 | % | 561 | ||||||||||
Foreign
medium-term notes, final maturity 2011, Euro
|
4.63 | % | 713 | 4.63 | % | 690 | ||||||||||
Pollution
control/industrial revenue bonds, varying maturities through
2038
|
5.21 | % | 1,114 | 5.61 | % | 904 | ||||||||||
Capital
lease obligations
|
- | 44 | - | 46 | ||||||||||||
Unamortized
debt discount
|
- | (485 | ) | - | (15 | ) | ||||||||||
Unexpended
construction funds
|
- | (26 | ) | - | (27 | ) | ||||||||||
Long-term
debt due within one year
|
- | (1,082 | ) | - | (1,454 | ) | ||||||||||
Total
long-term debt
|
- | $ | 19,152 | - | $ | 8,042 |
Annual
Installments on Long-Term Debt for Next Five Years
In
millions
|
||||
2010
|
$ | 1,082 | ||
2011
|
$ | 1,796 | ||
2012
|
$ | 2,843 | ||
2013
|
$ | 862 | ||
2014
|
$ | 2,201 |
|
(a)
|
the
obligation to maintain the ratio of the Company’s consolidated
indebtedness to consolidated capitalization at no greater than 0.65 to
1.00 at any time the aggregate outstanding amount of loans under the
primary credit agreements exceeds
$500 million,
|
|
(b)
|
a
default if the Company or an applicable subsidiary fails to make any
payment on indebtedness of $50 million or more when due, or any other
default under the applicable agreement permits the acceleration of
$200 million or more of principal, or results in the acceleration of
$100 million or more of principal,
and
|
|
(c)
|
a
default if the Company or any applicable subsidiary fails to discharge or
stay within 30 days after the entry of a final judgment of more than
$200 million.
|
Plan
Assets and Obligations Acquired from Rohm and Haas
on April 1, 2009
(1)
|
||||||||
In
millions
|
Defined
Benefit Pension
Plans
|
Other
Postretirement Benefits
|
||||||
Fair
value of plan assets
|
$ | 1,439 | $ | 18 | ||||
Projected
benefit obligation
|
$ | 2,168 | $ | 338 |
(1)
|
Does not include plan assets and obligations of Morton that were sold to K+S on October 1, 2009 (see Note E). |
|
Weighted-Average
Assumptions
for
All Pension Plans
|
Benefit
Obligations
at December 31 (1)
|
Net
Periodic Costs
for the Year (1)
|
||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Discount
rate
|
5.71 | % | 6.35 | % | 6.53 | % | 6.33 | % | ||||||||
Rate
of increase in future compensation levels
|
4.14 | % | 4.14 | % | 4.01 | % | 4.14 | % | ||||||||
Expected
long-term rate of return on plan assets
|
- | - | 8.03 | % | 8.12 | % |
Weighted-Average
Assumptions
for
U.S. Pension Plans
|
Benefit
Obligations
at December 31 (1)
|
Net
Periodic Costs
for the Year (1)
|
||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Discount
rate
|
5.97 | % | 6.61 | % | 6.82 | % | 6.75 | % | ||||||||
Rate
of increase in future compensation levels
|
4.50 | % | 4.50 | % | 4.31 | % | 4.50 | % | ||||||||
Expected
long-term rate of return on plan assets
|
- | - | 8.46 | % | 8.44 | % |
(1)
|
2008
assumptions do not include Rohm and Haas plans acquired on April 1,
2009.
|
|
Pension
Plans with Accumulated Benefit Obligations in Excess of Plan Assets at
December 31
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Projected
benefit obligations
|
$ | 18,113 | $ | 13,514 | ||||
Accumulated
benefit obligations
|
$ | 17,277 | $ | 13,027 | ||||
Fair
value of plan assets
|
$ | 12,679 | $ | 9,536 |
U.S.
Plan Assumptions for Other Postretirement Benefits
|
Benefit
Obligations
at
December 31
|
Net
Periodic Costs
for
the Year
|
||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
Discount
rate
|
5.69 | % | 6.91 | % | 7.11 | % | 6.57 | % | ||||||||
Expected
long-term rate of return on plan assets
|
- | - | 5.15 | % | 6.75 | % | ||||||||||
Initial
health care cost trend rate
|
9.13 | % | 9.72 | % | 9.71 | % | 10.30 | % | ||||||||
Ultimate
health care cost trend rate
|
5.00 | % | 6.00 | % | 6.00 | % | 6.00 | % | ||||||||
Year
ultimate trend rate to be reached
|
2019 | 2018 | 2018 | 2014 |
Net
Periodic Benefit Cost for All Significant Plans
|
||||||||||||||||||||||||
Defined
Benefit Pension Plans
|
Other
Postretirement Benefits
|
|||||||||||||||||||||||
In
millions
|
2009
|
2008
|
2007
|
2009
|
2008
|
2007
|
||||||||||||||||||
Service
cost
|
$ | 270 | $ | 264 | $ | 289 | $ | 16 | $ | 18 | $ | 21 | ||||||||||||
Interest
cost
|
1,081 | 961 | 881 | 138 | 117 | 113 | ||||||||||||||||||
Expected
return on plan assets
|
(1,254 | ) | (1,232 | ) | (1,179 | ) | (17 | ) | (29 | ) | (34 | ) | ||||||||||||
Amortization
of prior service cost (credit)
|
31 | 32 | 23 | (3 | ) | (4 | ) | (4 | ) | |||||||||||||||
Amortization
of unrecognized loss (gain)
|
106 | 43 | 191 | (1 | ) | (1 | ) | 3 | ||||||||||||||||
Curtailment/settlement/other
costs (1)
|
13 | 54 | 11 | - | 34 | 6 | ||||||||||||||||||
Net
periodic benefit cost
|
$ | 247 | $ | 122 | $ | 216 | $ | 133 | $ | 135 | $ | 105 |
(1)
|
See
Note C for information regarding curtailment and settlement costs recorded
in 2009, 2008 and 2007.
|
Other
Changes in Plan Assets and Benefit Obligations Recognized in Other
Comprehensive Income
for
All Significant Plans
|
||||||||||||||||||||||||
Defined
Benefit Pension Plans
|
Other
Postretirement Benefits
|
|||||||||||||||||||||||
In
millions
|
2009
|
2008
|
2007
|
2009
|
2008
|
2007
|
||||||||||||||||||
Net
loss (gain)
|
$ | 804 | $ | 4,669 | $ | (1,593 | ) | $ | (114 | ) | $ | 23 | $ | (201 | ) | |||||||||
Prior
service cost
|
2 | 4 | 140 | - | - | 2 | ||||||||||||||||||
Amortization
of prior service (cost) credit
|
(31 | ) | (32 | ) | (23 | ) | 3 | 4 | 4 | |||||||||||||||
Amortization
of unrecognized (loss) gain
|
(119 | ) | (43 | ) | (191 | ) | 1 | 1 | (3 | ) | ||||||||||||||
Total
recognized in other comprehensive loss (income)
|
$ | 656 | $ | 4,598 | $ | (1,667 | ) | $ | (110 | ) | $ | 28 | $ | (198 | ) | |||||||||
Total
recognized in net periodic benefit cost and other comprehensive loss
(income)
|
$ | 903 | $ | 4,720 | $ | (1,451 | ) | $ | 23 | $ | 163 | $ | (93 | ) |
Change
in Projected Benefit Obligations, Plan Assets and Funded Status of All
Significant Plans
|
||||||||||||||||
In
millions
|
Defined
Benefit
Pension Plans
|
Other
Postretirement
Benefits
|
||||||||||||||
Change
in projected benefit obligations
|
2009
|
2008
|
2009
|
2008
|
||||||||||||
Benefit
obligation at beginning of year
|
$ | 15,573 | $ | 15,604 | $ | 1,821 | $ | 1,890 | ||||||||
Service
cost
|
270 | 264 | 16 | 18 | ||||||||||||
Interest
cost
|
1,081 | 961 | 138 | 117 | ||||||||||||
Plan
participants’ contributions
|
27 | 21 | - | - | ||||||||||||
Amendments
|
2 | 15 | - | - | ||||||||||||
Actuarial
changes in assumptions and experience
|
1,718 | 72 | (75 | ) | (71 | ) | ||||||||||
Acquisition/divestiture/other
activity
|
2,175 | (8 | ) | 336 | - | |||||||||||
Benefits
paid
|
(1,239 | ) | (980 | ) | (171 | ) | (144 | ) | ||||||||
Currency
impact
|
307 | (420 | ) | 14 | (23 | ) | ||||||||||
Termination
benefits/curtailment cost
|
- | 44 | - | 34 | ||||||||||||
Benefit
obligations at end of year
|
$ | 19,914 | $ | 15,573 | $ | 2,079 | $ | 1,821 | ||||||||
Change
in plan assets
|
||||||||||||||||
Fair
value of plan assets at beginning of year
|
$ | 11,573 | $ | 16,130 | $ | 368 | $ | 432 | ||||||||
Actual
return on plan assets
|
2,155 | (3,442 | ) | 56 | (64 | ) | ||||||||||
Currency
impact
|
279 | (341 | ) | - | - | |||||||||||
Employer
contributions
|
355 | 185 | - | - | ||||||||||||
Plan
participants’ contributions
|
27 | 21 | - | - | ||||||||||||
Acquisition/divestiture/other
activity
|
1,439 | - | 18 | - | ||||||||||||
Benefits
paid
|
(1,239 | ) | (980 | ) | (75 | ) | - | |||||||||
Fair
value of plan assets at end of year
|
$ | 14,589 | $ | 11,573 | $ | 367 | $ | 368 | ||||||||
Funded
status at end of year
|
$ | (5,325 | ) | $ | (4,000 | ) | $ | (1,712 | ) | $ | (1,453 | ) | ||||
Net
amounts recognized in the consolidated balance sheets at December
31:
|
||||||||||||||||
Noncurrent
assets
|
$ | 110 | $ | 12 | - | - | ||||||||||
Current
liabilities
|
(54 | ) | (45 | ) | $ | (89 | ) | $ | (54 | ) | ||||||
Noncurrent
liabilities
|
(5,381 | ) | (3,967 | ) | (1,623 | ) | (1,399 | ) | ||||||||
Net
amounts recognized in the consolidated balance sheets
|
$ | (5,325 | ) | $ | (4,000 | ) | $ | (1,712 | ) | $ | (1,453 | ) | ||||
Pretax
amounts recognized in AOCI at December 31:
|
||||||||||||||||
Net
loss
|
$ | 6,376 | $ | 5,691 | $ | (86 | ) | $ | 27 | |||||||
Prior
service cost (credit)
|
216 | 245 | (13 | ) | (16 | ) | ||||||||||
Pretax
balance in AOCI at end of year
|
$ | 6,592 | $ | 5,936 | $ | (99 | ) | $ | 11 |
Estimated
Future Benefit Payments at December 31, 2009
|
||||||||
In
millions
|
Defined
Benefit Pension
Plans
|
Other
Postretirement Benefits
|
||||||
2010
|
$ | 1,226 | $ | 192 | ||||
2011
|
1,236 | 194 | ||||||
2012
|
1,147 | 189 | ||||||
2013
|
1,163 | 181 | ||||||
2014
|
1,183 | 174 | ||||||
2015
through 2019
|
6,402 | 786 | ||||||
Total
|
$ | 12,357 | $ | 1,716 |
Strategic
Weighted-Average Target Allocation of Plan Assets for All Significant
Plans
|
||||
Asset
Category
|
Target
Allocation
|
|||
Equity
securities
|
45 | % | ||
Fixed
Income securities
|
35 | % | ||
Alternative
investments
|
15 | % | ||
Other
investments
|
5 | % | ||
Total
|
100 | % |
Basis
of Fair Value Measurements of Pension Plan Assets
at
December 31, 2009
In
millions
|
Quoted
Prices in Active Markets for Identical Items
(Level
1)
|
Significant
Other Observable Inputs
(Level
2)
|
Significant
Unobservable Inputs
(Level
3)
|
Total
|
||||||||||||
Cash
and cash equivalents
|
$ | 100 | $ | 730 | - | $ | 830 | |||||||||
Equity
securities:
|
||||||||||||||||
U.S.
equity (1)
|
1,774 | $ | 142 | - | $ | 1,916 | ||||||||||
Non-U.S.
equity – developed countries
|
2,203 | 922 | - | 3,125 | ||||||||||||
Emerging
market
|
668 | 490 | - | 1,158 | ||||||||||||
Equity
derivatives
|
1 | 9 | - | 10 | ||||||||||||
Total
equity securities
|
$ | 4,646 | $ | 1,563 | - | $ | 6,209 | |||||||||
Fixed
income securities:
|
||||||||||||||||
U.S.
government and municipalities
|
- | $ | 991 | - | $ | 991 | ||||||||||
U.S.
agency and agency mortgage backed securities
|
- | 300 | - | 300 | ||||||||||||
Corporate
bonds – investment grade
|
- | 1,242 | - | 1,242 | ||||||||||||
Non-U.S.
governments – developed countries
|
- | 463 | - | 463 | ||||||||||||
Non-U.S.
corporate bonds – developed countries
|
- | 557 | - | 557 | ||||||||||||
Emerging
market debt
|
- | 30 | - | 30 | ||||||||||||
Other
asset-backed securities
|
- | 156 | $ | 25 | 181 | |||||||||||
Convertible
bonds
|
$ | 50 | 386 | - | 436 | |||||||||||
High
yield bonds
|
- | 176 | 25 | 201 | ||||||||||||
Other
fixed income funds
|
- | 878 | - | 878 | ||||||||||||
Fixed
income derivatives
|
(7 | ) | (36 | ) | - | (43 | ) | |||||||||
Total
fixed income securities
|
$ | 43 | $ | 5,143 | $ | 50 | $ | 5,236 | ||||||||
Alternative
investments:
|
||||||||||||||||
Real
estate
|
$ | 26 | $ | 46 | $ | 561 | $ | 633 | ||||||||
Private
equity
|
- | - | 802 | 802 | ||||||||||||
Absolute
return
|
- | 350 | 95 | 445 | ||||||||||||
Total
alternative investments
|
$ | 26 | $ | 396 | $ | 1,458 | $ | 1,880 | ||||||||
Other
|
- | $ | 391 | $ | 43 | $ | 434 | |||||||||
Total
assets at fair value
|
$ | 4,815 | $ | 8,223 | $ | 1,551 | $ | 14,589 |
(1)
|
Includes
$11 million of the Company’s common
stock.
|
Fair
Value Measurement of Level 3 Pension Plan Assets
In
millions
|
Equity
Securities
|
Fixed
Income Securities
|
Alternative
Investments
|
Other
Securities
|
Total
|
|||||||||||||||
Balance
at January 1, 2009
|
$ | 3 | $ | 28 | $ | 1,242 | $ | 20 | $ | 1,293 | ||||||||||
Acquisitions
and divestitures
|
- | 44 | 257 | 20 | 321 | |||||||||||||||
Actual
return on plan assets:
|
||||||||||||||||||||
Relating
to assets sold during 2009
|
(16 | ) | (6 | ) | (23 | ) | - | (45 | ) | |||||||||||
Relating
to assets held at Dec. 31, 2009
|
16 | 13 | (121 | ) | 2 | (90 | ) | |||||||||||||
Purchases,
sales and settlements
|
(3 | ) | (29 | ) | 99 | 1 | 68 | |||||||||||||
Foreign
currency impact
|
- | - | 4 | - | 4 | |||||||||||||||
Balance
at December 31, 2009
|
- | $ | 50 | $ | 1,458 | $ | 43 | $ | 1,551 |
Basis
of Fair Value Measurements of Other Postretirement Benefit Plan Assets at
December 31, 2009
In
millions
|
Quoted
Prices in Active Markets for Identical Items
(Level
1)
|
Significant
Other Observable Inputs
(Level
2)
|
Total
|
|||||||||
Cash
and cash equivalents
|
- | $ | 74 | $ | 74 | |||||||
Equity
securities (1)
|
$ | 82 | - | 82 | ||||||||
Fixed
income securities
|
3 | 208 | 211 | |||||||||
Total
assets at fair value
|
$ | 85 | $ | 282 | $ | 367 |
(1)
|
Includes
no common stock of the Company.
|
Minimum
Operating Lease Commitments at December 31, 2009
In
millions
|
||||
2010
|
$ | 245 | ||
2011
|
168 | |||
2012
|
132 | |||
2013
|
111 | |||
2014
|
85 | |||
2015
and thereafter
|
1,225 | |||
Total
|
$ | 1,966 |
VIE
Assets and Liabilities Included in the Consolidated Balance Sheet at
December 31
In
millions
|
2009
|
|||
Current
assets
|
$ | 102 | ||
Property
|
455 | |||
Other
noncurrent assets
|
81 | |||
Total
assets
|
$ | 638 | ||
Current
liabilities
|
$ | 183 | ||
Long-term
debt
|
125 | |||
Other
noncurrent liabilities
|
43 | |||
Total
liabilities
|
$ | 351 |
2009
|
2008
|
2007
|
||||||||||
Dividend
yield
|
3.8 | % | 4.4 | % | 3.5 | % | ||||||
Expected
volatility
|
43.78 | % | 29.57 | % | 23.33 | % | ||||||
Risk-free
interest rate
|
1.61 | % | 3.42 | % | 4.89 | % | ||||||
Expected
life of stock options granted during period
|
6.25
years
|
6
years
|
6
years
|
|||||||||
Life
of Employees’ Stock Purchase Plan
|
9
months
|
6.5
months
|
6.6
months
|
Employees’
Stock Purchase Plan
|
2009
|
|||||||
Shares
in thousands
|
Shares
|
Exercise Price (1)
|
||||||
Outstanding
at beginning of year
|
- | - | ||||||
Granted
|
10,538 | $ | 20.81 | |||||
Exercised
|
(6,563 | ) | $ | 20.81 | ||||
Forfeited/Expired
|
(3,975 | ) | $ | 20.81 | ||||
Outstanding
and exercisable at end of year
|
- | - | ||||||
(1)
Weighted-average per share
|
Additional
Information about ESPP
In
millions, except per share amounts
|
2009
|
2008
|
2007
|
|||||||||
Weighted-average
fair value per share of purchase rights granted
|
$ | 1.00 | $ | 4.33 | $ | 10.62 | ||||||
Total
compensation expense for ESPP
|
$ | 10 | $ | 20 | $ | 57 | ||||||
Related
tax benefit
|
$ | 4 | $ | 7 | $ | 21 | ||||||
Total
amount of cash received from the exercise of purchase
rights
|
$ | 137 | $ | 32 | $ | 145 | ||||||
Total
intrinsic value of purchase rights exercised (1)
|
$ | 38 | $ | 3 | $ | 65 | ||||||
Related
tax benefit
|
$ | 14 | $ | 1 | $ | 24 | ||||||
(1)
Difference between the market price at exercise and the price paid by the
employee to exercise the purchase rights
|
Stock
Options
|
2009
|
|||||||
Shares
in thousands
|
Shares
|
Exercise Price (1)
|
||||||
Outstanding
at beginning of year
|
53,777 | $ | 39.39 | |||||
Granted
|
11,416 | $ | 9.54 | |||||
Exercised
|
(10 | ) | $ | 27.55 | ||||
Forfeited/Expired
|
(4,939 | ) | $ | 33.52 | ||||
Outstanding
at end of year
|
60,244 | $ | 34.22 | |||||
Remaining
contractual life in years
|
5.40 | |||||||
Aggregate
intrinsic value in millions
|
$ | 203 | - | |||||
Exercisable
at end of year
|
40,671 | $ | 39.78 | |||||
Remaining
contractual life in years
|
3.98 | |||||||
Aggregate
intrinsic value in millions
|
$ | 1 | - | |||||
(1)
Weighted-average per share
|
Additional
Information about Stock Options
In
millions, except per share amounts
|
2009
|
2008
|
2007
|
|||||||||
Weighted-average
fair value per share of options granted
|
$ | 2.60 | $ | 8.88 | $ | 9.81 | ||||||
Total
compensation expense for stock option plans
|
$ | 46 | $ | 79 | $ | 86 | ||||||
Related
tax benefit
|
$ | 17 | $ | 29 | $ | 32 | ||||||
Total
amount of cash received from the exercise of options
|
- | $ | 40 | $ | 235 | |||||||
Total
intrinsic value of options exercised (1)
|
- | $ | 12 | $ | 103 | |||||||
Related
tax benefit
|
- | $ | 4 | $ | 38 | |||||||
(1)
Difference between the market price at exercise and the price paid by the
employee to exercise the options
|
Deferred
Stock
|
2009
|
|||||||
Shares
in thousands
|
Shares
|
Grant Date Fair Value
(1)
|
||||||
Nonvested
at beginning of year
|
8,116 | $ | 43.73 | |||||
Granted
|
6,155 | $ | 11.70 | |||||
Vested
|
(1,866 | ) | $ | 43.32 | ||||
Canceled
|
(192 | ) | $ | 26.99 | ||||
Nonvested
at end of year
|
12,213 | $ | 27.91 | |||||
(1)
Weighted-average per share
|
Additional
Information about Deferred Stock
|
||||||||||||
In
millions, except per share amounts
|
2009
|
2008
|
2007
|
|||||||||
Weighted-average
fair value per share of deferred stock granted
|
$ | 11.70 | $ | 38.38 | $ | 43.61 | ||||||
Total
fair value of deferred stock vested and delivered (1)
|
$ | 20 | $ | 11 | $ | 24 | ||||||
Related
tax benefit
|
$ | 7 | $ | 4 | $ | 9 | ||||||
Total
compensation expense for deferred stock awards
|
$ | 80 | $ | 95 | $ | 76 | ||||||
Related
tax benefit
|
$ | 30 | $ | 35 | $ | 28 |
(1)
|
Includes
the fair value of shares vested in prior years and delivered in the
reporting year.
|
Performance
Deferred Stock Awards
|
|||||||||
Shares
in millions
|
Performance
Period
|
Target Shares Granted
(1)
|
Grant Date Fair Value
(2)
|
||||||
2009
|
October
1, 2009 – September 30, 2011
|
1.1 | $ | 26.39 | |||||
2009
|
January
1, 2009 – December 31, 2011
|
1.2 | $ | 9.53 | |||||
2008
|
January
1, 2008 – December 31, 2010
|
1.1 | $ | 38.62 | |||||
2007
|
January
1, 2007 – December 31, 2009
|
1.0 | $ | 43.59 |
(1)
|
At the end of the performance period, the actual number of shares issued can range from zero to 250 percent of the target shares granted. | ||||||||
(2) | Weighted-average per share |
Performance
Deferred Stock
|
2009
|
|||||||
Shares
in thousands
|
Shares
|
Grant Date Fair Value
(1)
|
||||||
Nonvested
at beginning of year
|
1,995 | $ | 40.95 | |||||
Granted
|
2,339 | $ | 18.02 | |||||
Vested
|
(927 | ) | $ | 43.59 | ||||
Canceled
|
(51 | ) | $ | 21.39 | ||||
Nonvested
at end of year
|
3,356 | $ | 24.54 | |||||
(1) Weighted-average
per share
|
Additional
Information about Performance Deferred Stock
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Total
fair value of performance deferred stock vested and delivered (1)
|
$ | 1 | $ | 166 | $ | 127 | ||||||
Related
tax benefit
|
- | $ | 62 | $ | 47 | |||||||
Total
compensation expense for performance deferred stock awards
|
$ | (7 | ) | $ | 17 | $ | 69 | |||||
Related
tax benefit
|
$ | (2 | ) | $ | 6 | $ | 26 |
(1)
|
Includes
the fair value of shares vested in prior years and delivered in the
reporting year.
|
Reserved
Treasury Stock at December 31
|
||||||||||||
Shares
in millions
|
2009
|
2008
|
2007
|
|||||||||
Stock
option and deferred stock plans
|
12.2 | 57.0 | 41.0 |
Domestic
and Foreign Components of Income from Continuing Operations Before Income
Taxes
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Domestic
|
$ | (290 | ) | $ | (1,290 | ) | $ | 192 | ||||
Foreign
|
759 | 2,567 | 4,000 | |||||||||
Total
|
$ | 469 | $ | 1,277 | $ | 4,192 |
Reconciliation
to U.S. Statutory Rate
|
||||||||||||
In
millions
|
2009
|
2008
|
2007
|
|||||||||
Taxes
at U.S. statutory rate
|
$ | 164 | $ | 447 | $ | 1,467 | ||||||
Equity
earnings effect
|
(266 | ) | (309 | ) | (396 | ) | ||||||
Change
in legal ownership structure of EQUATE
|
- | - | (113 | ) | ||||||||
Foreign
income taxed at rates other than 35% (1)
|
(121 | ) | 261 | (686 | ) | |||||||
German
tax law change
|
- | - | 362 | |||||||||
U.S.
tax effect of foreign earnings and dividends
|
210 | 164 | 480 | |||||||||
Goodwill
impairment losses
|
3 | 75 | - | |||||||||
Change
in valuation allowances
|
9 | 60 | (124 | ) | ||||||||
Unrecognized
tax benefits
|
21 | 31 | 166 | |||||||||
Federal
tax accrual adjustments
|
(119 | ) | 29 | 5 | ||||||||
Other
– net
|
2 | (107 | ) | 69 | ||||||||
Total
tax provision
|
$ | (97 | ) | $ | 651 | $ | 1,230 | |||||
Effective
tax rate
|
(20.7 | )% | 51.0 | % | 29.3 | % |
(1)
|
Includes the tax provision for statutory taxable income in foreign jurisdictions for which there is no corresponding amount in “Income from Continuing Operations Before Income Taxes.” |
Provision
(Credit) for Income Taxes
|
||||||||||||||||||||||||||||||||||||
2009
|
2008
|
2007
|
||||||||||||||||||||||||||||||||||
In
millions
|
Current
|
Deferred
|
Total
|
Current
|
Deferred
|
Total
|
Current
|
Deferred
|
Total
|
|||||||||||||||||||||||||||
Federal
|
$ | 65 | $ | (538 | ) | $ | (473 | ) | $ | 3 | $ | (541 | ) | $ | (538 | ) | $ | 77 | $ | 128 | $ | 205 | ||||||||||||||
State
and local
|
27 | (15 | ) | 12 | 6 | (17 | ) | (11 | ) | 87 | 3 | 90 | ||||||||||||||||||||||||
Foreign
|
463 | (99 | ) | 364 | 918 | 282 | 1,200 | 586 | 349 | 935 | ||||||||||||||||||||||||||
Total
|
$ | 555 | $ | (652 | ) | $ | (97 | ) | $ | 927 | $ | (276 | ) | $ | 651 | $ | 750 | $ | 480 | $ | 1,230 |
Deferred
Tax Balances at December 31
|
2009
|
2008
|
||||||||||||||
In
millions
|
Deferred Tax Assets
(1)
|
Deferred Tax Liabilities
(2)
|
Deferred Tax Assets
(1)
|
Deferred
Tax Liabilities
|
||||||||||||
Property
|
$ | 20 | $ | 2,647 | $ | 99 | $ | 1,908 | ||||||||
Tax
loss and credit carryforwards
|
2,414 | - | 2,226 | - | ||||||||||||
Postretirement
benefit obligations
|
3,097 | 1,039 | 2,642 | 950 | ||||||||||||
Other
accruals and reserves
|
1,963 | 227 | 1,462 | 306 | ||||||||||||
Intangibles
|
40 | 1,646 | 56 | 76 | ||||||||||||
Inventory
|
203 | 182 | 139 | 200 | ||||||||||||
Long-term
debt
|
8 | 107 | 3 | 89 | ||||||||||||
Investments
|
103 | 21 | 186 | 1 | ||||||||||||
Other
– net
|
460 | 370 | 791 | 153 | ||||||||||||
Subtotal
|
$ | 8,308 | $ | 6,239 | $ | 7,604 | $ | 3,683 | ||||||||
Valuation
allowance
|
(721 | ) | - | (487 | ) | - | ||||||||||
Total
|
$ | 7,587 | $ | 6,239 | $ | 7,117 | $ | 3,683 |
(1)
|
Included in current deferred tax assets are prepaid tax assets totaling $151 million in 2009 and $141 million in 2008. | |||||||||||||||
(2)
|
The Company assumed $2,793 million of deferred tax liabilities with the April 1, 2009 acquisition of Rohm and Haas; see Note D. |
Total
Gross Unrecognized Tax Benefits
|
||||||||
In
millions
|
2009
|
2008
|
||||||
Balance
at January 1
|
$ | 736 | $ | 892 | ||||
Increases
related to positions taken on items from prior years
|
57 | 41 | ||||||
Decreases
related to positions taken on items from prior years
|
(25 | ) | (191 | ) | ||||
Increases
related to positions taken in the current year
|
71 | 34 | ||||||
Settlement
of uncertain tax positions with tax authorities
|
(172 | ) | (29 | ) | ||||
Decreases
due to expiration of statutes of limitations
|
(17 | ) | (11 | ) | ||||
Balance
at December 31
|
$ | 650 | $ | 736 |
Tax
Years Subject to Examination by Major Tax Jurisdiction at December
31
|
||
Jurisdiction
|
Earliest
Open Year
|
|
2009
|
2008
|
|
Argentina
|
2003
|
2002
|
Brazil
|
2004
|
2003
|
Canada
|
2002
|
2001
|
France
|
2007
|
2007
|
Germany
|
2002
|
2002
|
Italy
|
2004
|
2004
|
The
Netherlands
|
2008
|
2008
|
Spain
|
2004
|
2004
|
Switzerland
|
2008
|
2006
|
United
Kingdom
|
2007
|
2006
|
United
States:
|
||
Federal
income tax
|
2004
|
2001
|
State
and local income tax
|
1989
|
1989
|
|
·
|
Products: ACuPLANE™ CMP
slurries; AR™ antireflective coatings; AUROLECTROLESS™ immersion gold
process; COPPER GLEAM™ acid copper plating products; DURAPOSIT™
electroless nickel process; ENLIGHT™ products for photovoltaic
manufacturers; EPIC™ immersion photoresists; INTERVIA™ photodielectrics
for advanced packaging; LITHOJET™ digital imaging processes; OPTOGRADE™
metalorganic precursors; VISIONPAD™ CMP
pads
|
|
·
|
Products and Services:
Acrolein derivatives; ACUDYNE™ hair fixatives; ACULYN™ rheology modifiers;
ACUMER™ scale inhibitors and dispersants; AMBERLITE™ ion exchange resins;
AUTOMATE™ liquid dyes; Basic nitroparaffins and nitroparaffin-based
specialty chemicals; BOROL™ bleaching solution; CANGUARD™ BIT
preservatives; CELLOSIZE™ hydroxyethyl cellulose; Chiral compounds and
biocatalysts; CLEAR+STABLE™ carboxymethyl cellulose; CORRGUARD™ amino
alcohol; CYCLOTENE™ advanced electronics resins; DOW™ electrodeionization;
DOW™ latex powders; DOW™ ultrafiltration; DOWEX™ ion exchange resins;
DOWICIDE™ antimicrobial bactericides and fungicides; DURAPLUS™ floor care
polymers; ECOSURF™ biodegradable surfactants; EVOCAR™ vinyl acetate
ethylene; FILMTEC™ elements; FORTEFIBER™ soluble dietary fiber;
FOUNDATIONS™ latex; Hydrocarbon resins; Industrial biocides; METHOCEL™
cellulose ethers; MORTRACE™ marking technologies; NEOCAR™ branched vinyl
ester latexes; OPULYN™ opacifiers; POLYOX™ water-soluble resins; PRIMENE™
amines; Quaternaries; Reverse osmosis, electrodeionization and
ultrafiltration modules; SATINFX™ delivery system; SATISFIT™ Weight Care
Technology; SILK™ semiconductor dielectric resins; SOLTERRA™ Boost
ultraviolet protection-boosting polymers; SOLTEX™ waterproofing polymer;
SUNSPHERES™ SPF boosters; UCAR™ all-acrylic, styrene-acrylic and
vinyl-acrylic latexes; UCAR™ POLYPHOBE™ rheology modifiers; UCARE™
polymers; UCARHIDE™ opacifier; WALOCEL™ cellulose polymers; WALSRODER™
nitrocellulose
|
|
·
|
Products: ADCOTE™ and
AQUA-LAM™ laminating adhesives; MOR-FREE™ solventless adhesives; ROBOND™
acrylic adhesives; SERFENE™ barrier coatings; Solvent-based polyurethanes
and polyesters; TYMOR™ tie resins
|
|
·
|
Products: AQUASET™
acrylic thermosetting resins; CELLOSIZE™ hydroxyethyl cellulose;
FROTH-PAK™ polyurethane spray foam; GREAT STUFF™ polyurethane foam
sealant; INSTA-STIK™ roof insulation adhesive; POWERHOUSE™ solar shingle;
RHOPLEX™ aqueous acrylic polymer emulsions; STYROFOAM™ brand insulation
products (including extruded polystyrene and polyisocyanurate rigid foam
sheathing products); THERMAX™ insulation; TILE BOND™ roof tile adhesive;
WEATHERMATE™ weather barrier solutions (housewraps, sill pans, flashings
and tapes)
|
|
·
|
Products: ACRYSOL™
rheology modifiers; AVANSE™, ELASTENE™, PRIMAL™ and RHOPLEX™ acrylics;
CELLOSOLVE™ and the CARBITOL™ and DOWANOL™ series of oxygenated solvents;
D.E.H.™ curing agent and intermediates; D.E.R.™ and D.E.N.™ liquid and
epoxy resins; FORTEGRA™ Epoxy Tougheners; OROTAN™ and TAMOL™ dispersants;
ROPAQUE™ opaque polymers; TRITON™, TERGITOL™, DOWFAX™ and ECOSURF™ SA
surfactants
|
|
·
|
Products: AGROMEN™
seeds; BRODBECK™ seed; CLINCHER™ herbicide; DAIRYLAND™ seed; DELEGATE™
insecticide; DITHANE™ fungicide; FORTRESS™ fungicide; GARLON™ herbicide;
GLYPHOMAX™ herbicide; GRANITE™ herbicide; HERCULEX™ I, HERCULEX™ RW and
HERCULEX™ XTRA insect protection; KEYSTONE™ herbicides; LAREDO™ fungicide;
LONTREL™ herbicide; LORSBAN™ insecticides; MILESTONE™ herbicide; MUSTANG™
herbicide; MYCOGEN™ seeds; NEXERA™ canola and sunflower seeds; PHYTOGEN™
cottonseeds; PROFUME™ gas fumigant; RENZE™ seed; SENTRICON™ termite colony
elimination system; SIMPLICITY™ herbicide; STARANE™ herbicide; TELONE™
soil fumigant; TORDON™ herbicide; TRACER™ NATURALYTE™ insect control;
TRIUMPH™ seed; VIKANE™ structural fumigant; WIDESTRIKE™ insect
protection
|
|
·
|
Products: AERIFY™ diesel
particulate filters; BETAFOAM™ NVH acoustical foams; BETAMATE™ structural
adhesives; BETASEAL™ glass bonding systems; DOW™ polyethylene resins;
IMPAXX™ energy management foam; INSPIRE™ performance polymers; INTEGRAL™
adhesive films; ISONATE™ pure and modified methylene diphenyl diisocyanate
(MDI) products; MAGNUM™ ABS resins; PELLETHANE™ thermoplastic polyurethane
elastomers; Premium brake fluids and lubricants; PULSE™ engineering
resins; SPECFLEX™ semi-flexible polyurethane foam
systems
|
|
·
|
Products: ADVASTAB™
thermal stabilizer; AFFINITY™ polyolefin plastomers (POPs); AMPLIFY™
functional polymers; DOW™ Adhesive Film; DOW™ Backing Layer Film; DOW™
Medical Device Film; DOW™ Medical Packaging Film; DOW™ very low density
polyethylene; ENGAGE™ polyolefin elastomers; INFUSE™ olefin block
copolymers; INTEGRAL™ adhesive films; NORDEL™ hydrocarbon rubber; NYLOPAK™
nylon barrier films; OPTICITE™ films; PARALOID™ EXL impact modifier;
PRIMACOR™ copolymers; PROCITE™ window envelope films; PULSE™ engineering
resins; SARAN™ barrier resins; SARANEX™ barrier films; TRENCHCOAT™
protective films; TRYCITE™ polystyrene film; TYBRITE™ clear packaging
film; TYRIN™ chlorinated polyethylene; VERSIFY™ plastomers and
elastomers
|
|
·
|
Products: ENGAGE™ polyolefin elastomers; NORDEL™
hydrocarbon rubber; SI-LINK™ and REDI-LINK™ moisture crosslinkable
polyethylene-based wire and cable insulation compounds; TYRIN™ chlorinated
polyethylene; UNIGARD™ flame retardant compound for specialty wire and
cable applications
|
|
·
|
Products: AIRSTONE™
epoxy systems; Encapsulants and chemical compositions; ENFORCER™
Technology and ENHANCER™ Technology for polyurethane carpet and turf
backing; HYPERKOTE™, TRAFFIDECK™ and VERDISEAL™ waterproofing systems;
HYPOL™ hydrophilic polyurethane prepolymers; RENUVA™ Renewable Resource
Technology; SPECFIL™ urethane components; SPECFLEX™ copolymer polyols;
SPECTRIM™ reaction moldable products; VORACOR™ and VORALAST™ polyurethane
systems and VORALAST™ R renewable content system; VORAMER™ industrial
adhesives and binders; VORASTAR™ polymers; XITRACK™ polyurethane rail
ballast stabilization systems
|
|
·
|
Products: Alkyl
alkanolamines; Ethanolamines; Ethyleneamines; Isopropanolamines;
Piperazine; VERSENE™ chelating
agents
|
|
·
|
Products:
Styrene-butadiene latex
|
|
·
|
Products: D.E.H.™ epoxy
curing agents or hardeners; D.E.N.™ epoxy novolac resins; D.E.R.™ epoxy
resins (liquids, solids and solutions); Epoxy intermediates (acetone,
allyl chloride, epichlorohydrin and phenol); Epoxy resin waterborne
emulsions and dispersions; FORTEGRA™ epoxy tougheners; Glycidyl
methacrylate (GMA)
|
|
·
|
Products: Acetic esters;
Acetone derivatives; Alcohols; Aldehydes; Butyl CARBITOL™ and Butyl
CELLOSOLVE™ solvents; Carboxylic acids; DOWANOL™ glycol ethers; ECOSOFT™
IK solvent; PROGLYDE™ DMM solvent; UCAR™
propionates
|
|
·
|
Products: AMBITROL™ and
NORKOOL™ coolants; CARBOWAX™ and CARBOWAX SENTRY™ polyethylene glycols and
methoxypolyethylene glycols; DOW™ polypropylene glycols; DOW™ SYMBIO base
fluid; DOWFAX™, TERGITOL™ and TRITON™ surfactants; DOWFROST™ and DOWTHERM™
heat transfer fluids; ECOSURF™ biodegradable surfactants; SYNALOX™
lubricants; UCAR™ deicing fluids; UCON™
fluids
|
|
·
|
Products: Acrylic
acid/acrylic esters; ACUMER™, ACUSOL™, DURAMAX™, OPTIDOSE™, ROMAX™ and
TAMOL™ dispersants; Methyl
methacrylate
|
|
·
|
Products: ECHELON™
polyurethane prepolymer; ISONATE™ methylene diphenyl diisocyanate (MDI);
MONOTHANE™ single component polyurethane elastomers; PAPI™ polymeric MDI;
Propylene glycol; Propylene oxide; RENUVA™ Renewable Resource Technology;
VORANATE™ isocyanate; VORANOL™ VORACTIV™ polyether and copolymer
polyols
|
|
·
|
Products: ASPUN™ fiber
grade resins; ATTANE™ ultra low density polyethylene (ULDPE) resins;
CONTINUUM™ bimodal polyethylene resins; DOW™ high density polyethylene
(HDPE) resins; DOW™ low density polyethylene (LDPE) resins; DOWLEX™
polyethylene resins; ELITE™ enhanced polyethylene (EPE) resins; TUFLIN™
linear low density polyethylene (LLDPE) resins; UNIVAL™ HDPE
resins
|
|
·
|
Products: DOW™
homopolymer polypropylene resins; DOW™ impact copolymer polypropylene
resins; DOW™ random copolymer polypropylene resins; INSPIRE™ performance
polymers; UNIPOL™ PP process technology; SHAC™ and SHAC™ ADT catalyst
systems
|
|
·
|
Products: Licensing and
supply of related catalysts, process control software and services for the
Mass ABS process technology; STYRON A-TECH™ and C-TECH™ advanced
technology polystyrene resins and a full line of STYRON™ general purpose
polystyrene resins; STYRON™ high-impact polystyrene
resins
|
|
·
|
Products: Caustic soda;
Chlorine; Ethylene dichloride (EDC); Hydrochloric acid; Vinyl chloride
monomer (VCM)
|
|
·
|
Products: Ethylene oxide
(EO); Ethylene glycol (EG); METEOR™ EO/EG process technology and
catalysts
|
|
·
|
Products: Benzene;
Butadiene; Butylene; Cumene; Ethylene; Propylene; Styrene; Power, steam
and other utilities
|
Operating
Segment Information
|
||||||||||||||||||||||||||||||||||||||||
In
millions
|
Electronic
and Specialty Materials
|
Coatings
and Infrastructure
|
Health
and Ag Sciences
|
Perf
Systems
|
Perf
Products
|
Basic
Plastics
|
Basic
Chemicals
|
Hydrocarbons
and Energy
|
Corp
|
Total
|
||||||||||||||||||||||||||||||
2009
|
||||||||||||||||||||||||||||||||||||||||
Sales
to external customers
|
$ | 4,119 | $ | 4,156 | $ | 4,522 | $ | 5,744 | $ | 8,996 | $ | 9,925 | $ | 2,467 | $ | 4,241 | $ | 705 | $ | 44,875 | ||||||||||||||||||||
Intersegment
revenues
|
- | - | - | - | 51 | - | 52 | - | (103 | ) | - | |||||||||||||||||||||||||||||
Equity
in earnings of nonconsolidated affiliates
|
290 | 3 | 2 | 4 | 31 | 112 | 163 | 33 | (8 | ) | 630 | |||||||||||||||||||||||||||||
Goodwill
impairment losses (1)
|
- | - | - | - | 7 | - | - | - | - | 7 | ||||||||||||||||||||||||||||||
Restructuring
charges (2)
|
68 | 171 | (15 | ) | - | 73 | 1 | 75 | 65 | 251 | 689 | |||||||||||||||||||||||||||||
IPR&D
(3)
|
- | - | - | - | - | - | - | - | 7 | 7 | ||||||||||||||||||||||||||||||
Acquisition
and integration related expenses (4)
|
- | - | - | - | - | - | - | - | 166 | 166 | ||||||||||||||||||||||||||||||
EBITDA
(5)
|
1,046 | 367 | 573 | 674 | 1,142 | 1,665 | 103 | 391 | (1,133 | ) | 4,828 | |||||||||||||||||||||||||||||
Total
assets
|
17,018 | 6,663 | 5,475 | 5,752 | 8,363 | 7,503 | 2,875 | 3,645 | 8,643 | 65,937 | ||||||||||||||||||||||||||||||
Investment
in nonconsolidated affiliates
|
1,042 | 28 | 38 | 111 | 409 | 883 | 360 | 331 | 22 | 3,224 | ||||||||||||||||||||||||||||||
Depreciation
and amortization
|
490 | 375 | 137 | 326 | 554 | 542 | 275 | - | 128 | 2,827 | ||||||||||||||||||||||||||||||
Capital
expenditures
|
155 | 133 | 166 | 138 | 240 | 56 | 182 | 296 | 44 | 1,410 | ||||||||||||||||||||||||||||||
2008
|
||||||||||||||||||||||||||||||||||||||||
Sales
to external customers
|
$ | 2,620 | $ | 2,654 | $ | 4,535 | $ | 7,540 | $ | 12,216 | $ | 14,240 | $ | 4,265 | $ | 8,968 | $ | 323 | $ | 57,361 | ||||||||||||||||||||
Intersegment
revenues
|
- | - | - | - | 97 | - | 65 | - | (162 | ) | - | |||||||||||||||||||||||||||||
Equity
in earnings of nonconsolidated affiliates
|
370 | 1 | 4 | (2 | ) | 52 | 115 | 214 | 41 | (8 | ) | 787 | ||||||||||||||||||||||||||||
Goodwill
impairment losses (1)
|
- | - | - | 209 | - | 30 | - | - | - | 239 | ||||||||||||||||||||||||||||||
Restructuring
charges (2)
|
10 | 16 | 3 | 70 | 39 | 148 | 103 | 18 | 432 | 839 | ||||||||||||||||||||||||||||||
IPR&D
(3)
|
- | - | 44 | - | - | - | - | - | - | 44 | ||||||||||||||||||||||||||||||
Acquisition
and integration related expenses (4)
|
- | - | - | - | - | - | - | - | 49 | 49 | ||||||||||||||||||||||||||||||
Asbestos-related
credit (6)
|
- | - | - | - | - | - | - | - | (54 | ) | (54 | ) | ||||||||||||||||||||||||||||
EBITDA
(5)
|
835 | 134 | 872 | 235 | 1,050 | 1,746 | 278 | (70 | ) | (1,005 | ) | 4,075 | ||||||||||||||||||||||||||||
Total
assets
|
4,424 | 1,544 | 4,676 | 5,100 | 7,365 | 7,215 | 3,019 | 3,233 | 8,898 | 45,474 | ||||||||||||||||||||||||||||||
Investment
in nonconsolidated affiliates
|
889 | 4 | 41 | 111 | 299 | 843 | 479 | 520 | 18 | 3,204 | ||||||||||||||||||||||||||||||
Depreciation
and amortization
|
215 | 93 | 111 | 282 | 482 | 648 | 302 | - | 103 | 2,236 | ||||||||||||||||||||||||||||||
Capital
expenditures
|
269 | 148 | 191 | 323 | 507 | 186 | 258 | 389 | 5 | 2,276 | ||||||||||||||||||||||||||||||
2007
|
||||||||||||||||||||||||||||||||||||||||
Sales
to external customers
|
$ | 2,071 | $ | 1,836 | $ | 3,779 | $ | 6,597 | $ | 12,976 | $ | 14,167 | $ | 4,434 | $ | 7,105 | $ | 410 | $ | 53,375 | ||||||||||||||||||||
Intersegment
revenues
|
- | - | - | - | 103 | 5 | 64 | - | (172 | ) | - | |||||||||||||||||||||||||||||
Equity
in earnings of nonconsolidated affiliates
|
345 | 1 | 4 | 10 | 56 | 235 | 386 | 87 | (2 | ) | 1,122 | |||||||||||||||||||||||||||||
Restructuring
charges (2)
|
27 | 20 | 77 | 155 | 55 | 96 | 7 | 44 | 97 | 578 | ||||||||||||||||||||||||||||||
IPR&D
(3)
|
7 | - | 50 | - | - | - | - | - | - | 57 | ||||||||||||||||||||||||||||||
EBITDA
(5)
|
737 | 51 | 576 | 624 | 1,991 | 2,804 | 952 | (45 | ) | (854 | ) | 6,836 | ||||||||||||||||||||||||||||
Total
assets
|
4,458 | 1,351 | 4,152 | 5,790 | 8,805 | 9,672 | 3,824 | 3,370 | 7,379 | 48,801 | ||||||||||||||||||||||||||||||
Investment
in nonconsolidated affiliates
|
953 | 4 | 38 | 78 | 256 | 758 | 579 | 402 | 21 | 3,089 | ||||||||||||||||||||||||||||||
Depreciation
and amortization
|
186 | 62 | 109 | 272 | 545 | 626 | 288 | - | 102 | 2,190 | ||||||||||||||||||||||||||||||
Capital
expenditures
|
254 | 108 | 116 | 249 | 490 | 176 | 259 | 413 | 10 | 2,075 |
(1)
|
See Note I for information regarding the goodwill impairment losses. |
|
(2)
|
See Note C for information regarding restructuring charges. |
|
(3)
|
See Note D for information regarding purchased in-process research and development. |
|
(4)
|
See Note D for information regarding acquisition and integration related expenses. |
|
(5)
|
The Company
uses EBITDA (which Dow defines as earnings before interest, income taxes,
depreciation and amortization) as its measure of profit/loss for segment
reporting purposes. EBITDA by operating segment
includes all operating items relating to the businesses; items that
principally apply to the Company as a whole are assigned to Corporate. A
reconciliation of EBITDA to “Income from Continuing Operations
Before Income Taxes” is provided below:
|
|
In millions
|
2009
|
2008
|
2007
|
|||||||||
EBITDA
|
$ | 4,828 | $ | 4,075 | $ | 6,836 | ||||||
- Depreciation
and amortization
|
2,827 | 2,236 | 2,190 | |||||||||
+
Interest income
|
39 | 86 | 130 | |||||||||
- Interest
expense and amortization of debt discount
|
1,571 | 648 | 584 | |||||||||
Income
from Continuing Operations Before Income Taxes
|
$ | 469 | $ | 1,277 | $ | 4,192 |
(6)
|
See Note N for information regarding asbestos-related credit. |
|
Geographic
Area Information
|
||||||||||||||||
In
millions
|
United
States
|
Europe
|
Rest
of World
|
Total
|
||||||||||||
2009
|
||||||||||||||||
Sales
to external customers
|
$ | 14,145 | $ | 15,069 | $ | 15,661 | $ | 44,875 | ||||||||
Long-lived
assets (1)
|
$ | 9,212 | $ | 5,173 | $ | 3,756 | $ | 18,141 | ||||||||
2008
|
||||||||||||||||
Sales
to external customers
|
$ | 18,306 | $ | 21,850 | $ | 17,205 | $ | 57,361 | ||||||||
Long-lived
assets (1)
|
$ | 7,631 | $ | 4,343 | $ | 2,320 | $ | 14,294 | ||||||||
2007
|
||||||||||||||||
Sales
to external customers
|
$ | 18,133 | $ | 19,614 | $ | 15,628 | $ | 53,375 | ||||||||
Long-lived
assets (1)
|
$ | 7,586 | $ | 4,542 | $ | 2,260 | $ | 14,388 | ||||||||
(1)
Long-lived assets in Germany represented approximately 11 percent of
the total at December 31, 2009 and 14 percent of the total at
December 31, 2008 and December 31, 2007.
|
The
Dow Chemical Company and Subsidiaries
|
||||||||||||||||||||
Selected
Quarterly Financial Data
|
||||||||||||||||||||
In
millions, except per share amounts (Unaudited)
|
||||||||||||||||||||
2009
|
1st
|
2nd
|
3rd
|
4th
|
Year
|
|||||||||||||||
Net
sales
|
$ | 9,041 | $ | 11,322 | $ | 12,046 | $ | 12,466 | $ | 44,875 | ||||||||||
Cost
of sales
|
8,138 | 9,764 | 10,386 | 10,860 | 39,148 | |||||||||||||||
Gross
margin
|
903 | 1,558 | 1,660 | 1,606 | 5,727 | |||||||||||||||
Goodwill
impairment losses
|
- | - | - | 7 | 7 | |||||||||||||||
Restructuring
charges
|
19 | 662 | - | 8 | 689 | |||||||||||||||
Purchased
in-process research and development charges
|
- | - | - | 7 | 7 | |||||||||||||||
Acquisition
and integration related expenses
|
48 | 52 | 21 | 45 | 166 | |||||||||||||||
Net
income (loss) available for common stockholders
|
24 | (486 | ) | 711 | 87 | 336 | ||||||||||||||
Earnings (Loss) per common share
- basic (1)
|
0.03 | (0.47 | ) | 0.64 | 0.08 | 0.32 | ||||||||||||||
Earnings (Loss) per common share
- diluted (1)
|
0.03 | (0.47 | ) | 0.63 | 0.08 | 0.32 | ||||||||||||||
Common
stock dividends declared per share of common
stock
|
0.15 | 0.15 | 0.15 | 0.15 | 0.60 | |||||||||||||||
Market price range of common
stock: (2)
|
||||||||||||||||||||
High
|
16.68 | 18.99 | 27.24 | 29.50 | 29.50 | |||||||||||||||
Low
|
5.89 | 8.14 | 14.22 | 23.14 | 5.89 | |||||||||||||||
2008
|
1st
|
2nd
|
3rd
|
4th
|
Year
|
|||||||||||||||
Net
sales
|
$ | 14,791 | $ | 16,349 | $ | 15,371 | $ | 10,850 | $ | 57,361 | ||||||||||
Cost
of sales
|
12,884 | 14,621 | 13,949 | 10,459 | 51,913 | |||||||||||||||
Gross
margin
|
1,907 | 1,728 | 1,422 | 391 | 5,448 | |||||||||||||||
Goodwill
impairment losses
|
- | - | - | 239 | 239 | |||||||||||||||
Restructuring
charges
|
- | - | - | 839 | 839 | |||||||||||||||
Purchased
in-process research and development charges
|
- | - | 27 | 17 | 44 | |||||||||||||||
Acquisition
and integration related expenses
|
- | - | 18 | 31 | 49 | |||||||||||||||
Asbestos-related
credit
|
- | - | - | 54 | 54 | |||||||||||||||
Net
income (loss) available for common stockholders
|
941 | 762 | 428 | (1,552 | ) | 579 | ||||||||||||||
Earnings (Loss) per common share
- basic (3)
|
1.00 | 0.82 | 0.46 | (1.68 | ) | 0.62 | ||||||||||||||
Earnings (Loss) per common share
- diluted (3)
|
0.99 | 0.81 | 0.46 | (1.68 | ) | 0.62 | ||||||||||||||
Common
stock dividends declared per share of common
stock
|
0.42 | 0.42 | 0.42 | 0.42 | 1.68 | |||||||||||||||
Market price range of common
stock: (2)
|
||||||||||||||||||||
High
|
40.04 | 43.43 | 39.99 | 32.28 | 43.43 | |||||||||||||||
Low
|
33.01 | 34.30 | 30.82 | 14.93 | 14.93 | |||||||||||||||
See
Notes to the Consolidated Financial Statements.
|
||||||||||||||||||||
(1)
|
Due to an increase in the share count during 2009 and a loss in the 2nd quarter, the sum of the four quarters does not equal the earnings per share amount calculated for the year. |
(2)
|
Composite price as reported by the New York Stock Exchange. |
(3)
|
Due to a decline in the share count during 2008 and a loss in the 4th quarter, the sum of the four quarters does not equal the earnings per share amount calculated for the year. |
|
·
|
pertain
to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the
Company;
|
|
·
|
provide
reasonable assurance that transactions are recorded properly to allow for
the preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the
Company are being made only in accordance with authorizations of
management and Directors of the Company;
|
|
·
|
provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the Company’s assets that
could have a material effect on the consolidated financial statements;
and
|
|
·
|
provide
reasonable assurance as to the detection of
fraud.
|
/s/
ANDREW N. LIVERIS
|
/s/
WILLIAM H. WEIDEMAN
|
|
Andrew
N. Liveris
President,
Chief Executive Officer and
Chairman
of the Board
|
William
H. Weideman
Vice
President and Interim Chief Financial Officer
|
|
/s/
RONALD C. EDMONDS
|
||
Ronald
C. Edmonds
Vice
President and Controller
|
||
February
19, 2010
|
/s/
DELOITTE & TOUCHE LLP
|
||
Deloitte
& Touche
LLP
Midland,
Michigan
|
||
February
19, 2010
|
|
(1)
|
The
Company’s 2009 Consolidated Financial Statements and the Report of
Independent Registered Public Accounting Firm are included in Part II,
Item 8. Financial Statements and Supplementary
Data.
|
|
(2)
|
Financial
Statement Schedules – The following Financial Statement Schedule should be
read in conjunction with the Consolidated Financial Statements and Report
of Independent Registered Public Accounting Firm included in Part II, Item
8. Financial Statements and Supplementary
Data:
|
Schedule
II
|
Valuation
and Qualifying Accounts
|
|
(3)
|
Exhibits
– See the Exhibit Index on pages 166-172 of this Annual Report on Form
10-K for exhibits filed with this Annual Report on Form 10-K or
incorporated by reference. The following exhibits, listed on the Exhibit
Index, are filed with this Annual Report on Form
10-K:
|
Exhibit
No.
|
Description
of Exhibit
|
|
Computation
of Ratio of Earnings to Fixed Charges.
|
||
Subsidiaries
of The Dow Chemical Company.
|
||
Consent
of Independent Registered Public Accounting Firm.
|
||
Analysis,
Research & Planning Corporation’s Consent.
|
||
Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
XBRL
Instance Document (1)
|
|
101.SCH
|
XBRL
Taxonomy Extension Schema Document (1)
|
|
101.CAL
|
XBRL
Taxonomy Extension Calculation Linkbase Document (1)
|
|
101.LAB
|
XBRL
Taxonomy Extension Label Linkbase Document (1)
|
|
101.PRE
|
XBRL
Taxonomy Extension Presentation Linkbase Document (1)
|
|
(1)
|
Pursuant
to Rule 406T of Regulation S-T, this interactive data file is deemed not
filed or part of a registration statement or prospectus for purposes of
sections 11 or 12 of the Securities Act of 1933, is deemed not filed for
purposes of section 18 of the Securities Exchange Act of 1934, and
otherwise is not subject to liability under these
sections.
|
|
The
Dow Chemical Company and Subsidiaries
|
|
Schedule
II
|
Valuation and Qualifying Accounts | |||
In
millions
|
For
the Years Ended December 31
|
COLUMN
A
|
COLUMN
B
|
COLUMN
C
|
COLUMN
D
|
COLUMN
E
|
||||||||||||||
Description
|
Balance
at
Beginning
of
Year
|
Additions
to Reserves
|
Deductions
from
Reserves
|
Balance
at
End
of
Year
|
||||||||||||||
2009 | ||||||||||||||||||
RESERVES
DEDUCTED FROM ASSETS TO WHICH THEY APPLY:
|
||||||||||||||||||
For doubtful receivables | $ | 124 | 59 | 23 | (1) | $ | 160 | |||||||||||
Other
investments and noncurrent receivables
|
$ | 442 | 162 | 52 | $ | 552 | ||||||||||||
2008 | ||||||||||||||||||
RESERVES
DEDUCTED FROM ASSETS TO WHICH THEY APPLY:
|
||||||||||||||||||
For doubtful receivables | $ | 118 | 39 | 33 | (1) | $ | 124 | |||||||||||
Other
investments and noncurrent receivables
|
$ | 473 | 20 | 51 | $ | 442 | ||||||||||||
2007 | ||||||||||||||||||
RESERVES
DEDUCTED FROM ASSETS TO WHICH THEY APPLY:
|
||||||||||||||||||
For
doubtful receivables
|
$ | 122 | 14 | 18 | (1) | $ | 118 | |||||||||||
Other
investments and noncurrent receivables
|
$ | 365 | 122 | 14 | $ | 473 | ||||||||||||
2009
|
2008
|
2007
|
||||||||||
(1)
Deductions represent:
|
||||||||||||
Notes
and accounts receivable written off
|
$ | 21 | $ | 23 | $ | 22 | ||||||
Credits
to profit and loss
|
1 | 6 | - | |||||||||
Miscellaneous
other
|
1 | 4 | (4 | ) | ||||||||
$ | 23 | $ | 33 | $ | 18 |
THE
DOW CHEMICAL COMPAY
|
||
By
|
/s/ R.
C. EDMONDS
|
|
R.
C. Edmonds, Vice President and Controller
|
||
Date
|
February 10,
2010
|
By
|
/s/ A.
A. ALLEMANG
|
By
|
/s/ A.
N. LIVERIS
|
|
A.
A. Allemang, Director
|
A.
N. Liveris, Director, President, Chief Executive Officer and Chairman of
the Board
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/ J.
K. BARTON
|
By
|
/s/ P.
POLMAN
|
|
J.
K. Barton, Director
|
P.
Polman, Director
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/
J. A. BELL
|
By
|
/s/ D.
H. REILLEY
|
|
J.
A. Bell, Director
|
D.
H. Reilley, Director
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/ R.
C. EDMONDS
|
By
|
/s/ J.
M. RINGLER
|
|
R.
C. Edmonds, Vice President and Controller
|
J.
M. Ringler, Director
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/ J.
M. FETTIG
|
By
|
/s/ R.
G. SHAW
|
|
J.
M. Fettig, Director
|
R.
G. Shaw, Director
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/ B.
H. FRANKLIN
|
By
|
/s/ P.
G. STERN
|
|
B.
H. Franklin, Director
|
P.
G. Stern, Presiding Director
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
By
|
/s/ J.
B. HESS
|
By
|
/s/ W.
H. WEIDEMAN
|
|
J.
B. Hess, Director
|
W.
H. Weideman, Vice President and Interim Chief Financial
Officer
|
|||
Date
|
February 10,
2010
|
Date
|
February 10,
2010
|
|
EXHIBIT
NO.
|
DESCRIPTION
|
|
2(a)
|
Agreement
and Plan of Merger dated as of August 3, 1999 among Union Carbide
Corporation, The Dow Chemical Company and Transition Sub Inc.,
incorporated by reference to Annex A to the proxy statement/prospectus
included in The Dow Chemical Company’s Registration Statement on Form S-4,
File No. 333-88443, filed October 5,
1999.
|
|
2(b)
|
Agreement
and Plan of Merger, dated as of July 10, 2008, among The Dow Chemical
Company, Ramses Acquisition Corp. and Rohm and Haas Company, incorporated
by reference to Exhibit 2.1 to The Dow Chemical Company Current
Report on Form 8-K filed on July 10,
2008.
|
|
2(c)
|
Joint
Venture Formation Agreement, dated November 28, 2008, between The Dow
Chemical Company and Petroleum Industries Company (K.S.C.), incorporated
by reference to Exhibit 2.1 to The Dow Chemical Company Current
Report on Form 8-K filed on February 19,
2009.
|
|
2(d)
|
Stock
Purchase Agreement, dated as of April 1, 2009, between Rohm and Haas
Company and K+S Aktiengesellschaft, incorporated by reference to
Exhibit 2.1 to The Dow Chemical Company Current Report on
Form 8-K filed on April 7,
2009.
|
|
2(d)(i)
|
Amendment
No. 1, dated as of October 1, 2009, to the Stock Purchase
Agreement, dated as of April 1, 2009, between Rohm and Haas Company
and K+S Aktiengesellschaft, incorporated by reference to
Exhibit 2(d)(i) to The Dow Chemical Company Quarterly Report for the
quarter ended September 30, 2009.
|
|
3(i)
|
The
Restated Certificate of Incorporation of The Dow Chemical Company as filed
with the Secretary of State, State of Delaware on May 11, 2007,
incorporated by reference to Exhibit 3(i) to The Dow Chemical Company
Quarterly Report on Form 10-Q for the quarter ended June 30,
2007.
|
|
3(i)(a)
|
Certificate
of Designations for the Cumulative Convertible Perpetual Preferred Stock,
Series A, as filed with the Secretary of State, State of Delaware on
March 31, 2009, incorporated by reference to Exhibit 3.1 to The
Dow Chemical Company Current Report on Form 8-K filed on
April 1, 2009.
|
|
3(ii)
|
The
Bylaws of The Dow Chemical Company, as amended and re-adopted in full on
February 10, 2010, effective February 10, 2010, incorporated by
reference to Exhibit 99.1 to The Dow Chemical Company Current Report
on Form 8-K filed on February 12,
2010.
|
|
4
|
Indenture,
dated as of April 1, 1992, between The Dow Chemical Company and the First
National Bank of Chicago, as trustee (incorporated by reference to Exhibit
4.1 to The Dow Chemical Company’s Registration Statement on Form S-3, File
No. 333-88617 (the "S-3 Registration Statement")), as amended by the
Supplemental Indenture, dated as of January 1, 1994, between The Dow
Chemical Company and The First National Bank of Chicago, as trustee
(incorporated by reference to Exhibit 4.2 to the S-3 Registration
Statement), as amended by the Second Supplemental Indenture, dated as of
October 1, 1999, between The Dow Chemical Company and Bank One Trust
Company, N.A. (formerly The First National Bank of Chicago), as trustee
(incorporated by reference to Exhibit 4.3 to the S-3 Registration
Statement), as amended by the Third Supplemental Indenture, dated as of
May 15, 2001, between The Dow Chemical Company and Bank One Trust Company,
N.A. (formerly The First National Bank of Chicago), as trustee
(incorporated by reference to Exhibit 4.4 to The Dow Chemical Company’s
Registration Statement on Form S-4, File No. 333-67368); and all other
such indentures that define the rights of holders of long-term debt of The
Dow Chemical Company and its consolidated subsidiaries as shall be
requested to be furnished to the Securities and Exchange Commission
pursuant to Item 601(b)(4)(iii)(A) of Regulation
S-K.
|
|
4(a)
|
Indenture,
dated May 1, 2008, between The Dow Chemical Company and The Bank of
New York Trust Company, N.A., as trustee, incorporated by reference to
Exhibit 4.1 to Post-Effective Amendment No. 1 to The Dow
Chemical Company’s Registration Statement on Form S-3, File
No. 333-140859.
|
|
10(a)
|
The
Dow Chemical Company Executives’ Supplemental Retirement Plan, as amended,
restated and effective as of January 1, 2009, incorporated by
reference to Exhibit 10(a) to The Dow Chemical Company Annual Report
on Form 10-K for the year ended December 31,
2008.
|
|
10(b)
|
The
Dow Chemical Company 1979 Award and Option Plan, as amended and restated
on May 13, 1983, incorporated by reference to Exhibit 10(b) to
The Dow Chemical Company Quarterly Report on Form 10-Q for the quarter
ended March 31, 2009.
|
|
10(b)(i)
|
A
resolution adopted by the Board of Directors of The Dow Chemical Company
on April 12, 1984 amending The Dow Chemical Company 1979 Award and
Option Plan, incorporated by reference to Exhibit 10(b)(i) to The Dow
Chemical Company Quarterly Report on Form 10-Q for the quarter ended
March 31, 2009.
|
|
10(b)(ii)
|
A
resolution adopted by the Board of Directors of The Dow Chemical Company
on April 18, 1985 amending The Dow Chemical Company 1979 Award and
Option Plan, incorporated by reference to Exhibit 10(b)(ii) to The
Dow Chemical Company Quarterly Report on Form 10-Q for the quarter ended
March 31, 2009.
|
|
10(b)(iii)
|
A
resolution adopted by the Executive Committee of the Board of Directors of
The Dow Chemical Company on October 30, 1987 amending The Dow
Chemical Company 1979 Award and Option Plan, incorporated by reference to
Exhibit 10(b)(iii) to The Dow Chemical Company Quarterly Report on
Form 10-Q for the quarter ended March 31,
2009.
|
|
10(c)
|
The
Dow Chemical Company Voluntary Deferred Compensation Plan for Outside
Directors (for deferrals made through December 31, 2004), as amended
effective as of July 1, 1994, incorporated by reference to Exhibit 10(f)
to The Dow Chemical Company Annual Report on Form 10-K for the year ended
December 31, 1994, as amended in the manner described in the
definitive Proxy Statement for the Annual Meeting of Stockholders of The
Dow Chemical Company held on May 14, 1998, incorporated by
reference.
|
|
10(d)
|
Intentionally
left blank.
|
|
10(e)
|
The
Dow Chemical Company Dividend Unit Plan, incorporated by reference to
Exhibit 10(e) to The Dow Chemical Company Quarterly Report on Form 10-Q
for the quarter ended March 31,
2009.
|
|
10(f)
|
The
Dow Chemical Company 1988 Award and Option Plan, as amended and restated
on December 10, 2008, effective as of January 1, 2009,
incorporated by reference to Exhibit 10(f) to The Dow Chemical
Company Annual Report on Form 10-K for the year ended December 31,
2008.
|
|
10(g)
|
Intentionally
left blank.
|
|
10(h)
|
The
Dow Chemical Company 1994 Executive Performance Plan, as amended and
restated on December 10, 2008, effective as of January 1, 2009,
incorporated by reference to Exhibit 10(h) to The Dow Chemical
Company Annual Report on Form 10-K for the year ended December 31,
2008.
|
|
10(i)
|
The
Dow Chemical Company 1994 Non-Employee Directors’ Stock Plan, incorporated
by reference to Exhibit 10(i) to The Dow Chemical Company Quarterly
Report on Form 10-Q for the quarter ended March 31,
2009.
|
|
10(j)
|
Intentionally
left blank.
|
|
10(k)
|
A
written description of the 1998 Non-Employee Directors’ Stock Incentive
Plan, incorporated by reference to the definitive Proxy Statement for the
Annual Meeting of Stockholders of The Dow Chemical Company held on
May 14, 1998.
|
|
10(l)
|
A
written description of compensation for Directors of The Dow Chemical
Company, incorporated by reference to the definitive Proxy Statement for
the Annual Meeting of Stockholders of The Dow Chemical Company to be held
on May 13, 2010.
|
|
10(m)
|
A
written description of the manner in which compensation is set for the
Executive Officers of The Dow Chemical Company, incorporated by reference
to the definitive Proxy Statement for the Annual Meeting of Stockholders
of The Dow Chemical Company to be held on May 13,
2010.
|
|
10(n)
|
A
resolution adopted by the Board of Directors of The Dow Chemical Company
on May 5, 1971, and most recently amended on July 9, 1998,
describing the employee compensation program for decelerating Directors,
incorporated by reference to Exhibit 10(p) to The Dow Chemical Company
Annual Report on Form 10-K for the year ended December 31, 1998; as
amended, re-adopted in full and restated on March 21, 2003,
incorporated by reference to Exhibit 10(n) to The Dow Chemical Company
Quarterly Report on Form 10-Q for the quarter ended March 31, 2003;
as amended, re-adopted in full and restated on February 10, 2005,
incorporated by reference to Exhibit 10(n) to The Dow Chemical Company
Quarterly Report on Form 10-Q for the quarter ended March 31,
2005.
|
|
10(o)
|
The
template used for The Dow Chemical Company Key Employee Insurance Program
(“KEIP”), which provides benefits using insurance policies that replace
benefits otherwise payable under The Dow Chemical Company Executives’
Supplemental Retirement Plan and Company-Paid Life Insurance Plan,
incorporated by reference to Exhibit 10(o) to The Dow Chemical Company
Annual Report on Form 10-K for the year ended December 31, 2002. KEIP
is a component of the annual pension benefits listed in and incorporated
by reference to the definitive Proxy Statement for the Annual Meeting of
Stockholders of The Dow Chemical Company to be held on May 13,
2010.
|
|
10(p)
|
The
Dow Chemical Company Elective Deferral Plan (for deferrals made through
December 31, 2004), as amended, restated and effective as of
January 1, 2010, incorporated by reference to Exhibit 10.1 to
The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(q)
|
The
Rohm and Haas Company Non-Qualified Savings Plan (for deferrals made
through December 31, 2004), amended and restated effective as of
January 1, 2010, incorporated by reference to Exhibit 10.2 to
The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(r)
|
The
Rohm and Haas Company Non-Qualified Savings Plan (for deferrals made after
January 1, 2005), amended and restated effective as of
January 1, 2010, incorporated by reference to Exhibit 10.3 to
The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(s)
|
The
Summary Plan Description for The Dow Chemical Company Company-Paid Life
Insurance Plan, Employee-Paid Life Insurance Plan, and Dependent Life
Insurance Plan, amended and restated on October 19, 2009, effective
as of January 1, 2010, incorporated by reference to Exhibit 10.4
to The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(t)
|
The
Summary Plan Description for The Dow Chemical Company Retiree Company-Paid
Life Insurance Plan, Retiree Optional Life Insurance Plan, and Retiree
Dependent Life Insurance Plan, amended and restated on October 19,
2009, effective as of January 1, 2010, incorporated by reference to
Exhibit 10.5 to The Dow Chemical Company Current Report on Form 8-K
filed on February 18, 2010.
|
|
10(u)
|
Amended
and Restated 2003 Non-Employee Directors’ Stock Incentive Plan, adopted by
the Board of Directors of The Dow Chemical Company on December 10,
2007, incorporated by reference to Exhibit 10(u) to The Dow Chemical
Company Annual Report on Form 10-K for the year ended December 31,
2007.
|
|
10(v)
|
Non-Qualified
Stock Option Agreement Pursuant to The Dow Chemical Company 1994
Non-Employee Directors’ Stock Plan, incorporated by reference to
Exhibit 10.1 to The Dow Chemical Company Current Report on
Form 8-K filed on September 3,
2004.
|
|
10(w)
|
Non-Qualified
Stock Option Agreement Pursuant to The Dow Chemical Company 2003
Non-Employee Directors’ Stock Incentive Plan, incorporated by reference to
Exhibit 10(w) to The Dow Chemical Company Quarterly Report on
Form 10-Q for the quarter ended September 30,
2004.
|
|
10(x)
|
The
Performance Shares Deferred Stock Agreement Pursuant to The Dow Chemical
Company 1988 Award and Option Plan, as amended, restated and effective as
of January 1, 2009, incorporated by reference to Exhibit 10(x)
to The Dow Chemical Company Annual Report on Form 10-K for the year ended
December 31, 2008.
|
|
10(y)
|
The
Deferred Stock Agreement Pursuant to The Dow Chemical Company 1988 Award
and Option Plan, as amended, restated and effective as of January 1, 2009,
incorporated by reference to Exhibit 10(y) to The Dow Chemical
Company Annual Report on Form 10-K for the year ended December 31,
2008.
|
|
10(z)
|
The
Non-Qualified Stock Option Agreement Pursuant to The Dow Chemical Company
1988 Award and Option Plan, as amended, restated and effective as of
January 1, 2009, incorporated by reference to Exhibit 10(z) to
The Dow Chemical Company Annual Report on Form 10-K for the year ended
December 31, 2008.
|
|
10(aa)
|
Settlement
Agreement and General Release between Richard L. Manetta and The Dow
Chemical Company dated December 10, 2004, incorporated by reference
to Exhibit 10.1 to The Dow Chemical Company Current Report on
Form 8-K filed on December 16,
2004.
|
|
10(bb)
|
Deferred
Compensation Agreement between Richard L. Manetta and The Dow Chemical
Company dated December 10, 2004, incorporated by reference to Exhibit 10.2
to The Dow Chemical Company Current Report on Form 8-K filed on
December 16, 2004.
|
|
10(cc)
|
The
Dow Chemical Company Voluntary Deferred Compensation Plan for Non-Employee
Directors, effective for deferrals after January 1, 2005, as amended and
restated on December 10, 2008, effective as of January 1, 2009,
incorporated by reference to Exhibit 10(cc) to The Dow Chemical
Company Annual Report on Form 10-K for the year ended December 31,
2008.
|
|
10(dd)
|
The
Dow Chemical Company Elective Deferral Plan, effective for deferrals after
January 1, 2005, as amended, restated and effective as of January 1,
2010, incorporated by reference to Exhibit 10.6 to The Dow Chemical
Company Current Report on Form 8-K filed on February 18,
2010.
|
|
10(ee)
|
The
template for communication to employee Directors who are decelerating
pursuant to The Dow Chemical Company Retirement Policy for Employee
Directors, incorporated by reference to Exhibit 10(ee) to The Dow Chemical
Company Quarterly Report on Form 10-Q for the quarter ended June 30,
2005.
|
|
10(ff)
|
Purchase
and Sale Agreement dated as of September 30, 2005 between Catalysts,
Adsorbents and Process Systems, Inc. and Honeywell Specialty Materials
LLC, incorporated by reference to Exhibit 10(ff) to The Dow Chemical
Company Quarterly Report on Form 10-Q for the quarter ended September 30,
2005.
|
|
10(gg)
|
Employment
agreement with Geoffery Merszei, Executive Vice President and Chief
Financial Officer, incorporated by reference to Exhibit 10(gg) to The Dow
Chemical Company Annual Report on Form 10-K for the year ended December
31, 2005.
|
|
10(hh)
|
Employment
agreement dated June 18, 2005, between William F. Banholzer and The
Dow Chemical Company, incorporated by reference to the Current Report on
Form 8-K filed on March 16,
2006.
|
|
10(ii)
|
Employment
agreement dated February 14, 2006, between Heinz Haller and The Dow
Chemical Company, incorporated by reference to Exhibit 10(ii) to The
Dow Chemical Company Annual Report on Form 10-K for the year ended
December 31, 2008.
|
|
10(jj)
|
Change
in Control Executive Severance Agreement - Tier 1, incorporated by
reference to Exhibit 10(jj) to The Dow Chemical Company Annual Report on
Form 10-K for the year ended December 31,
2007.
|
|
10(kk)
|
Change
in Control Executive Severance Agreement - Tier 2, incorporated by
reference to Exhibit 10(kk) to The Dow Chemical Company Annual Report on
Form 10-K for the year ended December 31,
2007.
|
|
10(ll)
|
Voting
Agreement dated as of July 10, 2008, by and among Rohm and Haas
Company, The Dow Chemical Company and each of the persons and entities
listed on Schedule I thereto, incorporated by reference to
Exhibit 10.1 to The Dow Chemical Company Current Report on Form 8-K
filed on July 10, 2008.
|
|
10(mm)
|
Term
Loan Agreement, dated as of September 8, 2008, among The Dow Chemical
Company, as borrower, the lenders party thereto and Citibank, N.A, as
administrative agent for the lenders, incorporated by reference to
Exhibit 99.1 to The Dow Chemical Company Current Report on
Form 8-K filed on September 9,
2008.
|
|
10(mm)(i)
|
First
Amendment to the Term Loan Agreement, dated as of March 4, 2009,
among The Dow Chemical Company, the lenders party to the Term Loan
Agreement dated as of September 8, 2008, Citibank, N.A., as
administrative agent, and Merrill Lynch, Pierce, Fenner & Smith
Incorporated and Morgan Stanley Senior Funding, Inc., as co-syndication
agents, incorporated by reference to Exhibit 10.1 to The Dow Chemical
Company Current Report on Form 8-K filed on March 6,
2009.
|
|
10(nn)
|
Investment
Agreement, dated as of October 27, 2008, between The Dow Chemical
Company and Berkshire Hathaway Inc., incorporated by reference to
Exhibit 10.1 to The Dow Chemical Company Current Report on
Form 8-K filed on October 27,
2008.
|
|
10(oo)
|
Investment
Agreement, dated as of October 27, 2008, between The Dow Chemical
Company and The Kuwait Investment Authority, incorporated by reference to
Exhibit 10.2 to The Dow Chemical Company Current Report on
Form 8-K filed on October 27,
2008.
|
|
10(pp)
|
Securities
Issuance Letter, dated March 4, 2009, among The Dow Chemical Company,
Citigroup Global Markets Inc., Merrill Lynch, Pierce, Fenner &
Smith Incorporated and Morgan Stanley Senior Funding, Inc., incorporated
by reference to Exhibit 10.2 to The Dow Chemical Company Current
Report on Form 8-K filed on March 6,
2009.
|
|
10(qq)
|
Commitment
to Close, dated March 9, 2009, among The Dow Chemical Company, Ramses
Acquisition Corp. and Rohm and Haas Company, incorporated by reference to
Exhibit 10.1 to The Dow Chemical Company Current Report on
Form 8-K filed on March 12,
2009.
|
|
10(rr)
|
Investment
Agreement, dated March 9, 2009, among The Dow Chemical Company,
Paulson & Co. Inc. and the Haas Family Trusts, incorporated by
reference to Exhibit 10.2 to The Dow Chemical Company Current Report
on Form 8-K filed on March 12,
2009.
|
|
10(ss)
|
Letter
Agreement, dated March 9, 2009, among The Dow Chemical Company,
Ramses Acquisition Corp. and the Haas Family Trusts, incorporated by
reference to Exhibit 10.3 to The Dow Chemical Company Current Report
on Form 8-K filed on March 12,
2009.
|
|
10(tt)
|
Letter
Agreement, dated March 9, 2009, among The Dow Chemical Company,
Ramses Acquisition Corp. and Paulson & Co. Inc., incorporated by
reference to Exhibit 10.4 to The Dow Chemical Company Current Report
on Form 8-K filed on March 12,
2009.
|
|
10(uu)
|
Purchase
Agreement, dated May 5, 2009, among The Dow Chemical Company, Paulson
& Co. Inc. and the Haas Family Trusts, incorporated by reference to
Exhibit 10.1 to The Dow Chemical Company Current Report on
Form 8-K filed on May 11,
2009.
|
|
10(vv)
|
Stock
Purchase Agreement, dated May 11, 2009, between The Dow Chemical
Company and Fidelity Management Trust Services, as trustee of a trust
established under The Dow Chemical Company Employees’ Savings Plan,
incorporated by reference to Exhibit 1.1 to The Dow Chemical Company
Current Report on Form 8-K filed on May 14,
2009.
|
|
10(ww)
|
The
Deferred Stock Units Agreement Pursuant to The Dow Chemical Company 1988
Award and Option Plan, as amended, restated and effective as of
January 1, 2010, incorporated by reference to Exhibit 10.7 to
The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(xx)
|
The
Special Deferred Stock Agreement Pursuant to The Dow Chemical Company 1988
Award and Option Plan, as amended, restated and effective as of
January 1, 2010, incorporated by reference to Exhibit 10.8 to
The Dow Chemical Company Current Report on Form 8-K filed on
February 18, 2010.
|
|
10(yy)
|
The
Performance Shares Deferred Stock Units Agreement Pursuant to The Dow
Chemical Company 1988 Award and Option Plan, as amended, restated and
effective as of January 1, 2010, incorporated by reference to
Exhibit 10.9 to The Dow Chemical Company Current Report on Form 8-K
filed on February 18, 2010.
|
|
10(zz)
|
The
Special Performance Shares Deferred Stock Agreement Pursuant to The Dow
Chemical Company 1988 Award and Option Plan, as amended, restated and
effective as of January 1, 2010, incorporated by reference to
Exhibit 10.10 to The Dow Chemical Company Current Report on Form 8-K
filed on February 18, 2010.
|
|
10(aaa)
|
The
Stock Appreciation Rights Agreement Relating to a Stock Option Granted
Under The Dow Chemical Company 1988 Award and Option Plan, as amended,
restated and effective as of January 1, 2010, incorporated by
reference to Exhibit 10.11 to The Dow Chemical Company Current Report
on Form 8-K filed on February 18,
2010.
|
|
12.1
|
Computation
of Ratio of Earnings to Fixed
Charges.
|
|
14
|
Code
of Ethics for Principal Executive Officer, Principal Financial Officer and
Principal Accounting Officer, incorporated by reference to Exhibit 14
to The Dow Chemical Company Annual Report on Form 10-K for the year
ended December 31, 2003.
|
|
21
|
Subsidiaries
of The Dow Chemical Company.
|
|
23(a)
|
Consent
of Independent Registered Public Accounting
Firm.
|
|
23(b)
|
Analysis,
Research & Planning Corporation’s
Consent.
|
|
31(a)
|
Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
|
31(b)
|
Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
|
|
32(a)
|
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
32(b)
|
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
99.1
|
Replacement
Capital Covenant, dated April 1, 2009, relating to the Cumulative
Perpetual Preferred Stock, Series B, incorporated by reference to
Exhibit 99.2 to The Dow Chemical Company Current Report on
Form 8-K filed on April 1,
2009.
|
|
99.2
|
Replacement
Capital Covenant, dated April 1, 2009, relating to the Cumulative
Convertible Perpetual Preferred Stock, Series C, incorporated by
reference to Exhibit 99.3 to The Dow Chemical Company Current Report
on Form 8-K filed on April 1,
2009.
|
|
99.3
|
Guarantee
relating to the 5.60% Notes of Rohm and Haas Company, incorporated by
reference to Exhibit 99.4 to The Dow Chemical Company Current Report
on Form 8-K filed on April 1,
2009.
|
|
99.4
|
Guarantee
relating to the 6.00% Notes of Rohm and Haas Company, incorporated by
reference to Exhibit 99.5 to The Dow Chemical Company Current Report
on Form 8-K filed on April 1,
2009.
|
|
99.5
|
Guarantee
relating to the 9.80% Debentures of Rohm and Haas Company, incorporated by
reference to Exhibit 99.6 to The Dow Chemical Company Current Report
on Form 8-K filed on April 1,
2009.
|
|
101.INS
|
XBRL
Instance Document (1)
|
|
101.SCH
|
XBRL
Taxonomy Extension Schema Document (1)
|
|
101.CAL
|
XBRL Taxonomy Extension
Calculation Linkbase Document
(1)
|
|
101.LAB
|
XBRL
Taxonomy Extension Label Linkbase Document (1)
|
|
101.PRE
|
XBRL Taxonomy Extension
Presentation Linkbase Document
(1)
|
|
(1)
Pursuant to Rule 406T of Regulation S-T, this interactive data file is
deemed not filed or part of a registration statement or prospectus for
purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not
filed for purposes of section 18 of the Securities Exchange Act of 1934,
and otherwise is not subject to liability under these
sections.
|
The
|
following
trademarks or service marks of The Dow Chemical Company and certain
affiliated companies of Dow appear in this report: ACRYSOL,
ACUDYNE, ACULYN, ACUMER, ACuPLANE, ACUSOL, ADCOTE, ADVASTAB, AERIFY,
AFFINITY, AIRSTONE, AMBERLITE, AMBITROL, AMPLIFY, AQUA-LAM,
AQUASET, AR, ASPUN, ATTANE, AUROLECTROLESS, AUTOMATE, AVANSE, BETAFOAM,
BETAMATE, BETASEAL, BOROL, CANGUARD, CARBITOL, CARBOWAX, CARBOWAX SENTRY,
CELLOSIZE, CELLOSOLVE, CLEAR+STABLE, CONTINUUM, COPPER GLEAM, CORRGUARD,
CYCLOTENE, D.E.H., D.E.N., D.E.R., DOW, DOWANOL, DOWEX, DOWFAX, DOWFROST,
DOWICIDE, DOWLEX, DOWTHERM, DURAMAX, DURAPLUS, DURAPOSIT, ECHELON,
ECOSOFT, ECOSURF, ELASTENE, ELITE, ENDURANCE, ENFORCER, ENGAGE, ENHANCER,
ENLIGHT, EPIC, EVOCAR, FILMTEC, FORTEFIBER, FORTEGRA, FOUNDATIONS,
FROTH-PAK, GREAT STUFF, HYPERKOTE, HYPOL, IMPAXX, INFUSE, INSPIRE, INSITE,
INSTA-STIK, INTEGRAL, INTERVIA, ISONATE, LITHOJET, MAGNUM, METEOR,
METHOCEL, MONOTHANE, MOR-FREE, MORTRACE, NEOCAR, NORDEL, NORKOOL, NYLOPAK,
OPTICITE, OPTIDOSE, OPTOGRADE, OPULYN, OROTAN, PAPI, PARALOID, PELLETHANE,
POLYOX, POWERHOUSE, PRIMACOR, PRIMAL, PRIMENE, PROCITE, PROGLYDE, PULSE,
REDI-LINK, RENUVA, RHOPLEX, ROBOND, ROMAX, ROPAQUE, SARAN, SARANEX,
SATINFX, SATISFIT, SERFENE, SHAC, SI-LINK, SILK, SMARTFRESH, SOLTERRA,
SOLTEX, SPECFIL, SPECFLEX, SPECTRIM, STYROFOAM, STYRON, STYRON A-TECH,
STYRON C-TECH, SUNSPHERES, SYNALOX, TAMOL, TERGITOL, THERMAX, TILE BOND,
TRAFFIDECK, TRENCHCOAT, TRITON, TRYCITE, TUFLIN, TYBRITE, TYMOR, TYRIN,
UCAR, UCAR POLYPHOBE, UCARE, UCARHIDE, UCON, UNIGARD, UNIPOL, UNIVAL,
VERDISEAL, VERSENE, VERSIFY, VISIONPAD, VORACOR, VORACTIV, VORALAST,
VORAMER, VORANATE, VORANOL, VORASTAR, WALOCEL, WALSRODER, WEATHERMATE,
XITRACK
|
The
|
following
trademarks or service marks of Dow AgroSciences LLC and certain affiliated
companies of Dow AgroSciences LLC appear in this
report: AGROMEN, BRODBECK, CLINCHER, DAIRYLAND,
DELEGATE, DITHANE, FORTRESS, GARLON, GLYPHOMAX, GRANITE, HERCULEX,
KEYSTONE, LAREDO, LONTREL, LORSBAN, MILESTONE, MUSTANG, MYCOGEN, NEXERA,
PHYTOGEN, PROFUME, RENZE, SENTRICON, SIMPLICITY, STARANE, TELONE, TORDON,
TRACER NATURALYTE, TRIUMPH, VIKANE,
WIDESTRIKE
|
The
|
following
registered service mark of American Chemistry Council appears in this
report: Responsible Care
|
The
|
following
trademark of the Financial Accounting Standards Board appears in this
report: FASB Accounting Standards
Codification
|